"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","altmetric_score_mean_top25AltmScore","altmetric_score_min_top25AltmScore","altmetric_score_max_top25AltmScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internazionali","avg_ResultingPublications_per_grant","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","nClTrial_w_AltmScore","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n"
"IRCCS_SANMATTEO",2000,196,7.40816326530612,2.81122448979592,0.355716878402904,0.408163265306122,0.38265306122449,0.0561224489795918,0.168367346938776,6,75,29,9,71,0.38,0.15,0.05,0.36,30.48,0.672378877238158,0.13265306122449,0.98469387755102,0,0.448068381248938,0.328989192625556,0.396954113924051,0.329749103942652,"CATHERINE KLERSY;CARMINE TINELLI;R CAMPANI;ELOISA ARBUSTINI;LUIGI TAVAZZI;MARIO LAZZARINO;CAMILLO PORTA;FRANCO LOCATELLI;CARLO BERNASCONI;GIOVANNI PALLADINI;FERDINANDO DRAGHI;GIAMPAOLO MERLINI;ESTER ORLANDI;ANNA TERESA MAIOLO;L. SALVANESCHI;ANGELA PISTORIO;D. DE AMICI;MAURIZIO LUISETTI;ANTONELLO GAVAZZI;PAOLO IADAROLA","13;10;8;7;7;7;5;5;5;5;5;5;5;5;5;4;4;4;4;4","ELOISA ARBUSTINI;CATHERINE KLERSY;LUIGI TAVAZZI;STEFANO GHIO;CARLO CAMPANA;VITTORIO ROSTI;R CAMPANI;GIOVANNI BAROSI;ROBERTO FOGARI;D. DE AMICI;MONIA MARCHETTI;CAMILLO PORTA;CARMINE TINELLI;FERDINANDO DRAGHI;MARCO DANOVA;ALESSANDRO PECCI;LUCA LANZARINI;ANNA TERESA MAIOLO;GIOVANNI PALLADINI;D. COSCIA","2.12;2.07;1.68;1.62;1.49;1.34;1.22;1.17;1.17;1.15;1.08;1.06;1.01;0.99;0.89;0.83;0.83;0.76;0.72;0.7","CATHERINE KLERSY;CARMINE TINELLI;R CAMPANI;ELOISA ARBUSTINI;LUIGI TAVAZZI;MARIO LAZZARINO;CAMILLO PORTA;FRANCO LOCATELLI;CARLO BERNASCONI;GIOVANNI PALLADINI;FERDINANDO DRAGHI;GIAMPAOLO MERLINI;ESTER ORLANDI;ANNA TERESA MAIOLO;L. SALVANESCHI;ANGELA PISTORIO;D. DE AMICI;MAURIZIO LUISETTI;ANTONELLO GAVAZZI;FAUSTO BALDANTI","13;10;8;7;7;7;5;5;5;5;5;5;5;5;5;4;4;4;4;4","ELOISA ARBUSTINI;CATHERINE KLERSY;LUIGI TAVAZZI;STEFANO GHIO;CARLO CAMPANA;VITTORIO ROSTI;R CAMPANI;GIOVANNI BAROSI;ROBERTO FOGARI;D. DE AMICI;MONIA MARCHETTI;CAMILLO PORTA;CARMINE TINELLI;FERDINANDO DRAGHI;MARCO DANOVA;ALESSANDRO PECCI;LUCA LANZARINI;ANNA TERESA MAIOLO;GIOVANNI PALLADINI;D. COSCIA","2.12;2.07;1.68;1.62;1.49;1.34;1.22;1.17;1.17;1.15;1.08;1.06;1.01;0.99;0.89;0.83;0.83;0.76;0.72;0.7","CATHERINE KLERSY;LUIGI TAVAZZI;ANTONELLO GAVAZZI;CARMINE TINELLI;CARLO CAMPANA;CARLO NAPOLITANO;PETER J. SCHWARTZ;SILVIA G. PRIORI;F RECUSANI;MARIA LUISA LAUDISA;ROBERTA SEBASTIANI;STEFANO GHIO;AHARON MEDINA;ARTHUR J. MOSS;FRANK G. YANOWITZ;G. MICHAEL VINCENT;IGOR SPLAWSKI;JEFFREY A. TOWBIN;JENNIFER L. ROBINSON;JESAIA BENHORIN","1107;850;698;621;563;516;516;516;495;495;495;495;465;465;465;465;465;465;465;465","CATHERINE KLERSY;LUIGI TAVAZZI;ANTONELLO GAVAZZI;CARLO CAMPANA;F RECUSANI;MARIA LUISA LAUDISA;ROBERTA SEBASTIANI;STEFANO GHIO;CARMINE TINELLI;AHARON MEDINA;ARTHUR J. MOSS;CARLO NAPOLITANO;FRANK G. YANOWITZ;G. MICHAEL VINCENT;IGOR SPLAWSKI;JEFFREY A. TOWBIN;JENNIFER L. ROBINSON;JESAIA BENHORIN;JIAXIANG SHEN;JOLENE FOX","1047;850;698;555;495;495;495;495;484;465;465;465;465;465;465;465;465;465;465;465","CATHERINE KLERSY;CARMINE TINELLI;LUIGI TAVAZZI;ELOISA ARBUSTINI;ANNA TERESA MAIOLO;ESTER ORLANDI;FERDINANDO DRAGHI;L. SALVANESCHI;MAURIZIO LUISETTI;ANTONELLO GAVAZZI;D. COSCIA;FAUSTO BALDANTI;GIOVANNI BAROSI;GIOVANNI PALLADINI;CAMILLO PORTA;CARLO FÌLICE;CHIARA BROGLIA;MARA DE AMICI;S. GATTI;CARLO CAMPANA","12;8;8;7;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;GEOGRAPHY;MATERIALS SCIENCE;PSYCHOLOGY;SOCIOLOGY;ART;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;ECONOMICS;GEOLOGY","181;58;19;15;11;8;7;4;4;4;4;3;3;3;2;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;PATHOLOGY;GENETICS;CARDIOLOGY;GASTROENTEROLOGY;RADIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;VIROLOGY;PEDIATRICS;OPTICS;ONCOLOGY;ANESTHESIA;CANCER RESEARCH;PHARMACOLOGY;DERMATOLOGY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;MICROBIOLOGY;PSYCHIATRY","126;56;54;38;35;32;32;21;19;15;15;14;13;12;11;10;10;8;8;8;8;8","GENE;CHEMOTHERAPY;TRANSPLANTATION;ANTIBODY;HEART FAILURE;DISEASE;BONE MARROW;CANCER;REGIMEN;VIRUS;BLOOD PRESSURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);LYMPHOMA;RECEPTOR;BIOPSY;PLATELET;ANTIGEN;MULTIPLE MYELOMA;POPULATION;STEM CELL","25;19;19;16;15;12;11;11;10;10;9;9;9;8;8;7;7;6;6;6;6","CYCLOPHOSPHAMIDE;VIRAL LOAD;EJECTION FRACTION;MUTATION;VIRAL DISEASE;CARDIOMYOPATHY;DILATED CARDIOMYOPATHY;ETOPOSIDE;HEART TRANSPLANTATION;HEPATITIS B VIRUS;HUMAN LEUKOCYTE ANTIGEN;MYELOFIBROSIS;PRECOCIOUS PUBERTY;PROGENITOR CELL;RNA;AGONIST;ALLELE;AUTOANTIBODY;BREAST CANCER;CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION;CYTARABINE;EXON;GENOTYPE;HAEMATOPOIESIS;IMMUNOGLOBULIN LIGHT CHAIN;IMMUNOTHERAPY;MELPHALAN;MONOCLONAL ANTIBODY;NEURORADIOLOGY;PLASMAPHERESIS;POLYMERASE CHAIN REACTION;REVASCULARIZATION;SEROCONVERSION;STAPHYLOCOCCUS AUREUS;TYPE 2 DIABETES","10;8;7;7;6;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;VINCRISTINE;CENTRAL PRECOCIOUS PUBERTY;MONOCLONAL;PULMONARY THROMBOENDARTERECTOMY;REVERSE TRANSCRIPTASE;VANCOMYCIN;ZIDOVUDINE;ACE INHIBITOR;AL AMYLOIDOSIS;BUSERELIN;CARMUSTINE;CHROMATID;CHROMOSOME INSTABILITY;EOSINOPHIL CATIONIC PROTEIN;FLUORESCENCE IN SITU HYBRIDIZATION;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GENOTYPING;GLOMERULOSCLEROSIS;GONADOTROPIN-RELEASING HORMONE;HBSAG;LAMIVUDINE;LENTIVIRUS;PROGENITOR","6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;HIV INFECTIONS;ADOLESCENT;CHILD;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARDIOMYOPATHY, DILATED;TREATMENT OUTCOME;PUBERTY, PRECOCIOUS;ANTI-HIV AGENTS;ANTINEOPLASTIC AGENTS;CHILD, PRESCHOOL;CYCLOPHOSPHAMIDE;HEART FAILURE","138;82;79;61;57;53;31;28;26;24;24;22;22;18;17;16;16;16;16;14","MOLECULAR MECHANISMS OF AMYLOIDOSIS;LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;REGULATION OF PUBERTY AND REPRODUCTION;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;ORGAN TRANSPLANTATION AND REJECTION;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;BIOMEDICAL OPTICAL IMAGING AND SPECTROSCOPY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","6;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","REGIMEN;HIV;ANTIRETROVIRAL THERAPY;TREATMENT;CARDIAC IMAGING;CENTRAL PRECOCIOUS PUBERTY;CORD BLOOD;DILATED CARDIOMYOPATHY;ECHOCARDIOGRAPHY;HEART TRANSPLANT;HIV INFECTION;PRESENTATION (OBSTETRICS);REFRACTORY (PLANETARY SCIENCE);TRANSPLANTATION;DEEP VEIN THROMBOSIS;HEMATOLOGY;HEMATOPOIETIC CELL TRANSPLANTATION;HIV TRANSMISSION;INTERNATIONAL MYELOMA WORKING GROUP;LIGHT CHAIN AMYLOIDOSIS","10;8;7;6;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","HEART FAILURE;MULTIPLE MYELOMA;BONE MARROW;HIV-INFECTED PATIENTS;INTERMITTENT IMAGING;MARROW TRANSPLANTATION;PRECOCIOUS PUBERTY;STEM CELL;BREAST CANCER;CELL TRANSPLANTATION;CENTRAL PRECOCIOUS;DILATED CARDIOMYOPATHY;HEART TRANSPLANTATION;HEPATOCELLULAR CARCINOMA;LEFT VENTRICULAR;ORTHOTOPIC HEART;PLASMA LEVELS;PRIMARY AMYLOIDOSIS;PULSE INVERSION;THROMBOCYTOPENIC PURPURA;ACE INHIBITORS;ACTIVE ANTIRETROVIRAL;ACUTE MYOCARDIAL;ALLOGENEIC BONE;AMYLOIDOSIS AL;ANTIRETROVIRAL THERAPY;ASSOCIAZIONE ITALIANA;BLOOD STEM;CARCINOMA PATIENTS;CELL HISTIOCYTOSIS","5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CARDIOLOGIE INTERVENTIONELLE;CLINIQUE PASTEUR;DE CARDIOLOGIE;INTERVENTIONELLE CLINIQUE;PASTEUR TOULOUSE;TOULOUSE FRANCESEARCH;UNITE DE;VIRAL LOAD;CEMOC ISTITUTI;CENTRE CEMOC;CLINICI DI;COMMUNITY HEALTH;DI PERFEZIONAMENTO;HEALTH CENTRE;HIV RNA;ISTITUTI CLINICI;PERFEZIONAMENTO MILANOSEARCH;PLASMA HIV;RNA CONCENTRATIONS;ANTIRETROVIRAL THERAPY;DILATED CARDIOMYOPATHY;EBV INFECTION;FULL-TEXT VERSION;HAWTHORNE EFFECT;MIXED-GENOTYPE INFECTIONS;PAVIA ITALYSEARCH;PERIPHERAL BLOOD;SKELETAL MUSCLE;BLOOD PRESSURE;CHAIN REACTION","14;14;14;14;14;14;14;9;8;8;8;8;8;8;8;8;8;8;8;7;7;6;6;6;6;6;6;6;5;5",8,0.04,3,5.95,5.904,6,1.5,1,2,0,0,0,1,1,1,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,1.5,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.5,1,2,0,0,0,87.5,41,134,89,42,136,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2001,187,7.25268817204301,2.6505376344086,0.379310344827586,0.408602150537634,0.446236559139785,0.0645161290322581,0.224598930481283,5,57,22,8,79,0.3,0.12,0.04,0.42,50.62,1.10784919819324,0.155080213903743,0.962566844919786,0,0.405326042787563,0.312931984373435,0.391067538126362,0.3125,"CATHERINE KLERSY;ELOISA ARBUSTINI;CARMINE TINELLI;ALBERTO MARTINI;LUIGI TAVAZZI;M. MARTINETTI;L. SALVANESCHI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;CARLO CAMPANA;DANIELA LARIZZA;CARLA BADULLI;G. BORRONI;ANGELO RAVELLI;RENATO MASERATI;ALESSANDRA REPETTO;GIUSEPPE GERNA;MAURIZIO ARICÒ;MARCO DANOVA;ALESSANDRO CORSO","13;8;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","CATHERINE KLERSY;ELOISA ARBUSTINI;CARLO CAMPANA;LUIGI TAVAZZI;ANTONELLO GAVAZZI;ANTONINO MAZZONE;ROSANGELA INVERNIZZI;ALESSANDRA REPETTO;VANDERSON ROCHA;ALESSANDRO PECCI;F BARZIZZÁ;MARCO DANOVA;ALBERTO MARTINI;R LUPO;ANGELA PISANI;ANTONIO BRASCHI;ALESSANDRO CORSO;M. MARTINETTI;G. BORRONI;E MEVIO","1.97;1.5;1.49;1.24;1.22;1.22;1.05;1.04;1;1;1;0.98;0.98;0.95;0.92;0.84;0.77;0.75;0.7;0.69","CATHERINE KLERSY;ELOISA ARBUSTINI;CARMINE TINELLI;LUIGI TAVAZZI;M. MARTINETTI;L. SALVANESCHI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;CARLO CAMPANA;DANIELA LARIZZA;CARLA BADULLI;G. BORRONI;ANGELO RAVELLI;RENATO MASERATI;ALESSANDRA REPETTO;GIUSEPPE GERNA;MAURIZIO ARICÒ;MARCO DANOVA;ALESSANDRO CORSO;ANGELA PISTORIO","13;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3","CATHERINE KLERSY;ELOISA ARBUSTINI;CARLO CAMPANA;LUIGI TAVAZZI;ANTONELLO GAVAZZI;ANTONINO MAZZONE;ROSANGELA INVERNIZZI;ALESSANDRA REPETTO;VANDERSON ROCHA;ALESSANDRO PECCI;F BARZIZZÁ;MARCO DANOVA;R LUPO;ANGELA PISANI;ANTONIO BRASCHI;ALESSANDRO CORSO;M. MARTINETTI;G. BORRONI;E MEVIO;L. SALVANESCHI","1.97;1.5;1.49;1.24;1.22;1.22;1.05;1.04;1;1;1;0.98;0.95;0.92;0.84;0.77;0.75;0.7;0.69;0.67","CATHERINE KLERSY;LUIGI TAVAZZI;ELOISA ARBUSTINI;STEFANO GHIO;CARLO CAMPANA;ANTONELLO GAVAZZI;F RECUSANI;ROBERTA SEBASTIANI;C. INSERRA;VANDERSON ROCHA;A. BACHY;A. NIVELON-CHEVALIER;ALAIN VERLOÈS;ANDRÉ MÉGARBANÉ;B. I. JOFFE;C. RONALD KAHN;CHARLOTTE BOURUT;CORINNE VIGOUROUX;DIDIER LACOMBE;E SEEMANOVÁ","1707;1433;1388;1327;1292;1272;1241;1241;1211;774;707;707;707;707;707;707;707;707;707;707","CATHERINE KLERSY;LUIGI TAVAZZI;ELOISA ARBUSTINI;STEFANO GHIO;CARLO CAMPANA;ANTONELLO GAVAZZI;C. INSERRA;F RECUSANI;ROBERTA SEBASTIANI;VANDERSON ROCHA;SALVATORE SAVASTA;ALBERTO BOSI;ANDREA BACIGALUPO;BARBARA BRUNO;M. BARBANTI;MARIA TERESA VAN LINT;NICOLETTA SACCHI;P ALESSANDRINO;PAOLO BRUZZI;PAOLO DI BARTOLOMEO","1639;1397;1388;1297;1256;1242;1211;1211;1211;774;707;511;511;511;511;511;511;511;511;511","CATHERINE KLERSY;M. MARTINETTI;ELOISA ARBUSTINI;CARMINE TINELLI;ANNALISA DE SILVESTRI;L. SALVANESCHI;LUIGI TAVAZZI;CARLA BADULLI;DANIELA LARIZZA;MAURIZIO ARICÒ;CARLO CAMPANA;ALESSANDRA VIGLIO;CARLOMAURIZIO MONTECUCCO;FAUSTO BALDANTI;G. BORRONI;GINO ROBERTO CORAZZA;LUCA LANZARINI;MARCO PAULLI;P. VILLANI;RENATO MASERATI","11;9;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;SOCIOLOGY;MATHEMATICS;GEOLOGY;GEOGRAPHY;POLITICAL SCIENCE;BUSINESS;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY","166;77;20;12;8;7;6;5;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;PEDIATRICS;VIROLOGY;ENDOCRINOLOGY;RADIOLOGY;ANATOMY;ENVIRONMENTAL HEALTH;MICROBIOLOGY;ANESTHESIA;PSYCHIATRY;DERMATOLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY;PHARMACOLOGY","111;51;43;42;39;28;28;26;21;19;16;14;11;11;11;9;9;8;8;7;7;7","GENE;DISEASE;VIRUS;ANTIBODY;TRANSPLANTATION;ANTIGEN;BONE MARROW;CANCER;IMMUNE SYSTEM;IN VITRO;POPULATION;HEART FAILURE;CHEMOTHERAPY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);BLOOD PRESSURE;ANTIBIOTICS;ARTHRITIS;HEMODYNAMICS;ASYMPTOMATIC;CORONARY ARTERY DISEASE;LESION;MYOCARDIAL INFARCTION;ODDS RATIO;PREGNANCY","30;21;18;15;14;13;13;13;13;12;12;11;9;9;8;7;7;7;6;6;6;6;6;6","VIRAL LOAD;HUMAN LEUKOCYTE ANTIGEN;MUTATION;BREAST CANCER;CARDIOMYOPATHY;GENOTYPE;HUMAN CYTOMEGALOVIRUS;PERIPHERAL BLOOD MONONUCLEAR CELL;RNA;UNIVARIATE ANALYSIS;VIRAL DISEASE;ALLELE;CHROMOSOME;EJECTION FRACTION;HEART RATE;HEPATITIS B VIRUS;HEPATITIS C VIRUS;MYELOFIBROSIS;ANTIBACTERIAL AGENT;AUTOANTIBODY;AUTOIMMUNE DISEASE;AUTOIMMUNITY;COELIAC DISEASE;CYCLOPHOSPHAMIDE;CYTOTOXIC T CELL;DIASTOLE;HAEMATOPOIESIS;HEART TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MONOCLONAL ANTIBODY;PHENOTYPE;PLACEBO;PROTEASE;RADIOFREQUENCY ABLATION;SEROLOGY;STAPHYLOCOCCUS AUREUS;UNSTABLE ANGINA","10;8;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;REVERSE TRANSCRIPTASE;GANCICLOVIR;HBSAG;MONOCLONAL;ANTHRACYCLINE;ATROPHIC GASTRITIS;BAROREFLEX;CONNECTIVE TISSUE DISEASE;EPIRUBICIN;ESOPHAGITIS;EXTRAMEDULLARY HEMATOPOIESIS;KARYOTYPE;LAMIVUDINE;LARGE CELL;LYMPHOPROLIFERATIVE RESPONSE;METASTATIC BREAST CANCER;MIMOTOPE;OFLOXACIN;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);REFLUX ESOPHAGITIS","9;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;;ADOLESCENT;CHILD;HIV INFECTIONS;FOLLOW-UP STUDIES;ITALY;TIME FACTORS;ANTI-HIV AGENTS;AGED, 80 AND OVER;ANTI-BACTERIAL AGENTS;ARTHRITIS, JUVENILE;CELIAC DISEASE;LEUKOCYTES, MONONUCLEAR;PRIMARY MYELOFIBROSIS","146;97;86;60;57;37;36;30;26;24;19;19;17;16;14;14;14;14;13;13","HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS B INFECTION AND TREATMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATOCELLULAR CARCINOMA;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;ORGAN TRANSPLANTATION AND REJECTION;ASTHMA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF SPINAL INFECTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT","8;6;5;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","TREATMENT;ANTIRETROVIRAL THERAPY;CARDIAC IMAGING;CYTOMEGALOVIRUS;HIV;JUVENILE IDIOPATHIC ARTHRITIS;SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS;UNIVARIATE ANALYSIS;BETA-2 MICROGLOBULIN;ACUTE MYELOID LEUKEMIA;CONCOMITANT;DIAGNOSIS;ECHOCARDIOGRAPHY;FOSCARNET;HEMATOPOIETIC CELL TRANSPLANTATION;HEPATITIS B;HEPATOCELLULAR CARCINOMA;HISTOLOGY;METAPLASIA;MYELOFIBROSIS","8;6;5;5;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3","BONE MARROW;HEART FAILURE;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;BREAST CANCER;CELL TRANSPLANTATION;CHRONIC HEART;DILATED CARDIOMYOPATHY;FAMILY HISTORY;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY;MYELOID METAPLASIA;SINGLE CENTER;UNSTABLE ANGINA;VIRUS TYPE;ACUTE MYELOID;ADVANCED BREAST;ANGINA CORRELATION;CLINICAL FEATURES;COELIAC DISEASE;CONGESTIVE HEART;CONTACT DERMATITIS;CORONARY ARTERY;HEART TRANSPLANTATION;HLA CLASS;HUMAN CORONARY;HUMAN CYTOMEGALOVIRUS;II STUDY;IMMUNE RESPONSE;IMMUNODEFICIENCY VIRUS-INFECTED","6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;VITILIGO PATIENTS;HR CI;PGML NA;WILD TYPE;CD T-CELL;PUBMED GOOGLE;TETRAMER CELLS;HIV- RT;CERVICOVAGINAL SECRETIONS;INV DUPP;KD TER;HEART FAILURE;HIV- RNA;HUMAN IMMUNODEFICIENCY;PERIPHERAL BLOOD;TYPE DIABETES;UNSTABLE ANGINA;CELL LINES;CONFIDENCE INTERVAL;EQUILIBRIUM DISSOCIATION;EXP MED;GENE CLUSTERS;INTERVAL CI;MED -CROSSREF;NEPHROTIC SYNDROME;REVERSE TRANSCRIPTASE;TERNARY COMPLEX;VIRAL REPLICATION","53;39;13;12;12;11;10;10;10;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6",16,0.09,3,7.5,6,12,4.5,2,13,0,0,0,0,0,0,0,0,0,0,0,0,3.6,1,9,0,0,0,1.5,1,2,5.33,2,13,0,0,0,0,0,0,0,0,0,0,0,0,3,2,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,98.17,36,195,98.17,36,195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2002,158,7.74683544303798,2.63924050632911,0.378896882494005,0.367088607594937,0.411392405063291,0.113924050632911,0.189873417721519,5,51,20,17,61,0.32,0.13,0.11,0.39,37.47,0.679274233409368,0.151898734177215,0.987341772151899,0,0.429969174728301,0.382931354359926,0.385155153594262,0.428571428571429,"ELOISA ARBUSTINI;CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;CARMINE TINELLI;MAURIZIO LUISETTI;FAUSTO BALDANTI;M. MARTINETTI;ALBERTO MARTINI;ANNALISA DE SILVESTRI;JULIANNA LISZIEWICZ;FRANCO LOCATELLI;ANGELO RAVELLI;STEFANO DE SERVI;F CAFIERO;FRANCO LORI;ALESSANDRA REPETTO;ELENA PERCIVALLE;MAURIZIO DʼURBANO;FABRIZIO DE BENEDETTI","8;8;7;7;6;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4","GIUSEPPE GERNA;MAURIZIO LUISETTI;CATHERINE KLERSY;ELOISA ARBUSTINI;LUIGI TAVAZZI;STEFANO GHIO;FAUSTO BALDANTI;STEFANIA PAOLUCCI;ALESSANDRO PULSONI;ELENA PERCIVALLE;MARIA GRAZIA REVELLO;CARMINE TINELLI;M. MARTINETTI;JULIANNA LISZIEWICZ;FRANCO LORI;FRANCO PIOVELLA;LUCA LANZARINI;ANTONELLA SARASINI;ANDREA PIETRABISSA;ALBERTO MARTINI","2.2;2.17;1.44;1.4;1.18;1.11;1.03;1;1;0.9;0.9;0.82;0.79;0.75;0.75;0.75;0.7;0.65;0.64;0.64","ELOISA ARBUSTINI;CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;CARMINE TINELLI;MAURIZIO LUISETTI;FAUSTO BALDANTI;M. MARTINETTI;ANNALISA DE SILVESTRI;JULIANNA LISZIEWICZ;FRANCO LOCATELLI;STEFANO DE SERVI;FRANCO LORI;ALESSANDRA REPETTO;ELENA PERCIVALLE;FABRIZIO DE BENEDETTI;MARIA GRAZIA REVELLO;ENRICA MORRA;ANGELA PISTORIO;P. MARONE","8;8;7;7;6;6;6;6;4;4;4;4;4;4;4;4;4;4;3;3","GIUSEPPE GERNA;MAURIZIO LUISETTI;CATHERINE KLERSY;ELOISA ARBUSTINI;LUIGI TAVAZZI;STEFANO GHIO;FAUSTO BALDANTI;STEFANIA PAOLUCCI;ALESSANDRO PULSONI;ELENA PERCIVALLE;MARIA GRAZIA REVELLO;CARMINE TINELLI;M. MARTINETTI;JULIANNA LISZIEWICZ;FRANCO LORI;FRANCO PIOVELLA;LUCA LANZARINI;ANTONELLA SARASINI;ANDREA PIETRABISSA;ANNALISA DE SILVESTRI","2.2;2.17;1.44;1.4;1.18;1.11;1.03;1;1;0.9;0.9;0.82;0.79;0.75;0.75;0.75;0.7;0.65;0.64;0.6","ELOISA ARBUSTINI;LUIGI TAVAZZI;FRANCO LOCATELLI;ALESSANDRA REPETTO;FABRIZIO DE BENEDETTI;CARLO CAMPANA;ANDREA NEGRI;MAURIZIA GRASSO;ANDREA PESSION;CHIARA MESSINA;LAURA SCELSI;ANDREA PILOTTO;ANTONELLO GAVAZZI;ELISA BALDINI;MARTA DIEGOLI;ENRICA MORRA;FRANCO PIOVELLA;CRISTINA MEAZZA;WILLIAM OLLIER;CATHERINE KLERSY","616;556;538;483;451;437;424;348;338;338;333;331;331;331;331;330;325;321;312;307","ELOISA ARBUSTINI;LUIGI TAVAZZI;ALESSANDRA REPETTO;MAURIZIA GRASSO;CARLO CAMPANA;LAURA SCELSI;ANDREA NEGRI;ANDREA PILOTTO;ELISA BALDINI;MARTA DIEGOLI;FRANCO PIOVELLA;CRISTINA MEAZZA;FABRIZIO DE BENEDETTI;GIOVANNI BAROSI;P. PATRIZIA MANGIONE;SOFIA GIORGETTI;VITTORIO BELLOTTI;SALVATORE SAVASTA;FAUSTO BALDANTI;MARCO ZECCA","616;556;483;348;333;333;331;331;331;331;325;321;300;274;258;258;258;246;230;217","ELOISA ARBUSTINI;LUIGI TAVAZZI;CATHERINE KLERSY;GIUSEPPE GERNA;FAUSTO BALDANTI;CARMINE TINELLI;MAURIZIO LUISETTI;M. MARTINETTI;ALESSANDRA REPETTO;ANNALISA DE SILVESTRI;ELENA PERCIVALLE;MARIA GRAZIA REVELLO;STEFANO DE SERVI;ANDREA PIETRABISSA;ANTONELLA SARASINI;C BÍANCHI;FRANCO PIOVELLA;G. FILICE;L. MINOLI;MARCO DANOVA","8;7;7;7;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;HISTORY;MATERIALS SCIENCE;PSYCHOLOGY;ART;MATHEMATICS;SOCIOLOGY;GEOGRAPHY;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","133;66;14;13;7;7;4;4;4;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;PATHOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;VIROLOGY;ENDOCRINOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;PSYCHIATRY;ANESTHESIA;MICROBIOLOGY;ONCOLOGY;OPTICS;CELL BIOLOGY;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;UROLOGY","103;45;33;31;27;27;24;22;14;14;13;10;9;8;7;6;6;6;6;5;5;5;5;5","GENE;VIRUS;CHEMOTHERAPY;ENZYME;IN VITRO;DISEASE;POPULATION;CANCER;HEART FAILURE;IMMUNE SYSTEM;ANTIBODY;ANTIGEN;BONE MARROW;TRANSPLANTATION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);REGIMEN;MYOCARDIAL INFARCTION;ARTHRITIS;BLOOD PRESSURE;INCIDENCE (GEOMETRY);INFLAMMATION;LEUKEMIA;MULTIPLE MYELOMA;PLATELET;PREGNANCY","30;17;16;13;13;12;12;11;10;10;8;8;8;8;7;7;6;5;5;5;5;5;5;5;5","VIRAL DISEASE;VIRAL LOAD;GENOTYPE;HUMAN CYTOMEGALOVIRUS;ALLELE;CHROMOSOME;CYCLOPHOSPHAMIDE;PHENOTYPE;HUMAN LEUKOCYTE ANTIGEN;MUTATION;BREAST CANCER;CYTOTOXIC T CELL;DILATED CARDIOMYOPATHY;HEPATITIS C VIRUS;MYELODYSPLASTIC SYNDROMES;OVARIAN CANCER;PROTEASE;UNSTABLE ANGINA;ANGINA;CARDIOMYOPATHY;CD8;ENDOTHELIAL STEM CELL;FETUS;HAEMATOPOIESIS;LYMPHOPROLIFERATIVE DISORDERS;NEUTROPENIA;POLYMERASE CHAIN REACTION;RECOMBINANT DNA;STAPHYLOCOCCUS AUREUS;T CELL","9;9;7;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;KARYOTYPE;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;ABCIXIMAB;ACUTE LYMPHOCYTIC LEUKEMIA;BAROREFLEX;BRONCHIOLITIS OBLITERANS;CYTOGENETICS;EPTIFIBATIDE;GANCICLOVIR;LENTIVIRUS;METASTATIC BREAST CANCER;POUCHITIS;PRENATAL DIAGNOSIS;PROBAND;PROCTOCOLECTOMY;T-CELL RECEPTOR;TIROFIBAN;ABSOLUTE NEUTROPHIL COUNT;ACUTE AORTIC SYNDROME;ACUTE PROMYELOCYTIC LEUKEMIA;AFFINITY ELECTROPHORESIS;AL AMYLOIDOSIS;ALLELE FREQUENCY;ANAGRELIDE;ANEUPLOIDY;ASPARAGINASE;AUTONOMIC NERVOUS SYSTEM;BARORECEPTOR;BLADDER OUTLET OBSTRUCTION;BOND STRENGTH;BUSULFAN;CARBOPLATIN;CARDIAC INDEX;CARMUSTINE;CEFTAZIDIME;CHROMOSOME 7 (HUMAN);COLD AGGLUTININ DISEASE;COLONOSCOPY;COR TRIATRIATUM;CORONARY STENT;CTL*;DEBULKING;DIABETES MANAGEMENT;DIAGNOSIS OF MALARIA;DYSKINESIA;ENTEROBACTERIACEAE;ENTEROCHROMAFFIN-LIKE CELL;ENTEROENDOCRINE CELL;EPOXIDE HYDROLASE;ETHAMBUTOL;FIBROMUSCULAR DYSPLASIA;FISETIN;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;GENE DELIVERY;GENE MUTATION;GENETIC HETEROGENEITY;GLUCURONIDATION;GRANZYME B;HAPLOTYPE;HBSAG;HEMORRHAGIC CYSTITIS;HETEROZYGOTE ADVANTAGE;HUMAN UMBILICAL VEIN ENDOTHELIAL CELL;HYPERALGESIA;IMIPENEM;INSULIN-LIKE GROWTH FACTOR;INTERFERON ALFA;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTERSTITIAL PNEUMONITIS;KRUKENBERG TUMOR;LEVODOPA;LITHIUM CARBONATE;LMNA;LOSS OF HETEROZYGOSITY;LOWER URINARY TRACT SYMPTOMS;LYMPHOPOIESIS;MEAN ARTERIAL PRESSURE;MEROPENEM;MHC CLASS I;MICROCOCCACEAE;MISSENSE MUTATION;MULTICENTER TRIAL;NORFLOXACIN;NUCLEAR PROTEIN;OPPORTUNISTIC PATHOGEN;ORAL ANTICOAGULANT;PANCREATIC HORMONE;PARASITEMIA;PERFORIN;PIPERACILLIN;POLYMORPHISM (COMPUTER SCIENCE);POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;PROLYMPHOCYTIC LEUKEMIA;RECOMBINANT VIRUS;RESIDUAL URINE;RETEPLASE;REVERSE TRANSCRIPTASE;REVERSION;RIBAVIRIN;SATELLITE DNA;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS EPIDERMIDIS;STREPTOCOCCUS PYOGENES;SYNOVIAL FLUID;SYSTEMIC THERAPY;TAMOXIFEN;TANDEM REPEAT;TIMI;TISSUE FACTOR PATHWAY INHIBITOR;TISSUE TROPISM;TOBRAMYCIN;TOTAL BODY IRRADIATION;TRANSFERRIN SATURATION;VACCINIA;VINCRISTINE;VIRAL VECTOR;VOICE PROSTHESIS;ZIDOVUDINE","7;6;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ADOLESCENT;HIV INFECTIONS;CYTOMEGALOVIRUS;ITALY;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HIV-1;TIME FACTORS;CHILD;TREATMENT OUTCOME;ARTHRITIS, JUVENILE;MYOCARDIAL INFARCTION;CARDIOMYOPATHY, DILATED;CHILD, PRESCHOOL","135;72;70;49;42;36;27;27;24;22;19;19;18;18;17;17;15;15;14;14","EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;HEPATITIS C INFECTION AND TREATMENT;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;STRUCTURE AND FUNCTION OF THE NUCLEAR PORE COMPLEX;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MECHANISMS OF ALZHEIMER'S DISEASE;NATURAL KILLER CELLS IN IMMUNITY;ORGAN TRANSPLANTATION AND REJECTION;ORIGINS AND FUTURE OF MICROFLUIDICS","7;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","REGIMEN;TREATMENT;ANTIRETROVIRAL THERAPY;CYTOMEGALOVIRUS;HIV;CARDIAC IMAGING;DILATED CARDIOMYOPATHY;ECHOCARDIOGRAPHY;HEPATITIS C;HIV INFECTION;UNSTABLE ANGINA;ALPHA 1-ANTITRYPSIN DEFICIENCY;INFLAMMATION;LYMPHOPROLIFERATIVE DISORDERS;REFRACTORY (PLANETARY SCIENCE);SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS;TREATMENT OUTCOMES;ABCIXIMAB;ACUTE LYMPHOCYTIC LEUKEMIA;AMYLOID (MYCOLOGY)","7;7;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2","HEART FAILURE;HUMAN CYTOMEGALOVIRUS;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;DILATED CARDIOMYOPATHY;ANTIRETROVIRAL THERAPY;BREAST CANCER;CAPILLARY ELECTROPHORESIS;INHIBITORY FACTOR;MACROPHAGE MIGRATION;MIGRATION INHIBITORY;MULTIPLE MYELOMA;PROTEASE INHIBITORS;ACUTE LYMPHOBLASTIC;BAROREFLEX SENSITIVITY;CHILDHOOD ACUTE;CHRONIC HEART;COMBINATION THERAPY;DIFFERENTIAL DIAGNOSIS;DRUG RESISTANCE;ENDOTHELIAL CELLS;GROWTH FACTOR;HIV-POSITIVE PATIENTS;HUMAN LIVER;HUMAN UMBILICAL;IMPROVED OUTCOME;LYMPHOBLASTIC LEUKEMIA;MULTICENTRE STUDY;MULTIPLE LETTERS;MYOCARDIAL INFARCTION","5;5;5;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PATIENTS TREATED;PULMONARY HYPERTENSION;BLOOD PRESSURE;DENDRITIC CELLS;ENDOTHELIAL CELL;DE NOVO;NOVO APL;ACTIVATED LYMPHOCYTES;ANTI-CD ANTIBODIES;ANTIRETROVIRAL THERAPY;ARTERIAL BLOOD;CELL TROPISM;CHRONIC THROMBOEMBOLIC;SIGNIFICANT DIFFERENCE;ACUTE LYMPHOBLASTIC;ALPHA-ANTITRYPSIN DEFICIENCY;BARORECEPTOR STIMULATION;BIOLOGICAL PROPERTIES;BLOOD SAMPLES;BONE MARROW;CD COUNT;CELL CULTURES;CHROMOSOME ABERRATIONS;CLINICAL SAMPLES;EISENMENGER SYNDROME;FIBROUS PLAQUES;HIV INFECTION;IMMUNOCOMPROMISED PATIENTS;INDUCTION THERAPY;INTERNATIONAL REGISTRY","8;7;6;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",19,0.12,3,7.36,6,12.5,7.43,2,31,0,0,0,1,1,1,0,0,0,0,0,0,9,2,31,0,0,0,2,2,2,7.43,2,31,0,0,0,0,0,0,2,2,2,0,0,0,2,2,2,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,0,0,0,40,8,123,39.43,7,123,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2003,174,8.1264367816092,2.52298850574713,0.396355353075171,0.390804597701149,0.333333333333333,0.132183908045977,0.241379310344828,13,74,30,9,50,0.43,0.17,0.05,0.29,52.35,0.989092199346433,0.247126436781609,0.977011494252874,0,0.442382191602638,0.365126676602086,0.4,0.420454545454545,"CATHERINE KLERSY;LUIGI TAVAZZI;FAUSTO BALDANTI;RITA MACCARIO;GIUSEPPE GERNA;ANTONIA MORETTA;CARMINE TINELLI;FRANCO LOCATELLI;G RONDINI;MAURIZIO GASPARINI;UMBERTO MAGRINI;MARCO BENAZZO;CARLO CAMPANA;LUCA LANZARINI;ELOISA ARBUSTINI;ANNALISA DE SILVESTRI;CESARE DANESINO;EDOARDO GRONDA;MARCO PAULLI;CARLOMAURIZIO MONTECUCCO","16;11;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","LUIGI TAVAZZI;CATHERINE KLERSY;MARCO BENAZZO;DANIELE LILLERI;LORENZO MAGRASSI;FRANCO PIOVELLA;A. CUCCHI;MARCO ZECCA;N RUPERTO;GANCIA GP;REGISTRO OSSERVAZIONALE ANGINA INSTABILE INVESTIGATORS;ANTONELLA ROETTO;STANISLAO RIZZO;G KARDOS;B. ROVERETO;CARMINE TINELLI;GIUSEPPE GERNA;CARLO CAMPANA;ELOISA ARBUSTINI;CARLOMAURIZIO MONTECUCCO","3.15;1.82;1.46;1.26;1.17;1.17;1.12;1.05;1;1;1;1;1;1;0.95;0.84;0.83;0.79;0.76;0.76","CATHERINE KLERSY;LUIGI TAVAZZI;FAUSTO BALDANTI;RITA MACCARIO;GIUSEPPE GERNA;ANTONIA MORETTA;CARMINE TINELLI;FRANCO LOCATELLI;G RONDINI;UMBERTO MAGRINI;MARCO BENAZZO;CARLO CAMPANA;LUCA LANZARINI;ELOISA ARBUSTINI;ANNALISA DE SILVESTRI;CESARE DANESINO;MARCO PAULLI;CARLOMAURIZIO MONTECUCCO;RENATO MASERATI;MAURO RINALDI","16;11;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","LUIGI TAVAZZI;CATHERINE KLERSY;MARCO BENAZZO;DANIELE LILLERI;LORENZO MAGRASSI;FRANCO PIOVELLA;A. CUCCHI;MARCO ZECCA;N RUPERTO;GANCIA GP;REGISTRO OSSERVAZIONALE ANGINA INSTABILE INVESTIGATORS;ANTONELLA ROETTO;STANISLAO RIZZO;G KARDOS;B. ROVERETO;CARMINE TINELLI;GIUSEPPE GERNA;CARLO CAMPANA;ELOISA ARBUSTINI;CARLOMAURIZIO MONTECUCCO","3.15;1.82;1.46;1.26;1.17;1.17;1.12;1.05;1;1;1;1;1;1;0.95;0.84;0.83;0.79;0.76;0.76","CARLO NAPOLITANO;PETER J. SCHWARTZ;SILVIA G. PRIORI;ALESSANDRO VICENTINI;CARLA SPAZZOLINI;DONATA CAPPELLETTI;E RONCHETTI;GEORGIA BOTTELLI;JANNÌ NASTOLI;MASSIMILIANO GRILLO;RAFFAELLA BLOISE;ROBERTA FOLLI;CATHERINE KLERSY;IGNACE VERGOTE;L. GIURGEA;S. PECORELLI;SAVERIO TATEO;C. COENS;C. MADROÑAL;C. MANGIONI","1540;1540;1540;1415;1415;1415;1415;1415;1415;1415;1415;1415;998;664;664;664;664;643;643;643","ALESSANDRO VICENTINI;CATHERINE KLERSY;SAVERIO TATEO;CARLO L. BALDUINI;MARCO ZECCA;LUIGI TAVAZZI;FRANCO LOCATELLI;ALESSANDRO PECCI;PATRIZIA NORIS;MARCO PAULLI;CARMINE TINELLI;RITA MACCARIO;MARIA ANTONIETTA AVANZINI;FABRIZIO CALLIADA;PATRIZIA COMOLI;FAUSTO BALDANTI;GIOVANNA GIORGIANI;GIUSEPPE GERNA;CESARE PEROTTI;CLAUDIA DEL FANTE","1415;998;664;509;479;443;410;403;403;387;287;266;262;238;238;236;216;208;204;194","CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;FAUSTO BALDANTI;RITA MACCARIO;A. CUCCHI;CARMINE TINELLI;ELENA PERCIVALLE;ELOISA ARBUSTINI;LUCA LANZARINI;MARCO BENAZZO;MARIA GRAZIA REVELLO;MAURO RINALDI;PATRIZIA COMOLI;PATRIZIA MORBINI;ANTONIA MORETTA;CARLO CAMPANA;FRANCO LOCATELLI;RENATO MASERATI;ANNALISA DE SILVESTRI","15;10;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;PSYCHOLOGY;ART;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","158;67;13;13;7;4;4;4;4;3;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;CARDIOLOGY;PATHOLOGY;SURGERY;GASTROENTEROLOGY;BIOCHEMISTRY;VIROLOGY;PEDIATRICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;UROLOGY;RADIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;ANESTHESIA;DERMATOLOGY;PHARMACOLOGY","110;47;40;36;35;34;26;24;16;15;13;13;10;10;9;8;8;7;7;7","GENE;DISEASE;HEART FAILURE;IMMUNE SYSTEM;TRANSPLANTATION;VIRUS;ANTIBODY;IN VITRO;CANCER;ALTERNATIVE MEDICINE;CHEMOTHERAPY;MYOCARDIAL INFARCTION;POPULATION;ANTIGEN;HUMAN IMMUNODEFICIENCY VIRUS (HIV);RANDOMIZED CONTROLLED TRIAL;CYTOKINE;RECEPTOR;STEM CELL;ENZYME","31;19;16;15;15;15;13;13;12;9;9;9;9;8;8;8;7;7;7;6","CYTOTOXIC T CELL;T CELL;CHROMOSOME;EJECTION FRACTION;VIRAL DISEASE;VIRAL LOAD;CD8;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HUMAN CYTOMEGALOVIRUS;MONOCLONAL ANTIBODY;PHENOTYPE;MUTATION;AZATHIOPRINE;BASAL (MEDICINE);CARDIOMYOPATHY;CYCLOPHOSPHAMIDE;IMMUNOTHERAPY;INTERFERON GAMMA;KIDNEY TRANSPLANTATION;REVASCULARIZATION;RNA;UNIVARIATE ANALYSIS","9;9;7;7;7;7;6;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;HERPESVIRIDAE;KARYOTYPE;BK VIRUS;CYTOGENETICS;FLUORESCENCE IN SITU HYBRIDIZATION;ISCHEMIC CARDIOMYOPATHY;NATURAL KILLER CELL;SYNOVIAL FLUID;T-CELL RECEPTOR;ZIDOVUDINE;ACTIVE TUBERCULOSIS;ADOPTIVE CELL TRANSFER;ANDROGEN RECEPTOR;ANTI-NUCLEAR ANTIBODY;ANTIBODY TITER;ANTIGEN PRESENTATION;ANTIGEN-PRESENTING CELL;ATAXIA-TELANGIECTASIA;ATHERECTOMY;BENCE JONES PROTEIN;BENIGN PROSTATIC HYPERPLASIA (BPH);BILATERAL NEPHRECTOMY;BRADYCARDIA;BREAKPOINT;BREAST CARCINOMA;BRONCHIOLITIS OBLITERANS;BRONCHUS;BUSULFAN;CANDIDA KRUSEI;CATH LAB;CD40;CHEMOKINE RECEPTOR;CHLAMYDOPHILA PNEUMONIAE;CHROMOPHOBE CELL;CHROMOSOME 15;CHROMOSOME 7 (HUMAN);CHROMOSOME INSTABILITY;CMIN;CONNECTIVE TISSUE DISEASE;CORONARY RESTENOSIS;CTL*;DESTINATION THERAPY;DIABETES MANAGEMENT;DNA-BINDING PROTEIN;ENTEROCHROMAFFIN-LIKE CELL;ENTEROENDOCRINE CELL;EPIRUBICIN;ESOPHAGEAL MOTILITY DISORDER;ESOPHAGEAL SPASM;EXTRACORPOREAL PHOTOPHERESIS;FANCONI ANEMIA;FERROPORTIN;FINASTERIDE;FLUDARABINE;GANCICLOVIR;GENE DELIVERY;GENE MUTATION;GENE POLYMORPHISM;GENE PRODUCT;GENETICALLY MODIFIED MOUSE;GENOME INSTABILITY;GENOTYPING;GLYCOPROTEIN 130;GONADOTROPIN-RELEASING HORMONE;GROWTH HORMONE TREATMENT;HAMP;HELICASE;HEMORRHAGIC CYSTITIS;HEPACIVIRUS;HIV-1 PROTEASE;HYBRIDOMA TECHNOLOGY;IN SITU HYBRIDIZATION;INCREASED HEART RATE;INEFFECTIVE ERYTHROPOIESIS;INTERFERON Γ;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTESTINAL MALABSORPTION;JC VIRUS;JURKAT CELLS;KILLIP CLASS;LAMIVUDINE;LENTIVIRUS;LEUKOCYTE TRAFFICKING;LMNA;LOWER URINARY TRACT SYMPTOMS;LYMPHOEPITHELIOMA-LIKE CARCINOMA;MEGAKARYOCYTE;MISSENSE MUTATION;MONOCLONAL;NASBA;NESIRITIDE;NEUROPEPTIDE Y RECEPTOR;NUCLEAR PROTEIN;ONCOGENE;OPPORTUNISTIC INFECTION;ORTHOSTATIC INTOLERANCE;OXANDROLONE;PERCUTANEOUS ETHANOL INJECTION;PERIPHERAL BLOOD STEM CELLS;PERTUSSIS TOXIN;POLYCYSTIC OVARY;PROCESSIVITY;RENAL ONCOCYTOMA;RETINITIS;REVERSE TRANSCRIPTASE;RIBONUCLEOTIDE REDUCTASE;RNA-DEPENDENT RNA POLYMERASE;SECOND-HARMONIC IMAGING MICROSCOPY;SERUM AMYLOID A PROTEIN;SIDA;SLOW VIRUS;SMALL FOR GESTATIONAL AGE;SPLENIC MARGINAL ZONE LYMPHOMA;SUBSTANCE P;SYMBIOTIC BACTERIA;T HELPER CELL;TENECTEPLASE;THYMIDINE KINASE;TISSUE TROPISM;TROPHERYMA WHIPPLEI;TUBERCULIN TEST;VINCRISTINE;VINORELBINE","5;5;4;4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;HEART FAILURE;ADOLESCENT;CHILD;ITALY;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HIV-1;HIV INFECTIONS;INTERFERON-GAMMA;AGED, 80 AND OVER;CARCINOMA, SQUAMOUS CELL;LIVER NEOPLASMS","128;75;74;53;51;41;39;39;21;19;17;16;16;15;15;14;14;13;13;13","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;IMMUNOBIOLOGY OF DENDRITIC CELLS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;ORGAN TRANSPLANTATION AND REJECTION;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENOMIC IMPRINTING AND PARENTAL GENE EXPRESSION CONTROL;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA","6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;CARDIAC IMAGING;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;CYTOMEGALOVIRUS;HIV;MYOCARDIAL PERFUSION;ARRHYTHMIAS;BASAL (MEDICINE);BLADDER OUTLET OBSTRUCTION;EVEROLIMUS;HEMATOPOIETIC CELL TRANSPLANTATION;IMMUNOSUPPRESSION;LONG-QT SYNDROME;REFRACTORY (PLANETARY SCIENCE);REGIMEN;REVERSE-TRANSCRIPTASE INHIBITOR;ST-SEGMENT ELEVATION;UNIVARIATE ANALYSIS;","8;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;2","HEART FAILURE;HUMAN CYTOMEGALOVIRUS;TRANSPLANT RECIPIENTS;CARDIAC RESYNCHRONIZATION;CELL TRANSPLANTATION;INTENSIVE CARE;MYOCARDIAL INFARCTION;PERIPHERAL BLOOD;CONTRAST ECHOCARDIOGRAPHY;CORONARY ARTERY;DE NOVO;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;NOVO CARDIAC;STEM CELL;ACTIVE ANTIRETROVIRAL;ACUTE CORONARY;ACUTE PULMONARY;ARTERIAL MICROANASTOMOSES;ARTERY DISEASE;ATRIAL FIBRILLATION;BLOOD PROGENITOR;BRONCHOALVEOLAR LAVAGE;CANCER PATIENTS;CARDIAC TRANSPLANT;CARDIOVERTER DEFIBRILLATOR;CELL RESPONSE;CHRONIC HEART;DIABETES MELLITUS;DIPYRIDAMOLE STRESS","8;5;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PUBMED SCOPUS;CROSSREF PUBMED;REVERSE TRANSCRIPTASE;CELL RECEPTOR;DERMATOL -CROSSREF;MELAN-A AL;INVEST DERMATOL;ADJUVANT CHEMOTHERAPY;ANTIGEN RECOGNITION;RT MUTATIONS;HR CI;VITILIGO PATIENTS;CELLULAR IMMUNITY;EMG ACTIVITY;IMMUNOL -CROSSREF;MAJOR HISTOCOMPATIBILITY;PUBMED GOOGLE;RECOMBINANT HIV-;STATISTICALLY SIGNIFICANT;TURNER SYNDROME;AL PALERMO;ALSPECIFIC CYTOTOXIC;AMINO ACID;CELL CLONES;CELL LINES;CELL RECEPTORS;COMPLEXPEPTIDE TETRAMERS;HISTOCOMPATIBILITY COMPLEXPEPTIDE;HIV- STRAINS;LYMPHOCYTE RESPONSES","28;24;14;13;11;11;10;9;9;9;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6",23,0.13,3,15.5,6,57,4.83,2,10,0,0,0,0,0,0,0,0,0,7,7,7,2,1,3,0,0,0,2,1,3,5.5,2,10,0,0,0,0,0,0,0,0,0,0,0,0,4,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0.17,0,1,0,0,0,56.83,26,113,57,26,113,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2004,228,8.74561403508772,2.99122807017544,0.334310850439883,0.368421052631579,0.368421052631579,0.166666666666667,0.254385964912281,6,101,29,27,53,0.44,0.13,0.12,0.23,49.37,1.049288329066,0.219298245614035,0.978070175438597,0,0.45052459750883,0.452229696063777,0.462417994376757,0.467720685111989,"FRANCO LOCATELLI;LUIGI TAVAZZI;CATHERINE KLERSY;CARMINE TINELLI;CARLO CAMPANA;ANTONIO BRASCHI;GIUSEPPE GERNA;ELOISA ARBUSTINI;CESARE DANESINO;RITA MACCARIO;STEFANO GHIO;GIAMPAOLO MERLINI;EZIO BRAMUCCI;LAURA SCELSI;DIEGO ARDISSINO;MARIO CAZZOLA;MONIA MARCHETTI;GIOVANNI BAROSI;MARIA GRAZIA REVELLO;MARIO VIGANÒ","17;17;15;10;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6","LUIGI TAVAZZI;CATHERINE KLERSY;FRANCO LOCATELLI;ELOISA ARBUSTINI;STEFANO GHIO;GIAMPAOLO MERLINI;ANTONIO BRASCHI;STEFANIA PAOLUCCI;GIUSEPPE GERNA;CARMINE TINELLI;MARIO CAZZOLA;LAURA SCELSI;CARLO CAMPANA;MARIA GRAZIA REVELLO;G MARRA;GABRIELE VIA;GIULIO RUBERTO;ROSANGELA INVERNIZZI;MONIA MARCHETTI;MAURO RINALDI","3.74;1.85;1.8;1.74;1.67;1.63;1.48;1.28;1.2;1.17;1.15;1.02;1.02;1.02;1;1;1;0.9;0.9;0.78","FRANCO LOCATELLI;LUIGI TAVAZZI;CATHERINE KLERSY;CARMINE TINELLI;CARLO CAMPANA;ANTONIO BRASCHI;GIUSEPPE GERNA;ELOISA ARBUSTINI;CESARE DANESINO;RITA MACCARIO;STEFANO GHIO;GIAMPAOLO MERLINI;EZIO BRAMUCCI;LAURA SCELSI;DIEGO ARDISSINO;MARIO CAZZOLA;MONIA MARCHETTI;GIOVANNI BAROSI;MARIA GRAZIA REVELLO;MARIO VIGANÒ","17;17;15;10;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6","LUIGI TAVAZZI;CATHERINE KLERSY;FRANCO LOCATELLI;ELOISA ARBUSTINI;STEFANO GHIO;GIAMPAOLO MERLINI;ANTONIO BRASCHI;STEFANIA PAOLUCCI;GIUSEPPE GERNA;CARMINE TINELLI;MARIO CAZZOLA;LAURA SCELSI;CARLO CAMPANA;MARIA GRAZIA REVELLO;G MARRA;GABRIELE VIA;GIULIO RUBERTO;ROSANGELA INVERNIZZI;MONIA MARCHETTI;MAURO RINALDI","3.74;1.85;1.8;1.74;1.67;1.63;1.48;1.28;1.2;1.17;1.15;1.02;1.02;1.02;1;1;1;0.9;0.9;0.78","PETER J. SCHWARTZ;CARLO NAPOLITANO;RAFFAELLA BLOISE;SILVIA G. PRIORI;LUIGI TAVAZZI;CATHERINE KLERSY;HELEN TAGER‐FLUSBERG;IGOR SPLAWSKI;KAREN CONDOURIS;KATHERINE W. TIMOTHY;LEAH M. SHARPE;MARK T. KEATING;MICHAEL C. SANGUINETTI;NIELS DECHER;PRADEEP KUMAR;ROBERT M. JOSEPH;FRANCO LOCATELLI;ANDERS WALDENSTRÖM;ARNE WESTHEIM;ARTHUR M. FELDMAN","2245;2183;2183;2183;1996;1575;1521;1521;1521;1521;1521;1521;1521;1521;1521;1521;1199;1144;1144;1144","PETER J. SCHWARTZ;LUIGI TAVAZZI;CATHERINE KLERSY;FRANCO LOCATELLI;GAETANO MARIA DE FERRARI;GIUSEPPE GERNA;ANDREW E. EPSTEIN;ARTHUR J. MOSS;ATTILIO ODERO;CARLA SPAZZOLINI;CARLO NAPOLITANO;CUILAN LI;DAYI HU;JENNIFER L. ROBINSON;LAURI TOIVONEN;MARINA CERRONE;PAUL A. BRINK;RAFFAELLA BLOISE;SILVIA G. PRIORI;WILLIAM J. HALL","2183;1995;1575;813;735;680;662;662;662;662;662;662;662;662;662;662;662;662;662;662","LUIGI TAVAZZI;CATHERINE KLERSY;FRANCO LOCATELLI;CARLO CAMPANA;CARMINE TINELLI;ANTONIO BRASCHI;GIUSEPPE GERNA;ELOISA ARBUSTINI;RITA MACCARIO;STEFANO GHIO;MARIA GRAZIA REVELLO;EZIO BRAMUCCI;GIAMPAOLO MERLINI;ALESSANDRA REPETTO;FAUSTO BALDANTI;GIOVANNI BAROSI;CAMILLO PORTA;LAURA SCELSI;MONIA MARCHETTI;STEFANIA PAOLUCCI","17;15;15;9;8;8;8;7;7;7;6;6;5;5;5;5;5;5;5;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;MATHEMATICS;PHILOSOPHY;BUSINESS;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOLOGY","210;96;17;16;10;9;8;5;5;3;3;1;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;PEDIATRICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;MOLECULAR BIOLOGY;VIROLOGY;CANCER RESEARCH;ANESTHESIA;ENVIRONMENTAL HEALTH;ONCOLOGY;RADIOLOGY;OPTICS;ANATOMY;CELL BIOLOGY","154;66;58;54;47;37;30;25;23;19;18;18;18;17;15;12;12;12;11;10;10","GENE;DISEASE;TRANSPLANTATION;HEART FAILURE;STEM CELL;BONE MARROW;IMMUNE SYSTEM;ANTIBODY;CHEMOTHERAPY;MYOCARDIAL INFARCTION;HUMAN IMMUNODEFICIENCY VIRUS (HIV);LEUKEMIA;POPULATION;RANDOMIZED CONTROLLED TRIAL;CANCER;IN VITRO;VIRUS;ALTERNATIVE MEDICINE;ANTIGEN;CLINICAL TRIAL;DIABETES MELLITUS;INCIDENCE (GEOMETRY);PLATELET;PREGNANCY","37;34;30;23;18;17;16;14;13;13;12;12;12;11;10;10;10;8;8;8;8;8;8;8","HAEMATOPOIESIS;MUTATION;PHENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL DISEASE;VIRAL LOAD;ALLELE;CD34;EJECTION FRACTION;CD8;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;GENOTYPE;HUMAN LEUKOCYTE ANTIGEN;MYELODYSPLASTIC SYNDROMES;MYELOFIBROSIS;T CELL;CARDIOMYOPATHY;DILATED CARDIOMYOPATHY;HUMAN CYTOMEGALOVIRUS;IMMUNOGLOBULIN LIGHT CHAIN","13;11;10;9;9;8;7;7;7;5;5;5;5;5;5;5;5;4;4;4;4","ANTIRETROVIRAL THERAPY;FLUDARABINE;HAPLOTYPE;HERPESVIRIDAE;JUVENILE MYELOMONOCYTIC LEUKEMIA;LENTIVIRUS;THIOTEPA;ACUTE LYMPHOCYTIC LEUKEMIA;AL AMYLOIDOSIS;BONE MARROW TRANSPLANT;BRONCHIOLITIS OBLITERANS;BUSULFAN;CYTOGENETICS;FAS RECEPTOR;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IL-2 RECEPTOR;LEUKAPHERESIS;LIPOPROTEIN(A);MACE;PERFORIN;REVERSE TRANSCRIPTASE;RUBELLA;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SOMATIC HYPERMUTATION;THROMBOMODULIN;VASCULAR DEMENTIA;VESICOURETERAL REFLUX","8;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;ITALY;HIV INFECTIONS;ADOLESCENT;MYOCARDIAL INFARCTION;TREATMENT OUTCOME;CHILD;FOLLOW-UP STUDIES;FIBRINOLYTIC AGENTS;HIV-1;HEART FAILURE;POSTOPERATIVE COMPLICATIONS;ANTI-HIV AGENTS;CORONARY RESTENOSIS","156;97;94;64;61;60;45;35;29;26;26;26;22;20;18;18;16;16;15;15","HEMATOPOIETIC STEM CELL BIOLOGY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ORGAN TRANSPLANTATION AND REJECTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;HEPATITIS C INFECTION AND TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS","8;8;7;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3","TREATMENT;HEMATOPOIETIC CELL TRANSPLANTATION;HIV;CARDIAC IMAGING;ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;CORD BLOOD;DILATED CARDIOMYOPATHY;HEMATOLOGY;MYELOFIBROSIS;VENOUS THROMBOEMBOLISM;CORONARY STENTS;CYTOMEGALOVIRUS;DEEP VEIN THROMBOSIS;LEFT VENTRICULAR FUNCTION;POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE;TREATMENT OUTCOMES;ACUTE MYELOID LEUKEMIA;DIAGNOSIS","14;9;8;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3","HEART FAILURE;STEM CELL;CELL TRANSPLANTATION;TRANSPLANT RECIPIENTS;ACUTE MYOCARDIAL;HUMAN CYTOMEGALOVIRUS;ITALIAN REGISTRY;ITALIAN SOCIETY;MYOCARDIAL INFARCTION;ACTIVE ANTIRETROVIRAL;ANTIRETROVIRAL THERAPY;BONE MARROW;CARDIAC RESYNCHRONISATION;CELL CARCINOMA;CORD BLOOD;GROWTH HORMONE;HEMATOPOIETIC STEM;HIGHLY ACTIVE;JUVENILE MYELOMONOCYTIC;LUNG TRANSPLANT;MYELOID METAPLASIA;MYELOMONOCYTIC LEUKEMIA;PLASMA LEVELS;PULMONARY HYPERTENSION;RANDOMIZED TRIAL;RESYNCHRONISATION THERAPY;ABC PATIENTS;ACUTE LYMPHOBLASTIC;ADVANCED BREAST;ALZHEIMERS DISEASE","11;9;6;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","HEART FAILURE;APOLIPOPROTEIN A-I;MUTATION FREQUENCY;CHRONIC HEART;PATIENTS AFFECTED;TRANSPLANT RECIPIENTS;CORD BLOOD;PREEMPTIVE THERAPY;SINGLE BASE-PAIR;BASE-PAIR SUBSTITUTIONS;DABIGATRAN ETEXILATE;PATIENTS RECEIVING;PHENOTYPIC ASSAY;REVERSE TRANSCRIPTASE;STEM CELL;AMINO ACID;AUTOLOGOUS ALLOGENEIC;BONE MARROW;CYTOMEGALOVIRUS HCMV;DAILY MG;DNAEMIA CUTOFF;FAILURE PATIENTS;HEART TRANSPLANTATION;HUMAN CYTOMEGALOVIRUS;INFECTED PATIENTS;MMM PATIENTS;NEGATIVE PREDICTIVE;NON-COELIAC CONTROLS;PATIENTS TREATED;PERIODIC FEVER","19;9;9;8;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",27,0.12,3,12.86,6,39.506,10.78,2,46,1,1,1,5,5,5,0,0,0,2,2,2,11,1,46,0,0,0,1.2,1,2,11.44,2,46,1,1,1,1,1,1,5,5,5,0,0,0,5,2,8,0,0,0,0,0,0,4,4,4,1,1,1,0.11,0,1,0.44,0,2,131.56,19,638,132.11,19,640,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2005,298,8.78523489932886,3.03355704697987,0.329646017699115,0.379194630872483,0.409395973154362,0.10738255033557,0.281879194630872,12,153,37,22,66,0.51,0.12,0.07,0.22,44.16,0.834050023658012,0.295302013422819,0.976510067114094,0,0.492078949655362,0.458205551623811,0.488071284851969,0.478395061728395,"LUIGI TAVAZZI;FRANCO LOCATELLI;CARMINE TINELLI;CATHERINE KLERSY;MARIO LAZZARINO;MARIO REGAZZI;MAURIZIO LANDOLINA;ELOISA ARBUSTINI;MICHELE PASOTTI;CARLO CAMPANA;GAETANO MARIA DE FERRARI;ALDO P. MAGGIONI;P. VILLANI;PAOLO BERNASCONI;FAUSTO BALDANTI;RITA MACCARIO;ROBERTO RORDORF;GIAMPAOLO MERLINI;FOLCO FRATTINI;VITTORIO ROSTI","28;24;17;17;17;16;12;10;10;10;9;9;8;8;8;8;8;8;8;7","LUIGI TAVAZZI;VITTORIO ROSTI;CATHERINE KLERSY;FRANCO LOCATELLI;GAETANO BERGAMASCHI;LUCA MALCOVATI;MATTEO GIOVANNI DELLA PORTA;CARMINE TINELLI;RITA MACCARIO;MARIO LAZZARINO;MONIA MARCHETTI;MAURIZIO LANDOLINA;MARIO REGAZZI;MICHELE PASOTTI;CARLO CAMPANA;STEFANO GHIO;GIORGIO CIPRANDI;GIAN LUIGI MARSEGLIA;ELOISA ARBUSTINI;GAETANO MARIA DE FERRARI","5.5;3.33;2.75;2.41;2.18;2.08;2.08;2.02;1.68;1.66;1.44;1.4;1.33;1.27;1.27;1.25;1.2;1.2;1.03;1.02","LUIGI TAVAZZI;FRANCO LOCATELLI;CARMINE TINELLI;CATHERINE KLERSY;MARIO LAZZARINO;MARIO REGAZZI;MAURIZIO LANDOLINA;ELOISA ARBUSTINI;MICHELE PASOTTI;CARLO CAMPANA;GAETANO MARIA DE FERRARI;P. VILLANI;PAOLO BERNASCONI;FAUSTO BALDANTI;RITA MACCARIO;ROBERTO RORDORF;GIAMPAOLO MERLINI;FOLCO FRATTINI;VITTORIO ROSTI;GIANLUCA VIARENGO","28;24;17;17;17;16;12;10;10;10;9;8;8;8;8;8;8;8;7;7","LUIGI TAVAZZI;VITTORIO ROSTI;CATHERINE KLERSY;FRANCO LOCATELLI;GAETANO BERGAMASCHI;LUCA MALCOVATI;MATTEO GIOVANNI DELLA PORTA;CARMINE TINELLI;RITA MACCARIO;MARIO LAZZARINO;MONIA MARCHETTI;MAURIZIO LANDOLINA;MARIO REGAZZI;MICHELE PASOTTI;CARLO CAMPANA;STEFANO GHIO;GIAN LUIGI MARSEGLIA;ELOISA ARBUSTINI;GAETANO MARIA DE FERRARI;KATHARINA FLEISCHHAUER","5.5;3.33;2.75;2.41;2.18;2.08;2.08;2.02;1.68;1.66;1.44;1.4;1.33;1.27;1.27;1.25;1.2;1.03;1.02;1","LUIGI TAVAZZI;DIRK J. VAN VELDHUISEN;ROBERTO FERRARI;ALAIN COHEN‐SOLAL;ALEXANDER PARKHOMENKO;ANDREW J.S. COATS;DAN L. DUMITRAŞCU;JIŘÍ TOMAN;JORDI SOLER‐SOLER;JOSZEF BORBOLA;LENKA ŠPINAROVÁ;MARCELO C. SHIBATA;MARCUS FLATHER;MICHAEL BÖHM;PHILIP A. POOLE‐WILSON;PHILIPPE LECHAT;SIMON G. THOMPSON;STEFAN D. ANKER;MARIO LAZZARINO;MARIO CAZZOLA","3642;1970;1858;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1571;1188;1131","LUIGI TAVAZZI;MARIO CAZZOLA;MARIO LAZZARINO;PAOLO BERNASCONI;MARINA BONI;LUCA ARCAINI;FRANCO LOCATELLI;ROSANGELA INVERNIZZI;LUCA MALCOVATI;MATTEO GIOVANNI DELLA PORTA;CRISTIANA PASCUTTO;ERICA TRAVAGLINO;FRANCESCO PASSAMONTI;MARGHERITA MAFFIOLI;CATHERINE KLERSY;CARMINE TINELLI;FAUSTO BALDANTI;MARIA GRAZIA REVELLO;GIUSEPPE GERNA;DANIELE LILLERI","3241;1131;983;963;951;937;916;906;852;852;842;842;842;842;693;672;586;501;472;407","LUIGI TAVAZZI;FRANCO LOCATELLI;CARMINE TINELLI;CATHERINE KLERSY;MARIO LAZZARINO;MARIO REGAZZI;MAURIZIO LANDOLINA;CARLO CAMPANA;MICHELE PASOTTI;FAUSTO BALDANTI;GAETANO MARIA DE FERRARI;RITA MACCARIO;ELOISA ARBUSTINI;STEFANO GHIO;GIAMPAOLO MERLINI;GIOVANNI BAROSI;FOLCO FRATTINI;DANIELE LILLERI;PAOLO BERNASCONI;VITTORIO ROSTI","25;24;17;17;12;11;11;10;9;8;8;8;8;7;7;7;7;7;7;7","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;MATHEMATICS;GEOGRAPHY;PHILOSOPHY;ART;ENVIRONMENTAL SCIENCE;POLITICAL SCIENCE","272;111;25;23;11;9;5;5;3;3;3;2;2;1;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;SURGERY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ONCOLOGY;PEDIATRICS;VIROLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;RADIOLOGY;PHARMACOLOGY;ANESTHESIA;OPTICS;PHYSICAL THERAPY","231;81;77;61;59;56;50;30;29;23;23;23;22;19;16;16;15;13;12;10","TRANSPLANTATION;GENE;DISEASE;HEART FAILURE;BONE MARROW;IMMUNE SYSTEM;MYOCARDIAL INFARCTION;CHEMOTHERAPY;STEM CELL;BLOOD PRESSURE;CANCER;VIRUS;POPULATION;IN VITRO;LYMPHOMA;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INCIDENCE (GEOMETRY);REGIMEN;DIABETES MELLITUS;LEUKEMIA;RECEPTOR","49;47;37;34;24;22;19;18;18;17;17;17;16;15;14;13;12;12;11;11;11","HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;T CELL;CYCLOPHOSPHAMIDE;EJECTION FRACTION;VIRAL LOAD;CARDIOMYOPATHY;HAEMATOPOIESIS;PHENOTYPE;RITUXIMAB;VIRAL DISEASE;CD8;PERIPHERAL BLOOD MONONUCLEAR CELL;CHROMOSOME;CYTOPENIA;PLACEBO;ALLELE;CD34;CYTOTOXIC T CELL;DILATED CARDIOMYOPATHY;HUMAN CYTOMEGALOVIRUS;HUMAN LEUKOCYTE ANTIGEN;MYELODYSPLASTIC SYNDROMES","14;13;13;11;10;10;9;9;9;9;9;8;8;7;7;7;6;6;6;6;6;6;6","ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;CARDIAC RESYNCHRONIZATION THERAPY;FLUDARABINE;KARYOTYPE;MONOCLONAL;VINCRISTINE;BREAKPOINT;CTL*;GANCICLOVIR;HUMAN METAPNEUMOVIRUS;IMMUNOGLOBULIN M;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;PROBAND;ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE PROMYELOCYTIC LEUKEMIA;BRONCHIAL HYPERREACTIVITY;BRONCHIOLITIS OBLITERANS;CYTOGENETICS;DOPPLER ECHOCARDIOGRAPHY;ELISPOT;FLUORESCENCE IN SITU HYBRIDIZATION;GENE MUTATION;GROWTH HORMONE DEFICIENCY;IMATINIB MESYLATE;INTRA-AORTIC BALLOON PUMPING;JUVENILE MYELOMONOCYTIC LEUKEMIA;LEUKAPHERESIS;LOWER URINARY TRACT SYMPTOMS;LYMPHOPLASMACYTIC LYMPHOMA;MISSENSE MUTATION;POLYMORPHISM (COMPUTER SCIENCE);POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;SENTINEL LYMPH NODE;SENTINEL NODE;T-CELL RECEPTOR","7;6;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;;ADULT;MIDDLE AGED;AGED;CHILD;ITALY;ADOLESCENT;HIV INFECTIONS;HEART FAILURE;MYOCARDIAL INFARCTION;CHILD, PRESCHOOL;CYTOMEGALOVIRUS INFECTIONS;TREATMENT OUTCOME;HEMATOPOIETIC STEM CELL TRANSPLANTATION;RISK FACTORS;AGED, 80 AND OVER;ANTI-HIV AGENTS","192;132;128;97;82;76;51;41;37;36;35;32;32;29;23;22;21;20;19;18","ACUTE MYELOID LEUKEMIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;ORGAN TRANSPLANTATION AND REJECTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND TREATMENT OF HEART FAILURE;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;STANDARDISATION OF LOWER URINARY TRACT FUNCTION","9;9;9;8;7;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4","REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;ANTIRETROVIRAL THERAPY;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CYTOPENIA;HIV;TREATMENT;CYTOMEGALOVIRUS;DEEP VEIN THROMBOSIS;DILATED CARDIOMYOPATHY;ECHOCARDIOGRAPHY;ACUTE LYMPHOBLASTIC LEUKEMIA;CUMULATIVE INCIDENCE;LEFT VENTRICULAR FUNCTION;THERAPEUTIC DRUG MONITORING;TRANSFUSION THERAPY;UNIVARIATE ANALYSIS;CLINICAL ENDPOINT;DYSSYNCHRONY","12;11;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4","HEART FAILURE;STEM CELL;CELL TRANSPLANTATION;BONE MARROW;CHRONIC HEART;MARROW TRANSPLANTATION;MYOCARDIAL INFARCTION;HEMATOPOIETIC STEM;HUMAN CYTOMEGALOVIRUS;ACUTE LYMPHOBLASTIC;FAILURE PATIENTS;MYELOID METAPLASIA;RISK FACTORS;UNRELATED DONOR;ACUTE MYELOID;ACUTE MYOCARDIAL;ALLERGIC RHINITIS;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION;CYTOMEGALOVIRUS INFECTION;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;LEFT VENTRICULAR;LYMPHOBLASTIC LEUKEMIA;ADVANCED HEART;ALLERGIC INFLAMMATION;ALLOGENEIC HEMATOPOIETIC;CLINICAL EXPERIENCE;COELIAC DISEASE;DIABETES MELLITUS","22;15;12;10;9;8;8;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","AUTOLOGOUS EBV-SPECIFIC;PERIPHERAL BLOOD;HEART FAILURE;IRCCS POLICLINICO;MATTEO PAVIA;BLOOD PRESSURE;CTL LINES;EBV DNA;RF ABLATION;TRANSPLANT IMMUNOLOGY;TRANSPLANT RECIPIENTS;EBV-SPECIFIC CTL;EBV-SPECIFIC CTLS;HEMATOLOGYONCOLOGY IRCCS;IL- IL-;MONONUCLEAR CELLS;PAVIA ITALYSEARCH;PEDIATRIC HEMATOLOGYONCOLOGY;BLOOD MONONUCLEAR;EBV-RELATED PTLD;LEFT VENTRICULAR;PEDIATRIC NEPHROLOGY;PLATELET AGGREGATION;ABLATION LINE;ACTIVATION TIME;ADVERSE EVENTS;ALZHEIMER DISEASE;APOLIPOPROTEIN A-I;AUTOMATED RIBOTYPING;BIDIRECTIONAL ISTHMUS","13;13;12;10;10;9;9;9;9;9;9;8;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6",37,0.12,3,8.23,6,20.85,9.77,2,55,0,0,0,1,1,1,0,0,0,0,0,0,9.09,1,55,0,0,0,1.75,1,3,10.62,3,55,0,0,0,1,1,1,8,8,8,0,0,0,2.5,1,4,0,0,0,2,2,2,5,5,5,1,1,1,0,0,0,0,0,0,112.54,7,637,112.54,7,637,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2006,266,8.42857142857143,2.46992481203008,0.404870624048706,0.345864661654135,0.338345864661654,0.191729323308271,0.289473684210526,18,118,37,22,59,0.44,0.14,0.08,0.22,36.58,0.716062485136353,0.236842105263158,0.962406015037594,0,0.498264835226895,0.467997172222524,0.495497026338148,0.495403677058353,"LUIGI TAVAZZI;CATHERINE KLERSY;GIAN LUIGI MARSEGLIA;CARMINE TINELLI;GIOVANNI BAROSI;FRANCO LOCATELLI;GIORGIO CIPRANDI;MAURIZIO GASPARINI;STEFANO GHIO;L. SALVANESCHI;ANNALISA DE SILVESTRI;MAURIZIO LANDOLINA;MARIO LAZZARINO;IGNAZIO CIRILLO;CLAUDIA DEL FANTE;MARIA ANTONIETTA AVANZINI;MAURIZIO LUNATI;EDOARDO GRONDA;JOHN G.F. CLELAND;GIANLUCA VIARENGO","25;23;12;10;10;9;9;9;9;9;8;8;8;8;7;7;6;6;6;6","LUIGI TAVAZZI;NULL AUTHOR_ID;GIAMPIERO BELUFFI;CATHERINE KLERSY;STEFANO GHIO;GIAN LUIGI MARSEGLIA;GIOVANNI BAROSI;MAURO STRONATI;GIORGIO CIPRANDI;IGNAZIO CIRILLO;GIUSEPPE GERNA;MICHELE PASOTTI;ALESSANDRO CORSO;VINCENZO SEPE;SILVIA MANGIACAVALLI;PATRIZIA ZAPPASODI;ANDREA FOLI;L. SANTAMBROGIO;FRANCO LORI;LUCA MALCOVATI","4.67;4;3.25;2.89;1.99;1.93;1.75;1.5;1.48;1.35;1.32;1.25;1.16;1.12;1.05;1.05;1;1;1;1","LUIGI TAVAZZI;CATHERINE KLERSY;GIAN LUIGI MARSEGLIA;CARMINE TINELLI;GIOVANNI BAROSI;FRANCO LOCATELLI;MAURIZIO GASPARINI;STEFANO GHIO;L. SALVANESCHI;ANNALISA DE SILVESTRI;MAURIZIO LANDOLINA;MARIO LAZZARINO;CLAUDIA DEL FANTE;MARIA ANTONIETTA AVANZINI;MAURIZIO LUNATI;EDOARDO GRONDA;JOHN G.F. CLELAND;GIANLUCA VIARENGO;NICK FREEMANTLE;ORSETTA ZUFFARDI","25;23;12;10;10;9;9;9;9;8;8;8;7;7;6;6;6;6;6;6","LUIGI TAVAZZI;NULL AUTHOR_ID;GIAMPIERO BELUFFI;CATHERINE KLERSY;STEFANO GHIO;GIAN LUIGI MARSEGLIA;GIOVANNI BAROSI;MAURO STRONATI;GIUSEPPE GERNA;MICHELE PASOTTI;ALESSANDRO CORSO;VINCENZO SEPE;SILVIA MANGIACAVALLI;PATRIZIA ZAPPASODI;ANDREA FOLI;L. SANTAMBROGIO;FRANCO LORI;LUCA MALCOVATI;RENATO MASERATI;MATTEO GIOVANNI DELLA PORTA","4.67;4;3.25;2.89;1.99;1.93;1.75;1.5;1.32;1.25;1.16;1.12;1.05;1.05;1;1;1;1;1;1","LUIGI TAVAZZI;CATHERINE KLERSY;D L BRUTSAERT;FERENC FOLLÁTH;H. DREXLER;JOHAN LASSUS;JOSÉ LÓPEZ‐SENDÓN;KENNETH DICKSTEIN;M KOMAJDA;M. HOCHADEL;MARKKU S. NIEMINEN;PIOTR PONIKOWSKI;V.‐P. HARJOLA;MAURIZIO GASPARINI;GIOVANNI BAROSI;ANA CEBRIÁN;ANDREJS ĒRGLIS;BÉLA MERKELY;CECILIA FANTONI;CHRISTIAN SPAULDING","1671;1423;1216;1216;1216;1216;1216;1216;1216;1216;1216;1216;1216;677;596;571;571;571;571;571","LUIGI TAVAZZI;CATHERINE KLERSY;GIOVANNI BAROSI;EZIO BRAMUCCI;ESTER ORLANDI;ANNALISA DE SILVESTRI;MARCO PAULLI;P ALESSANDRINO;CESARE PEROTTI;CLAUDIA DEL FANTE;GAETANO BERGAMASCHI;CARMINE TINELLI;CARLOMAURIZIO MONTECUCCO;GIAN LUIGI MARSEGLIA;ROBERTO CAPORALI;ELOISA ARBUSTINI;MAURO RINALDI;GIUDITTA COMOLLI;LORENZO MAGRASSI;MAURIZIO LUISETTI","1671;1423;596;571;502;472;370;330;271;271;251;242;231;210;210;202;189;180;175;172","LUIGI TAVAZZI;CATHERINE KLERSY;CARMINE TINELLI;FRANCO LOCATELLI;GIAN LUIGI MARSEGLIA;GIOVANNI BAROSI;MAURIZIO LANDOLINA;STEFANO GHIO;ANNALISA DE SILVESTRI;L. SALVANESCHI;MARIO LAZZARINO;MARIA ANTONIETTA AVANZINI;CLAUDIA DEL FANTE;CESARE PEROTTI;GIAMPIERO BELUFFI;M. MARTINETTI;ELOISA ARBUSTINI;GIAMPAOLO MERLINI;GIUSEPPE GERNA;MARCO DANOVA","23;23;10;9;9;9;8;8;7;7;6;6;6;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;ECONOMICS;PSYCHOLOGY;POLITICAL SCIENCE;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;HISTORY","246;88;21;15;10;8;7;6;5;4;3;3;2;1","INTERNAL MEDICINE;IMMUNOLOGY;CARDIOLOGY;GENETICS;SURGERY;PATHOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;OPTICS;CANCER RESEARCH;RADIOLOGY;VIROLOGY;ANATOMY;PHARMACOLOGY;UROLOGY;CELL BIOLOGY;MOLECULAR BIOLOGY;PEDIATRICS","187;70;62;58;56;44;41;30;25;21;21;20;16;14;13;13;12;11;11;10;10;10","GENE;HEART FAILURE;TRANSPLANTATION;DISEASE;CHEMOTHERAPY;STEM CELL;CANCER;VIRUS;IMMUNE SYSTEM;INCIDENCE (GEOMETRY);POPULATION;BONE MARROW;BLOOD PRESSURE;MULTIPLE MYELOMA;IN VITRO;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNOSUPPRESSION;LYMPHOMA;RECEPTOR;ANTIBODY;ASTHMA;DIABETES MELLITUS;MYOCARDIAL INFARCTION","39;35;32;25;20;20;17;17;16;15;15;14;12;11;10;9;9;9;9;8;8;8;8","EJECTION FRACTION;VIRAL DISEASE;CD34;GENOTYPE;HAEMATOPOIESIS;MUTATION;VIRAL LOAD;ALLELE;CUMULATIVE INCIDENCE;HUMAN LEUKOCYTE ANTIGEN;T CELL;CD8;CELL CYCLE;GENE EXPRESSION;HEART TRANSPLANTATION;HUMAN CYTOMEGALOVIRUS;KIDNEY TRANSPLANTATION;OVARIAN CANCER;PHENOTYPE;SPIROMETRY","15;10;9;8;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5","CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;AL AMYLOIDOSIS;LAMIVUDINE;ALPHA (FINANCE);ASPARTATE TRANSAMINASE;BRONCHIAL HYPERREACTIVITY;CUTANEOUS T-CELL LYMPHOMA;CYTOGENETICS;DIFFUSING CAPACITY;DOPPLER ECHOCARDIOGRAPHY;EPIRUBICIN;FILGRASTIM;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;HAPLOTYPE;IMATINIB MESYLATE;IN SITU HYBRIDIZATION;KARYOTYPE;METHACHOLINE;MOLECULAR MEDICINE;ONCOGENE;SEED DORMANCY;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SUBLINGUAL IMMUNOTHERAPY;THYMOGLOBULIN;VINCRISTINE;ZIDOVUDINE","12;5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;;ADULT;MIDDLE AGED;AGED;HEART FAILURE;HIV INFECTIONS;ITALY;ADOLESCENT;CHILD;TREATMENT OUTCOME;ANTINEOPLASTIC AGENTS;CYTOMEGALOVIRUS INFECTIONS;CHILD, PRESCHOOL;ANTI-HIV AGENTS;FOLLOW-UP STUDIES;RETROSPECTIVE STUDIES;RHINITIS, ALLERGIC, PERENNIAL","162;102;99;98;73;68;58;41;36;34;33;27;27;21;21;18;17;17;16;15","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND TREATMENT OF HEART FAILURE;HEMATOPOIETIC STEM CELL BIOLOGY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MULTIPOTENT MESENCHYMAL STEM CELLS;;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ORGAN TRANSPLANTATION AND REJECTION;ROLE OF FIBROBLAST ACTIVATION IN CANCER PROGRESSION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;STANDARDISATION AND MANAGEMENT OF COPD;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS","13;8;7;7;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;2","TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY;ECHOCARDIOGRAPHY;HEMATOPOIETIC CELL TRANSPLANTATION;IMMUNOSUPPRESSION;CUMULATIVE INCIDENCE;GRAFT-VERSUS-HOST DISEASE;HIV INFECTION;MESENCHYMAL STEM CELLS;TRANSPLANTATION;CARDIAC IMAGING;CYTOMEGALOVIRUS;REFRACTORY (PLANETARY SCIENCE);REGIMEN;VENTRICULAR ARRHYTHMIAS;;ANTIRETROVIRAL THERAPY;DIAGNOSIS;HIV;RHINOMANOMETRY","12;11;10;9;9;6;6;6;6;6;5;5;5;5;5;4;4;4;4;4","HEART FAILURE;ACUTE HEART;FAILURE PATIENTS;BONE MARROW;STEM CELL;CELL TRANSPLANTATION;CARDIAC RESYNCHRONIZATION;CHRONIC HEART;GRAFT-VERSUS-HOST DISEASE;LEFT VENTRICULAR;OVARIAN CANCER;RESYNCHRONIZATION THERAPY;TRANSPLANT RECIPIENTS;ALLERGIC RHINITIS;ITALIAN SOCIETY;MARROW TRANSPLANTATION;ACUTE GRAFT-VERSUS-HOST;ACUTE MYOCARDIAL;ARTERY DISEASE;CANCER RESULTS;CORONARY ARTERY;CYTOMEGALOVIRUS INFECTION;HEART TRANSPLANT;HUMAN CYTOMEGALOVIRUS;IDIOPATHIC MYELOFIBROSIS;II STUDY;ITALIAN SURVEY;MESENCHYMAL STEM;MESENCHYMAL STROMAL;MULTIPOTENT MESENCHYMAL","27;10;8;7;7;6;5;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CD CD;HEART FAILURE;INTESTINAL A-GVHD;MYOCARDIAL INFARCTION;STEM CELL;ATRIAL FIBRILLATION;BONE MARROW;HYPERTENSIVE PATIENTS;LEFT VENTRICULAR;SIGNIFICANTLY LOWER;CELL TRANSPLANTATION;PERIPHERAL BLOOD;CD T-CELLS;GRAFT-VERSUS-HOST DISEASE;HCMV INFECTION;HCMV-SPECIFIC CD;BREAST MILK;CD CELLS;CD CTL;CHRONIC GVHD;EBV-SERONEGATIVE CHILDREN;EJECTION FRACTION;HF PATIENTS;HIGHLY ACTIVE;HR CI;MM HG;NEPHROTIC SYNDROME;PEDIATRIC PATIENTS;RHEUMATOID FACTOR;ACTIVE ANTIRETROVIRAL","15;13;10;10;10;9;9;9;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;5",27,0.1,3,8.18,6,20.08,8.92,1,39,0,0,0,1,1,1,0,0,0,1,1,1,12.29,1,39,0,0,0,2,1,3,9.58,1,39,0,0,0,1.5,1,2,0,0,0,0,0,0,1.5,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0.08,0,1,0.5,0,2,115.5,0,628,116.08,0,629,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2007,279,10.1218637992832,2.85663082437276,0.350062735257215,0.315412186379928,0.372759856630824,0.222222222222222,0.258064516129032,6,125,40,29,57,0.45,0.14,0.1,0.2,44.19,0.83724396532069,0.268817204301075,0.992831541218638,0,0.467791628050849,0.471362571989115,0.484126984126984,0.359661172161172,"CATHERINE KLERSY;LUIGI TAVAZZI;CARMINE TINELLI;GIAN LUIGI MARSEGLIA;GIOVANNI BAROSI;GIORGIO CIPRANDI;FRANCO LOCATELLI;MAURO STRONATI;ORSETTA ZUFFARDI;GIAMPIERO CAROSI;GIUSEPPE GERNA;GIAMPAOLO MERLINI;VITTORIO ROSTI;FAUSTO BALDANTI;RENATO MASERATI;MAURIZIO GASPARINI;ANTONIO DAL CANTON;STEFANO GHIO;GIULIA CAMPANINI;MARIA ANTONIETTA AVANZINI","30;15;14;12;11;10;9;8;8;8;8;8;7;6;6;6;6;6;6;6","CATHERINE KLERSY;MARILENA GREGORINI;GIOVANNI BAROSI;GIAN LUIGI MARSEGLIA;GIORGIO CIPRANDI;LUIGI TAVAZZI;CARMINE TINELLI;CESARE PEROTTI;MAURO STRONATI;GIUSEPPE GERNA;GIANLUCA FASOLI;GIAMPAOLO MERLINI;M. LUISETTI;F MERIGGI;GIULIA CAMPANINI;FRANCESCO BENAZZO;GAETANO MARIA DE FERRARI;RENATO MASERATI;FRANCO LOCATELLI;G. BORRONI","3.8;2.1;2.09;1.8;1.71;1.69;1.39;1.34;1.33;1.11;1.09;1;1;0.83;0.83;0.82;0.82;0.79;0.77;0.75","CATHERINE KLERSY;LUIGI TAVAZZI;CARMINE TINELLI;GIAN LUIGI MARSEGLIA;GIOVANNI BAROSI;FRANCO LOCATELLI;MAURO STRONATI;ORSETTA ZUFFARDI;GIUSEPPE GERNA;GIAMPAOLO MERLINI;VITTORIO ROSTI;FAUSTO BALDANTI;RENATO MASERATI;ANTONIO DAL CANTON;STEFANO GHIO;GIULIA CAMPANINI;MARIA ANTONIETTA AVANZINI;MAURIZIO LANDOLINA;MARIO LAZZARINO;L. MINOLI","30;15;14;12;11;9;8;8;8;8;7;6;6;6;6;6;6;6;6;6","CATHERINE KLERSY;MARILENA GREGORINI;GIOVANNI BAROSI;GIAN LUIGI MARSEGLIA;LUIGI TAVAZZI;CARMINE TINELLI;CESARE PEROTTI;MAURO STRONATI;GIUSEPPE GERNA;GIANLUCA FASOLI;GIAMPAOLO MERLINI;M. LUISETTI;F MERIGGI;GIULIA CAMPANINI;FRANCESCO BENAZZO;GAETANO MARIA DE FERRARI;RENATO MASERATI;FRANCO LOCATELLI;G. BORRONI;IGNAZIO CIRILLO","3.8;2.1;2.09;1.8;1.69;1.39;1.34;1.33;1.11;1.09;1;1;0.83;0.83;0.82;0.82;0.79;0.77;0.75;0.75","CARMINE TINELLI;CATHERINE KLERSY;SANDRO ROSSI;EMANUELA ROLLE;LUIGI SOLBIATI;M. STASI;MARIA FRANCA MELONI;TITO LIVRAGHI;LUIGI TAVAZZI;GIOVANNI BAROSI;FRANCO PIOVELLA;GIAMPAOLO MERLINI;TIZIANO BARBUI;ORSETTA ZUFFARDI;HERVÉ DECOUSUS;OMBRETTA LUINETTI;ALOK S. PACHORI;ARJUN DEB;HUI MU;LUNAN ZHANG","1576;1118;1065;1059;1059;1059;1059;1059;760;757;634;627;625;601;547;527;522;522;522;522","CARMINE TINELLI;CATHERINE KLERSY;SANDRO ROSSI;LUIGI TAVAZZI;FRANCO PIOVELLA;GIAMPAOLO MERLINI;OMBRETTA LUINETTI;MASSIMILIANO GNECCHI;GIOVANNI BAROSI;FAUSTO BALDANTI;S. CORONA;VITTORIO ROSTI;GAETANO MARIA DE FERRARI;MARGHERITA MASSA;GIUSEPPE GERNA;GAETANO BERGAMASCHI;ORSETTA ZUFFARDI;P MARASCHIO;GIULIA CAMPANINI;FRANCESCA ROVIDA","1559;1069;1065;760;634;609;527;522;502;450;420;394;389;377;337;322;322;278;272;262","CATHERINE KLERSY;LUIGI TAVAZZI;CARMINE TINELLI;FRANCO LOCATELLI;GIOVANNI BAROSI;GIAMPAOLO MERLINI;GIAN LUIGI MARSEGLIA;GIUSEPPE GERNA;VITTORIO ROSTI;MAURO STRONATI;FAUSTO BALDANTI;MAURIZIO LANDOLINA;STEFANO GHIO;GIULIA CAMPANINI;ORSETTA ZUFFARDI;RENATO MASERATI;MARIA ANTONIETTA AVANZINI;FRANCESCA ROVIDA;FRANCO PIOVELLA;ANTONIO DAL CANTON","28;15;12;10;10;7;7;7;7;7;6;6;6;6;6;6;6;5;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;ENGINEERING;SOCIOLOGY;PHILOSOPHY;ECONOMICS;GEOLOGY;PSYCHOLOGY;GEOGRAPHY;HISTORY;POLITICAL SCIENCE","256;113;22;19;12;9;8;7;6;5;4;2;2;1;1;1","INTERNAL MEDICINE;IMMUNOLOGY;GENETICS;SURGERY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;PEDIATRICS;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;ANESTHESIA;RADIOLOGY;ENVIRONMENTAL HEALTH;OPTICS;PHARMACOLOGY;VIROLOGY;CANCER RESEARCH;CELL BIOLOGY","193;74;70;56;49;42;39;32;25;24;24;19;18;16;15;14;14;14;13;12","GENE;DISEASE;TRANSPLANTATION;HEART FAILURE;BONE MARROW;STEM CELL;CANCER;IMMUNE SYSTEM;BLOOD PRESSURE;ANTIBODY;HUMAN IMMUNODEFICIENCY VIRUS (HIV);CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);POPULATION;IN VITRO;MYOCARDIAL INFARCTION;PREGNANCY;CHEMOTHERAPY;RECEPTOR;VIRUS","47;28;28;26;21;20;19;17;16;15;15;14;14;13;12;12;12;11;11;11","VIRAL LOAD;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;CHROMOSOME;CD34;MYELOFIBROSIS;GENOTYPE;HAEMATOPOIESIS;HAZARD RATIO;CARDIOMYOPATHY;RESPIRATORY TRACT INFECTIONS;T CELL;CYCLOPHOSPHAMIDE;GRAFT-VERSUS-HOST DISEASE;IMATINIB;PHENOTYPE;UNIVARIATE ANALYSIS;BREAST CANCER;CHEMOKINE;CHROMOSOMAL TRANSLOCATION;DIASTOLE;GENE EXPRESSION;GENOME;GESTATIONAL AGE;HUMAN LEUKOCYTE ANTIGEN;IMMUNOTHERAPY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);PERIPHERAL BLOOD MONONUCLEAR CELL;POLYMERASE CHAIN REACTION;PROGENITOR CELL;VENOUS THROMBOEMBOLISM","17;13;12;12;11;10;10;7;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;KARYOTYPE;BREAKPOINT;BUSULFAN;IMATINIB MESYLATE;CYTOGENETICS;CORONAVIRUS DISEASE 2019 (COVID-19);FLUDARABINE;IL-2 RECEPTOR;SMALL FOR GESTATIONAL AGE;ANTI-NUCLEAR ANTIBODY;CHEMOKINE RECEPTOR;CXCR4;DASATINIB;DIFFUSING CAPACITY;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;EPIRUBICIN;FONDAPARINUX;GENOTYPING;HAPLOTYPE;HERPESVIRIDAE;HIV-1 PROTEASE;HUMAN METAPNEUMOVIRUS;POINT MUTATION;PROBAND;RUXOLITINIB;SPLENIC MARGINAL ZONE LYMPHOMA;SUBLINGUAL IMMUNOTHERAPY","11;10;7;5;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;;AGED;HIV INFECTIONS;ITALY;TREATMENT OUTCOME;ADOLESCENT;CHILD;HEART FAILURE;ANTI-HIV AGENTS;VENTRICULAR DYSFUNCTION, LEFT;CHILD, PRESCHOOL;ANIMALS;INFANT;PROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS","193;131;130;85;83;73;52;50;44;43;41;30;30;28;27;24;23;23;23;19","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HEMATOPOIETIC STEM CELL BIOLOGY;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;EPIDEMIOLOGY AND PATHOGENESIS OF RESPIRATORY VIRAL INFECTIONS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;ORGAN TRANSPLANTATION AND REJECTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;BONE TISSUE ENGINEERING AND BIOMATERIALS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EFFICACY AND RESISTANCE IN CML TREATMENT;IMMUNOBIOLOGY OF DENDRITIC CELLS","13;9;7;6;6;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3","CARDIAC RESYNCHRONIZATION THERAPY;TREATMENT;DYSSYNCHRONY;HEMATOPOIETIC CELL TRANSPLANTATION;ANTIRETROVIRAL THERAPY;ETIOLOGY;HIV INFECTION;BREAKPOINT;IMATINIB MESYLATE;MYELOFIBROSIS;UNIVARIATE ANALYSIS;VENTRICULAR DYSSYNCHRONY;CHROMOSOME DUPLICATION;ECHOCARDIOGRAPHY;EPIDURAL ANALGESIA;GRAFT-VERSUS-HOST DISEASE;HEART RATE VARIABILITY;HIV;IMMUNOSUPPRESSION;LEFT VENTRICULAR DYSFUNCTION","11;9;8;8;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","HEART FAILURE;STEM CELL;CARDIAC RESYNCHRONIZATION;LEFT VENTRICULAR;RESYNCHRONIZATION THERAPY;CELL TRANSPLANTATION;HEMATOPOIETIC STEM;MYOCARDIAL INFARCTION;TRANSPLANT RECIPIENTS;ACUTE CORONARY;ICD ITALIAN;MARROW TRANSPLANTATION;ACUTE RHINOSINUSITIS;ALLERGIC RHINITIS;CARE UNIT;CD CELLS;CHRONIC MYELOID;CHRONIC THROMBOEMBOLIC;CONDITIONING REGIMEN;CORONARY ARTERY;CORONARY SYNDROMES;HIV-POSITIVE PATIENTS;HUMAN OSTEOBLASTS;IDIOPATHIC ARTHRITIS;INSYNCINSYNC ICD;INTENSIVE CARE;ITALIAN REGISTRY;JUVENILE IDIOPATHIC;LONGITUDINAL STUDY;MYELODYSPLASTIC SYNDROMES","14;13;8;8;8;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;STEM CELL;PERIPHERAL BLOOD;BONE MARROW;IMMUNOL -CROSSREF;CD T-CELL;SIGNIFICANTLY LOWER;SPOTS CELLS;AMYLOID FIBRILS;CELL TRANSPLANTATION;CELL COUNT;LEFT VENTRICULAR;PATIENTS TREATED;AMYLOID DEPOSITION;MARROW BIOPSY;COLLAGEN FIBERS;DE STEFANO;GRAFT DYSFUNCTION;LV DYSSYNCHRONY;PG PBMC;PROTEIN SCI;PUBMED GOOGLE;PURKINJE CELLS;SCI -CROSSREF;ATOMIC FORCE;CONFIDENCE INTERVAL;FIBRILLAR COLLAGEN;IFNΓ-PRODUCING CELLS;PROTEIN SOLUTION","84;60;18;17;16;16;15;14;12;11;11;10;10;10;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7",31,0.11,3,9.66,6,25.544,5.1,2,10,0,0,0,1.5,1,2,0,0,0,1,1,1,2.67,1,5,0,0,0,1.33,1,2,5.4,2,11,0,0,0,1,1,1,5,5,5,0,0,0,3,1,5,0,0,0,2,2,2,1,1,1,2,2,2,0.5,0,3,0,0,0,100.1,14,279,100.6,15,279,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2008,333,9.99099099099099,2.59459459459459,0.385416666666667,0.315315315315315,0.309309309309309,0.201201201201201,0.339339339339339,16,168,65,16,51,0.5,0.2,0.05,0.15,100.7,1.83512417991608,0.324324324324324,0.984984984984985,0,0.502473547063986,0.452500933184024,0.528036066497605,0.426482213438735,"CATHERINE KLERSY;LUIGI TAVAZZI;FRANCO LOCATELLI;CARMINE TINELLI;MAURIZIO LANDOLINA;ANGELO RAVELLI;ELOISA ARBUSTINI;ALBERTO MARTINI;GIUSEPPE GERNA;SILVIA MAGNI‐MANZONI;CARLO CAMPANA;MICHELE PASOTTI;PETER J. SCHWARTZ;GIORGIO CIPRANDI;STEFANO GHIO;MARCO ZECCA;MAURIZIO GASPARINI;MARIA ANTONIETTA AVANZINI;ALDO P. MAGGIONI;MAURIZIO LUNATI","30;23;17;15;14;12;11;11;11;10;10;9;9;9;9;8;8;8;8;7","GIAMPIERO BELUFFI;CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;CARMINE TINELLI;FILIPPO MANGIONE;FABRIZIO GROSJEAN;FRANCO LOCATELLI;MAURIZIO LANDOLINA;GIORGIO CIPRANDI;BÁRBARA GARDELLA;MARIO CAZZOLA;MARIO U. MONDELLI;DANIELE LILLERI;ANGELO RAVELLI;PETER J. SCHWARTZ;CARLO CAMPANA;I. BIANCHESSI;GIANLUCA FASOLI;COLLOVÀ","4.53;3.38;2.5;2.07;2.04;2;2;1.96;1.67;1.37;1.24;1.24;1.21;1.06;1.05;1.04;1.04;1;1;1","CATHERINE KLERSY;LUIGI TAVAZZI;FRANCO LOCATELLI;CARMINE TINELLI;MAURIZIO LANDOLINA;ELOISA ARBUSTINI;GIUSEPPE GERNA;SILVIA MAGNI‐MANZONI;CARLO CAMPANA;MICHELE PASOTTI;PETER J. SCHWARTZ;STEFANO GHIO;MARCO ZECCA;MARIA ANTONIETTA AVANZINI;CARLOMAURIZIO MONTECUCCO;RENATO MASERATI;GIAN LUIGI MARSEGLIA;ORSETTA ZUFFARDI;MAURIZIA GRASSO;GIOVANNI BAROSI","30;23;17;15;14;11;11;10;10;9;9;9;8;8;7;7;7;7;7;7","GIAMPIERO BELUFFI;CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;CARMINE TINELLI;FILIPPO MANGIONE;FABRIZIO GROSJEAN;FRANCO LOCATELLI;MAURIZIO LANDOLINA;BÁRBARA GARDELLA;MARIO CAZZOLA;MARIO U. MONDELLI;DANIELE LILLERI;PETER J. SCHWARTZ;CARLO CAMPANA;I. BIANCHESSI;GIANLUCA FASOLI;COLLOVÀ;LUIGI VILLA;MARIAROSA ARRA","4.53;3.38;2.5;2.07;2.04;2;2;1.96;1.67;1.24;1.24;1.21;1.06;1.04;1.04;1;1;1;1;1","LUIGI BOLONDI;ALEJANDRO FORNER;ANDRÉ COSME DE OLIVEIRA;ARMANDO SANTORO;CAMILLO PORTA;D. VOLIOTIS;DIETER HÄUSSINGER;EDWARD GANE;IVAN BORBATH;JEAN FRANÇOIS SEITZ;JEAN FRÉDÉRIC BLANC;JEAN‐LUC RAOUL;JORDI BRUIX;JOSEP M. LLOVET;M. MOSCOVICI;MINGHUA SHAN;MYRON SCHWARTZ;PETER R. GALLE;PHILIP HILGARD;SERGIO RICCI","12473;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718;11718","CAMILLO PORTA;FRANCO LOCATELLI;MARIA ESTER BERNARDO;CATHERINE KLERSY;LUIGI TAVAZZI;STEFANO GHIO;GIOVANNI BAROSI;SAVERIO TATEO;MAURIZIO LANDOLINA;CARLO CAMPANA;PETER J. SCHWARTZ;MARIO VIGANÒ;ORSETTA ZUFFARDI;GAETANO MARIA DE FERRARI;CARLO FÌLICE;CHIARA FERRANDI;ATTILIO ODERO;MICHELE PASOTTI;ALESSANDRA SERIO;LIA CROTTI","11718;3015;2613;2245;2035;1856;1714;1468;1137;1104;1075;938;914;822;755;742;703;690;688;662","CATHERINE KLERSY;LUIGI TAVAZZI;MAURIZIO LANDOLINA;CARMINE TINELLI;FRANCO LOCATELLI;GIUSEPPE GERNA;SILVIA MAGNI‐MANZONI;CARLO CAMPANA;ELOISA ARBUSTINI;MICHELE PASOTTI;STEFANO GHIO;MARCO ZECCA;PETER J. SCHWARTZ;GIOVANNI BAROSI;MARIA ANTONIETTA AVANZINI;ORSETTA ZUFFARDI;GIAMPIERO BELUFFI;MARIO VIGANÒ;MAURIZIA GRASSO;MAURO STRONATI","30;21;13;13;12;11;10;9;9;9;9;8;8;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;PHILOSOPHY;MATERIALS SCIENCE;POLITICAL SCIENCE;ECONOMICS;ART;GEOGRAPHY;HISTORY;SOCIOLOGY;BUSINESS;GEOLOGY","294;129;29;24;18;17;16;11;7;6;4;3;2;2;2;2;1;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;CARDIOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;VIROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;ONCOLOGY;PEDIATRICS;RADIOLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;ANATOMY;PHARMACOLOGY;PSYCHIATRY;CELL BIOLOGY;ENVIRONMENTAL HEALTH","217;87;83;72;63;49;46;33;30;24;24;23;23;22;19;16;16;15;14;13","GENE;HEART FAILURE;TRANSPLANTATION;DISEASE;VIRUS;CHEMOTHERAPY;STEM CELL;BONE MARROW;IMMUNE SYSTEM;BLOOD PRESSURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);ANTIBODY;POPULATION;RHEUMATOLOGY;ARTHRITIS;ATRIAL FIBRILLATION;LEUKEMIA;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;DIABETES MELLITUS;IN VITRO","57;49;30;29;24;22;21;20;20;16;15;14;14;14;13;13;13;13;12;12;12","EJECTION FRACTION;VIRAL LOAD;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;HUMAN CYTOMEGALOVIRUS;CHROMOSOME;HAEMATOPOIESIS;PHENOTYPE;VIRAL DISEASE;CARDIOMYOPATHY;GENOTYPE;ALLELE;CYCLOPHOSPHAMIDE;MYELOFIBROSIS;CD8;HAZARD RATIO;HUMAN LEUKOCYTE ANTIGEN;T CELL;CD34;DIASTOLE;HEART TRANSPLANTATION;MYELODYSPLASTIC SYNDROMES","25;15;14;13;11;10;10;10;10;9;9;8;8;8;7;7;7;7;6;6;6;6","CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;KARYOTYPE;PROBAND;BREAKPOINT;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LAMIVUDINE;PRENATAL DIAGNOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;ADULT STEM CELL;AL AMYLOIDOSIS;ALLELE FREQUENCY;BLADDER PAIN SYNDROME;BUSULFAN;COMPARATIVE GENOMIC HYBRIDIZATION;CONNECTIVE TISSUE DISEASE;COPY-NUMBER VARIATION;CYTOGENETICS;EPIRUBICIN;FILGRASTIM;FLUDARABINE;HAPLOINSUFFICIENCY;HEART RATE VARIABILITY;HEMATOPOIETIC CELL;LMNA;MACE;MICRODELETION SYNDROME;MISSENSE MUTATION;STROKE VOLUME;SUBLINGUAL IMMUNOTHERAPY;VAGUS NERVE STIMULATION;VINCRISTINE","20;9;9;7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;HEART FAILURE;ITALY;ADOLESCENT;TREATMENT OUTCOME;HIV INFECTIONS;CHILD;VENTRICULAR DYSFUNCTION, LEFT;FOLLOW-UP STUDIES;AGED, 80 AND OVER;CARDIAC PACING, ARTIFICIAL;CHILD, PRESCHOOL;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES","208;155;133;112;93;93;79;76;48;41;41;37;30;27;23;22;22;22;22;22","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;ACUTE MYELOID LEUKEMIA;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;INDUCTION AND DIFFERENTIATION OF PLURIPOTENT STEM CELLS;LYMPHOID NEOPLASMS;MULTIPOTENT MESENCHYMAL STEM CELLS;NATURAL KILLER CELLS IN IMMUNITY;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY","24;15;11;10;8;7;6;6;6;5;5;5;5;5;5;5;5;5;4;4","CARDIAC RESYNCHRONIZATION THERAPY;TREATMENT;ECHOCARDIOGRAPHY;JUVENILE IDIOPATHIC ARTHRITIS;SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS;ANTIRETROVIRAL THERAPY;CYTOMEGALOVIRUS;LEFT VENTRICULAR DYSFUNCTION;CARDIAC IMAGING;DYSSYNCHRONY;HEMATOPOIETIC CELL TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;MYELOFIBROSIS;ANTIVIRAL THERAPY;CORD BLOOD;DIAGNOSIS;DILATED CARDIOMYOPATHY;ETIOLOGY;HIV;ATRIAL FIBRILLATION","24;16;15;10;10;8;8;8;7;7;7;7;7;6;6;6;6;6;6;5","HEART FAILURE;CARDIAC RESYNCHRONIZATION;LEFT VENTRICULAR;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;RESYNCHRONIZATION THERAPY;STEM CELL;HUMAN CYTOMEGALOVIRUS;ATRIAL FIBRILLATION;ARTHRITIS JIA;CELL TRANSPLANTATION;FAILURE PATIENTS;CORD BLOOD;HEART RATE;HEMATOPOIETIC STEM;MULTIPLE MYELOMA;PATIENTS TREATED;PRIMARY MYELOFIBROSIS;STEM CELLS;ADVANCED HEART;CHRONIC HEART;CHRONIC HEPATITIS;HEPATOCELLULAR CARCINOMA;NORTHERN ITALY;PATIENTS UNDERGOING;PERIPHERAL BLOOD;VIRUS INFECTION;BONE MARROW;BONE MARROW-DERIVED;CARDIOCENTRO TICINO","30;11;11;10;10;10;10;8;7;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3","PUBMED SCOPUS;IGA NEPHROPATHY;CROSSREF PUBMED;STEM CELL;HEART FAILURE;HUMAN CYTOMEGALOVIRUS;STEM CELLS;BONE MARROW;GRAFT-VERSUS-HOST DISEASE;HEALTHY CONTROLS;PEGYLATED INTERFERON;UNIPARENTAL DISOMY;CELL TRANSPLANTATION;CONFIDENCE INTERVAL;IDIOPATHIC NEPHROTIC;LYSIS SYNDROME;MESENCHYMAL STEM;MYELODYSPLASTIC SYNDROME;TUMOR LYSIS;CONCURRENT ABACAVIR;CYTOMEGALOVIRUS INFECTION;MULTIVARIATE ANALYSIS;NEPHROTIC SYNDROME;CD T-CELL;CORD BLOOD;FUNCTIONAL CLASS;HCMV INFECTION;LV DYSSYNCHRONY;MIXED CHIMERISM;MONONUCLEAR CELLS","35;25;23;17;16;15;14;13;13;13;12;12;11;11;11;10;10;10;10;9;9;9;9;8;8;8;8;8;8;8",36,0.11,6,20.73,11.85,40.46,14.11,2,50,1,1,1,1.25,1,2,1,1,1,1.5,1,3,17.2,1,50,0,0,0,1.75,1,2,14.67,2,50,0,0,0,0,0,0,2.33,1,4,0,0,0,1.33,1,2,1,1,1,1,1,1,1.4,1,3,1,1,1,0.22,0,1,0.22,0,1,307.56,111,1014,308,111,1016,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2009,368,9.5054347826087,3.10597826086957,0.321959755030621,0.361413043478261,0.342391304347826,0.293478260869565,0.320652173913043,15,178,61,38,65,0.48,0.17,0.1,0.18,41.22,0.891047696429699,0.277173913043478,0.991847826086957,0,0.490798229998954,0.409766701603199,0.472254335260116,0.458542133134307,"FRANCO LOCATELLI;CATHERINE KLERSY;CARMINE TINELLI;ELOISA ARBUSTINI;GIAMPIERO BELUFFI;LUIGI TAVAZZI;GINO ROBERTO CORAZZA;PETER J. SCHWARTZ;GIUSEPPE GERNA;MAURO STRONATI;ARSENIO SPINILLO;STEFANO GHIO;ANTONIO GASBARRINI;MATTEO GIOVANNI DELLA PORTA;MARIO VIGANÒ;VITTORIO ROSTI;MARCO ZECCA;GIOVANNI BAROSI;ANNALISA DE SILVESTRI;FRANCESCO PASSAMONTI","23;23;16;15;12;12;12;11;11;10;10;10;9;9;9;8;8;8;7;7","GIAMPIERO BELUFFI;ANTONIO GASBARRINI;CATHERINE KLERSY;FRANCO LOCATELLI;GINO ROBERTO CORAZZA;PETER J. SCHWARTZ;GIUSEPPE GERNA;CARMINE TINELLI;ELOISA ARBUSTINI;MATTEO GIOVANNI DELLA PORTA;ANTONIETTA MARCHI;ARSENIO SPINILLO;MARIO VIGANÒ;MARIO CAZZOLA;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;ESTER ORLANDI;EMILIO PAOLO ALESSANDRINO;PAOLO BERNASCONI;FAUSTO BALDANTI","8.75;2.75;2.29;2.08;2.06;1.98;1.95;1.92;1.87;1.64;1.55;1.53;1.41;1.38;1.36;1.22;1.19;1.19;1.17;1.12","FRANCO LOCATELLI;CATHERINE KLERSY;CARMINE TINELLI;ELOISA ARBUSTINI;GIAMPIERO BELUFFI;LUIGI TAVAZZI;GINO ROBERTO CORAZZA;PETER J. SCHWARTZ;GIUSEPPE GERNA;MAURO STRONATI;ARSENIO SPINILLO;STEFANO GHIO;MATTEO GIOVANNI DELLA PORTA;MARIO VIGANÒ;VITTORIO ROSTI;MARCO ZECCA;GIOVANNI BAROSI;ANNALISA DE SILVESTRI;FRANCESCO PASSAMONTI;SILVIA MAGNI‐MANZONI","23;23;16;15;12;12;12;11;11;10;10;10;9;9;8;8;8;7;7;7","GIAMPIERO BELUFFI;CATHERINE KLERSY;FRANCO LOCATELLI;GINO ROBERTO CORAZZA;PETER J. SCHWARTZ;GIUSEPPE GERNA;CARMINE TINELLI;ELOISA ARBUSTINI;MATTEO GIOVANNI DELLA PORTA;ANTONIETTA MARCHI;ARSENIO SPINILLO;MARIO VIGANÒ;MARIO CAZZOLA;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;ESTER ORLANDI;EMILIO PAOLO ALESSANDRINO;PAOLO BERNASCONI;FAUSTO BALDANTI;MARIA CHIARA LEONI","8.75;2.29;2.08;2.06;1.98;1.95;1.92;1.87;1.64;1.55;1.53;1.41;1.38;1.36;1.22;1.19;1.19;1.17;1.12;1.1","PETER J. SCHWARTZ;STEFANO GHIO;LUIGI TAVAZZI;CATHERINE KLERSY;FRANCO LOCATELLI;GIOVANNI MARTINELLI;GIUSEPPE GERNA;LUCA ARCAINI;CRISTINA BASSO;GAETANO THIENE;A. BIFFI;ANTONIO PELLICCIA;ARIS ANASTASAKIS;ASTERIOS DELIGIANNIS;B. J. MARON;DOMENICO CORRADO;DORIAN DUGMORE;ERIK EKKER SOLBERG;FRANÇOIS CARRÉ;GIANFRANCO BUJA","1513;1162;1145;1030;978;910;865;804;796;796;793;793;793;793;793;793;793;793;793;793","PETER J. SCHWARTZ;STEFANO GHIO;CATHERINE KLERSY;LUIGI TAVAZZI;GIUSEPPE GERNA;LUCA ARCAINI;MAURIZIO LANDOLINA;CARMINE TINELLI;LAURA SCELSI;MATTEO GIOVANNI DELLA PORTA;CESARE PEROTTI;ELOISA ARBUSTINI;GIAMPAOLO MERLINI;LUCA MALCOVATI;PAOLO G. GOBBI;FRANCO LOCATELLI;MARIA GRAZIA REVELLO;SILVIA MAGNI‐MANZONI;ROSANGELA INVERNIZZI;ROBERTO DORE","1511;1162;906;868;865;672;542;533;499;477;449;394;392;380;379;352;349;344;335;321","CATHERINE KLERSY;CARMINE TINELLI;ELOISA ARBUSTINI;GIAMPIERO BELUFFI;FRANCO LOCATELLI;LUIGI TAVAZZI;GIUSEPPE GERNA;GINO ROBERTO CORAZZA;PETER J. SCHWARTZ;STEFANO GHIO;MAURO STRONATI;FAUSTO BALDANTI;GIOVANNI BAROSI;MARIO VIGANÒ;MATTEO GIOVANNI DELLA PORTA;MAURIZIO LANDOLINA;SILVIA MAGNI‐MANZONI;ANNALISA DE SILVESTRI;ROSANGELA INVERNIZZI;ARSENIO SPINILLO","22;16;14;12;11;11;11;10;10;10;8;7;7;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE;PHILOSOPHY;ECONOMICS;HISTORY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;SOCIOLOGY;GEOLOGY","339;124;29;23;11;10;9;8;7;5;4;3;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;ONCOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;VIROLOGY;PEDIATRICS;CANCER RESEARCH;ANESTHESIA;CELL BIOLOGY;PHYSICAL THERAPY;DERMATOLOGY;PSYCHIATRY","261;84;80;73;72;65;46;38;37;36;34;27;26;26;24;22;18;18;15;14;14","GENE;POPULATION;DISEASE;HEART FAILURE;CHEMOTHERAPY;TRANSPLANTATION;BONE MARROW;ANTIBODY;CANCER;VIRUS;CONFIDENCE INTERVAL;BLOOD PRESSURE;IN VITRO;STEM CELL;LEUKEMIA;PREGNANCY;IMMUNE SYSTEM;PLATELET;RANDOMIZED CONTROLLED TRIAL;THROMBOSIS","55;36;35;33;32;32;31;26;26;23;18;17;17;17;14;13;12;12;12;12","EJECTION FRACTION;MYELODYSPLASTIC SYNDROMES;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;MUTATION;VIRAL LOAD;HAZARD RATIO;GENOTYPE;ALLELE;CHROMOSOME;MYELOFIBROSIS;GENE EXPRESSION;HAEMATOPOIESIS;CD34;ESSENTIAL THROMBOCYTHEMIA;FETUS;HUMAN CYTOMEGALOVIRUS;PLACEBO;BREAST CANCER;GESTATIONAL AGE;HEART RATE;HUMAN LEUKOCYTE ANTIGEN;MONOCLONAL ANTIBODY;MUTANT;PERIPHERAL BLOOD MONONUCLEAR CELL;RITUXIMAB;SEROLOGY;THROMBOCYTOSIS;VIRAL DISEASE","17;16;13;12;11;11;10;9;8;8;8;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;KARYOTYPE;VINCRISTINE;AL AMYLOIDOSIS;FONDAPARINUX;HEART RATE VARIABILITY;IL-2 RECEPTOR;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;ACUTE LYMPHOCYTIC LEUKEMIA;ADULT STEM CELL;BREAKPOINT;BUSULFAN;CARBOPLATIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHROMOSOME 7 (HUMAN);CYTOGENETICS;DIFFUSING CAPACITY;DNA METHYLATION;FILGRASTIM;FLUDARABINE;HAPLOTYPE;IGHV@;IMATINIB MESYLATE;INDUCED PLURIPOTENT STEM CELL;INTERNATIONAL PROGNOSTIC INDEX;INTESTINAL MALABSORPTION;ISCHEMIC CARDIOMYOPATHY;JUVENILE MYELOMONOCYTIC LEUKEMIA;KRAS;LAMIVUDINE;LOSARTAN;OOGENESIS;OXALIPLATIN;PENETRANCE;PRENATAL DIAGNOSIS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REVERSE TRANSCRIPTASE;SOMATIC HYPERMUTATION;UMBILICAL ARTERY;VAGUS NERVE STIMULATION","14;7;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;HEART FAILURE;ITALY;TREATMENT OUTCOME;ADOLESCENT;YOUNG ADULT;CHILD;HIV INFECTIONS;CHILD, PRESCHOOL;AGED, 80 AND OVER;PROGNOSIS;TIME FACTORS;ANIMALS;FOLLOW-UP STUDIES","232;164;152;125;104;95;80;78;46;46;43;35;31;31;29;24;22;22;21;21","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ACUTE MYELOID LEUKEMIA;LYMPHOID NEOPLASMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;ORGAN TRANSPLANTATION AND REJECTION;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEMATOPOIETIC STEM CELL BIOLOGY;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;MULTIPOTENT MESENCHYMAL STEM CELLS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","16;15;11;10;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4","TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC IMAGING;ECHOCARDIOGRAPHY;LEFT VENTRICULAR DYSFUNCTION;REGIMEN;DYSSYNCHRONY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;ATRIAL FIBRILLATION;CARDIAC REMODELING;CYTOMEGALOVIRUS;JUVENILE IDIOPATHIC ARTHRITIS;PATHOGENESIS;REFRACTORY (PLANETARY SCIENCE);THROMBOCYTOSIS;ABVD;ANTIRETROVIRAL THERAPY;CLINICAL ENDPOINT;CONCOMITANT;DILATED CARDIOMYOPATHY","15;14;11;10;9;9;7;6;5;5;5;5;5;5;5;4;4;4;4;4","HEART FAILURE;MYELODYSPLASTIC SYNDROMES;CARDIAC RESYNCHRONIZATION;RESYNCHRONIZATION THERAPY;STEM CELL;ATRIAL FIBRILLATION;CELL TRANSPLANTATION;ITALIAN SOCIETY;LEFT VENTRICULAR;TRANSPLANT RECIPIENTS;ACUTE MYELOID;CANCER PATIENTS;PATIENTS UNDERGOING;REVISED EDITION;ACUTE LYMPHOBLASTIC;BONE MARROW;CASO CLINICO;CONSENSUS CONFERENCE;FAILURE PATIENTS;FLOW CYTOMETRY;HUMAN CYTOMEGALOVIRUS;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;RANDOMIZED STUDY;AL AMYLOIDOSIS;ALLOGENEIC STEM;ATHEROSCLEROTIC PLAQUES;CORONARY ATHEROSCLEROTIC","17;11;10;9;8;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3","HEART FAILURE;STEM CELL;BONE MARROW;HR CI;CELL TRANSPLANTATION;CONFIDENCE INTERVAL;LEFT VENTRICULAR;MYELODYSPLASTIC SYNDROMES;PERIPHERAL BLOOD;HAZARD RATIO;MYELOID LEUKEMIA;STEM CELLS;WHIPPLES DISEASE;EJECTION FRACTION;INACTIVE DISEASE;MESENCHYMAL STROMAL;STROMAL CELLS;TRANSPLANT RECIPIENTS;CORONARY BIFURCATIONS;HEART DISEASE;HEMATOPOIETIC STEM;INHERITED MACROTHROMBOCYTOPENIAS;JOINT COUNTS;ODDS RATIO;CARDIAC RESYNCHRONIZATION;CORONARY ARTERY;DILATED CARDIOMYOPATHY;HEART ASSOCIATION;LV EJECTION;MEDIAN AGE","15;15;14;13;12;12;11;11;11;10;10;10;10;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7",49,0.13,3,11.06,6,54.938,9.06,1,77,2,2,2,2,1,4,0,0,0,1,1,1,11.7,1,77,0,0,0,1.67,1,2,9.89,1,77,1,1,1,1,1,1,2.75,1,7,0,0,0,1.67,1,2,1,1,1,3,3,3,1.25,1,2,1,1,1,0.11,0,1,0.06,0,1,108.78,23,458,108.94,23,459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2010,335,9.07761194029851,3.25074626865672,0.307621671258035,0.42089552238806,0.426865671641791,0.229850746268657,0.283582089552239,11,140,51,25,95,0.42,0.15,0.07,0.28,33.87,0.749396476709715,0.256716417910448,0.991044776119403,0,0.466497813803627,0.365721800116891,0.448235672373603,0.451536080019052,"CARMINE TINELLI;CATHERINE KLERSY;FRANCO LOCATELLI;MARCO ZECCA;MAURO STRONATI;GIOVANNI BAROSI;GIAN LUIGI MARSEGLIA;FRANCESCO PASSAMONTI;STEFANO GHIO;LETIZIA LUPO;ALESSANDRA RICCI;ELISABETTA DE SANDO;CARLOMAURIZIO MONTECUCCO;GIAMPIERO BELUFFI;ILARIA BRAMBILLA;FAUSTO BALDANTI;GIULIA MASA;GIULIA RUFFINAZZI;ANTONIO DAL CANTON;PATRIZIA BULZOMÌ","20;20;18;14;13;13;12;10;8;8;8;7;7;7;7;7;7;7;7;7","GIAMPIERO BELUFFI;CARMINE TINELLI;CATHERINE KLERSY;MAURO STRONATI;NICOLETTA SERPIERI;GIAN LUIGI MARSEGLIA;FRANCO LOCATELLI;ANTONIO DAL CANTON;MARCO ZECCA;GIOVANNI BAROSI;STEFANIA PERRINI;MARIA CUSATO;CARLOMAURIZIO MONTECUCCO;ALESSANDRA RICCI;LIDIA DECEMBRINO;PATRIZIA COMOLI;GIULIA RUFFINAZZI;ROBERTA MARAGLIANO;MARIA CHIARA LEONI;FAUSTO BALDANTI","6;2.4;2.36;2.03;2;1.95;1.92;1.76;1.57;1.46;1.33;1.29;1.21;1.2;1.09;1.09;1.08;1.08;1.07;1.07","CARMINE TINELLI;CATHERINE KLERSY;FRANCO LOCATELLI;MARCO ZECCA;MAURO STRONATI;GIOVANNI BAROSI;GIAN LUIGI MARSEGLIA;FRANCESCO PASSAMONTI;STEFANO GHIO;LETIZIA LUPO;ALESSANDRA RICCI;ELISABETTA DE SANDO;CARLOMAURIZIO MONTECUCCO;GIAMPIERO BELUFFI;ILARIA BRAMBILLA;FAUSTO BALDANTI;GIULIA MASA;GIULIA RUFFINAZZI;ANTONIO DAL CANTON;PATRIZIA BULZOMÌ","20;20;18;14;13;13;12;10;8;8;8;7;7;7;7;7;7;7;7;7","GIAMPIERO BELUFFI;CARMINE TINELLI;CATHERINE KLERSY;MAURO STRONATI;NICOLETTA SERPIERI;GIAN LUIGI MARSEGLIA;FRANCO LOCATELLI;ANTONIO DAL CANTON;MARCO ZECCA;GIOVANNI BAROSI;STEFANIA PERRINI;MARIA CUSATO;CARLOMAURIZIO MONTECUCCO;ALESSANDRA RICCI;LIDIA DECEMBRINO;PATRIZIA COMOLI;GIULIA RUFFINAZZI;ROBERTA MARAGLIANO;MARIA CHIARA LEONI;FAUSTO BALDANTI","6;2.4;2.36;2.03;2;1.95;1.92;1.76;1.57;1.46;1.33;1.29;1.21;1.2;1.09;1.09;1.08;1.08;1.07;1.07","CATHERINE KLERSY;GAETANO MARIA DE FERRARI;MARIO LAZZARINO;PETER J. SCHWARTZ;CARMINE TINELLI;FRANCESCO PASSAMONTI;ELISA RUMI;FRANCO LOCATELLI;ALBERTO MARTINI;ANGELO RAVELLI;HELMUT KLEIN;LUIGIA SCUDELLER;DANIELA PIETRA;CRISTIANA PASCUTTO;LUCA ARCAINI;ANGELA PISTORIO;NICOLINO RUPERTO;SILVIA MAGNI‐MANZONI;EMANUELA BOVERI;ANTONELLO GAVAZZI","1131;953;787;750;744;648;610;560;554;554;545;538;534;524;514;501;501;501;488;481","CATHERINE KLERSY;GAETANO MARIA DE FERRARI;CARMINE TINELLI;LUIGIA SCUDELLER;SILVIA MAGNI‐MANZONI;PETER J. SCHWARTZ;EMANUELA BOVERI;ANTONIO SANZO;STEFANO GHIO;GIUSEPPE GERNA;FRANCO PIOVELLA;FRANCO LOCATELLI;MARIO LAZZARINO;GIOVANNI BAROSI;GIORGIO ANTONIO IOTTI;LUCA MALCOVATI;RICCARDO ALBERTINI;MARCO ZECCA;MARIO REGAZZI;ISA CERVERI","1131;953;744;538;501;490;488;481;473;446;400;393;359;336;329;306;292;289;283;282","CATHERINE KLERSY;CARMINE TINELLI;MARCO ZECCA;GIOVANNI BAROSI;GIAN LUIGI MARSEGLIA;FRANCO LOCATELLI;MAURO STRONATI;LETIZIA LUPO;STEFANO GHIO;CARLOMAURIZIO MONTECUCCO;GIAMPIERO BELUFFI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;GIUSEPPE GERNA;MARIA ANTONIETTA AVANZINI;LUIGIA SCUDELLER;ANTONIO DAL CANTON;VITTORIO ROSTI;MARIO REGAZZI;CRISTIANA PASCUTTO","20;18;14;13;11;11;10;8;8;7;7;6;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;SOCIOLOGY;PSYCHOLOGY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;ART;GEOGRAPHY;HISTORY;PHILOSOPHY","316;122;35;23;11;10;8;8;7;5;3;3;2;2;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;GENETICS;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;PEDIATRICS;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;INTENSIVE CARE MEDICINE;DERMATOLOGY;OPTICS;CELL BIOLOGY;VIROLOGY;ANESTHESIA;PHARMACOLOGY;ONCOLOGY","230;82;71;69;55;52;46;39;35;34;34;29;23;21;21;20;17;16;16;15","DISEASE;GENE;POPULATION;BONE MARROW;ANTIBODY;STEM CELL;HEART FAILURE;INCIDENCE (GEOMETRY);TRANSPLANTATION;MYOCARDIAL INFARCTION;BLOOD PRESSURE;LUNG;VIRUS;CHEMOTHERAPY;IMMUNE SYSTEM;DIABETES MELLITUS;PREGNANCY;ADVERSE EFFECT;CANCER;RANDOMIZED CONTROLLED TRIAL","52;51;35;28;25;24;20;20;20;18;15;15;15;14;14;13;13;12;12;12","GENOTYPE;MYELOFIBROSIS;HAEMATOPOIESIS;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;FETUS;PERCUTANEOUS CORONARY INTERVENTION;ALLELE;ESSENTIAL THROMBOCYTHEMIA;IMMUNOGLOBULIN LIGHT CHAIN;INSULIN RESISTANCE;TOLERABILITY;VIRAL LOAD;AUTOANTIBODY;CYCLOPHOSPHAMIDE;EX VIVO;HEART RATE;LENALIDOMIDE;MYELODYSPLASTIC SYNDROMES;SEROLOGY","17;16;14;12;11;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5","AL AMYLOIDOSIS;CARDIAC RESYNCHRONIZATION THERAPY;MYELOPROLIFERATIVE NEOPLASM;ADIPONECTIN;ANTIRETROVIRAL THERAPY;POLYMORPHISM (COMPUTER SCIENCE);GLYCATED HEMOGLOBIN;HERPESVIRIDAE;KIDNEY TRANSPLANT;MISSENSE MUTATION;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;TOTAL BODY IRRADIATION;ADIPOKINE;ALISKIREN;ANAGRELIDE;ANEMIA OF CHRONIC DISEASE;ANTI-NUCLEAR ANTIBODY;BUSULFAN;CENTRAL PRECOCIOUS PUBERTY;CONGENITAL SYPHILIS;CORONAVIRUS DISEASE 2019 (COVID-19);CUTANEOUS MASTOCYTOSIS;GENE POLYMORPHISM;HAPLOTYPE;IN UTERO;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;JUVENILE MYELOMONOCYTIC LEUKEMIA;LOSARTAN;OLIGOARTHRITIS;P2Y12;PHARMACOGENETICS;REVERSE TRANSCRIPTASE;RUXOLITINIB;STEM CELL FACTOR;SUBLINGUAL IMMUNOTHERAPY;TICLOPIDINE;TIMI;TIROFIBAN;TRAVOPROST;VAGUS NERVE STIMULATION","5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;HEART FAILURE;ADOLESCENT;PROSPECTIVE STUDIES;YOUNG ADULT;CHILD;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;ANIMALS;CHILD, PRESCHOOL;MYOCARDIAL INFARCTION;VENTRICULAR DYSFUNCTION, LEFT","198;133;130;127;94;77;70;39;35;34;28;26;26;24;23;22;20;20;20;20","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEMATOPOIETIC STEM CELL BIOLOGY;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;MULTIPOTENT MESENCHYMAL STEM CELLS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND RELATED DISORDERS;LYMPHOID NEOPLASMS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA","17;8;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3","TREATMENT;HIV;MYELOFIBROSIS;REFRACTORY (PLANETARY SCIENCE);CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;ECHOCARDIOGRAPHY;HEMATOPOIETIC CELL TRANSPLANTATION;LEFT VENTRICULAR FUNCTION;MYELOPROLIFERATIVE DISORDERS;PRESENTATION (OBSTETRICS);REGIMEN;SUBCLINICAL INFECTION;TOLERABILITY;AL AMYLOIDOSIS;CARDIAC AMYLOIDOSIS;CARDIAC ELECTROPHYSIOLOGY;CARDIOVASCULAR RISK ASSESSMENT;EX VIVO;MYELOPROLIFERATIVE NEOPLASM","15;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5","HEART FAILURE;LEFT VENTRICULAR;CARDIAC RESYNCHRONIZATION;CASO DI;MYOCARDIAL INFARCTION;RESYNCHRONIZATION THERAPY;SYSTEMIC SCLEROSIS;ATRIAL FIBRILLATION;AUTOMATED PERIMETRY;COMPUTED TOMOGRAPHY;ETÀ PEDIATRICA;MYELOPROLIFERATIVE NEOPLASM;PERCUTANEOUS CORONARY;RISK FACTORS;SINDROME DI;STEM CELL;AL AMYLOIDOSIS;BLOOD TRANSPLANTATION;CHRONIC HEART;CLINICAL OUTCOME;CORD BLOOD;CORONARY ARTERY;CRITICALLY ILL;DI CELLULE;DI SINDROME;EMBRYONIC STEM;FIXED COMBINATION;GLAUCOMA SUSPECTS;HUMAN CYTOMEGALOVIRUS;IDIOPATHIC ARTHRITIS","7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","FOLLICULAR LYMPHOMA;LEFT VENTRICULAR;MYELOPROLIFERATIVE NEOPLASMS;LOW RISK;STEM CELLS;APOLIPOPROTEIN A-I;HOSPITAL STAY;MILD ANEMIA;RR CI;CIRCLE VAS;NUMBERED CIRCLE;RISK FACTORS;BODY WEIGHT;BONE MARROW;COMBINATION THERAPY;CORONARY MDCT;HEART FAILURE;HEART RATE;INTERMEDIATE RISK;MMHG NA;PLATELET LYSATE;POOR RESPONDERS;ANGIOTENSIN-CONVERTING ENZYME;BLOOD PRESSURE;CM HORIZONTAL;CONFIDENCE INTERVAL;CONSECUTIVE PATIENTS;ESTROGEN-PROGESTIN HRT;FACTOR VIII;GM-CSF SIGNALING","17;13;13;11;10;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5",39,0.12,3,11.34,6,28,9.17,2,59,1,1,1,1,1,1,0,0,0,2,1,4,9.33,1,55,0,0,0,1.5,1,3,9.92,2,59,0,0,0,1,1,1,2.33,1,4,0,0,0,1,1,1,0,0,0,1,1,1,2,1,3,0,0,0,0.08,0,1,0,0,0,124.17,17,391,286.25,17,2336,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2011,367,10.5967302452316,2.7574931880109,0.362648221343874,0.335149863760218,0.362397820163488,0.258855585831063,0.381471389645777,11,162,74,43,62,0.44,0.2,0.12,0.17,39.75,0.934460098642465,0.286103542234332,0.986376021798365,0,0.445602345176791,0.432278762467442,0.441758241758242,0.457076420311714,"CATHERINE KLERSY;CARLOMAURIZIO MONTECUCCO;CARMINE TINELLI;MARCO ZECCA;GIOVANNI BAROSI;FAUSTO BALDANTI;LAURA OBICI;GIAMPAOLO MERLINI;MAURO STRONATI;FRANCO LOCATELLI;MAURIZIO LANDOLINA;LUCA ARCAINI;ALESSANDRO M. VANNUCCHI;ROBERTO CAPORALI;GIOVANNI PALLADINI;ARSENIO SPINILLO;LUIGIA SCUDELLER;VITTORIO ROSTI;MARCO LUCIONI;ANNALISA DE SILVESTRI","20;16;15;14;14;13;13;13;12;12;12;11;11;11;11;9;8;8;8;7","CARLOMAURIZIO MONTECUCCO;CATHERINE KLERSY;MASSIMO ALLEGRI;CARMINE TINELLI;ROBERTO CAPORALI;LIA CROTTI;FAUSTO BALDANTI;MANUELA MONTI;MAURO STRONATI;GIAMPAOLO MERLINI;MARCO ZECCA;C. MIGOTTO;LAURA OBICI;LUIGIA SCUDELLER;VALERIA CALCATERRA;FILIPPO MANGIONE;FABRIZIO GROSJEAN;NICOLETTA SERPIERI;VITTORIO ROSTI;ARSENIO SPINILLO","2.39;2.28;1.86;1.79;1.78;1.77;1.66;1.64;1.37;1.23;1.17;1.16;1.15;1.12;1.11;1.08;1.08;1.08;1.08;1.06","CATHERINE KLERSY;CARLOMAURIZIO MONTECUCCO;CARMINE TINELLI;MARCO ZECCA;GIOVANNI BAROSI;FAUSTO BALDANTI;LAURA OBICI;GIAMPAOLO MERLINI;MAURO STRONATI;FRANCO LOCATELLI;MAURIZIO LANDOLINA;LUCA ARCAINI;ROBERTO CAPORALI;GIOVANNI PALLADINI;ARSENIO SPINILLO;LUIGIA SCUDELLER;VITTORIO ROSTI;MARCO LUCIONI;ANNALISA DE SILVESTRI;FRANCESCA LAVATELLI","20;16;15;14;14;13;13;13;12;12;12;11;11;11;9;8;8;8;7;7","CARLOMAURIZIO MONTECUCCO;CATHERINE KLERSY;MASSIMO ALLEGRI;CARMINE TINELLI;ROBERTO CAPORALI;LIA CROTTI;FAUSTO BALDANTI;MANUELA MONTI;MAURO STRONATI;GIAMPAOLO MERLINI;MARCO ZECCA;C. MIGOTTO;LAURA OBICI;LUIGIA SCUDELLER;VALERIA CALCATERRA;FILIPPO MANGIONE;FABRIZIO GROSJEAN;NICOLETTA SERPIERI;VITTORIO ROSTI;ARSENIO SPINILLO","2.39;2.28;1.86;1.79;1.78;1.77;1.66;1.64;1.37;1.23;1.17;1.16;1.15;1.12;1.11;1.08;1.08;1.08;1.08;1.06","ERICA TRAVAGLINO;MARIO CAZZOLA;LUCA ARCAINI;MATTEO GIOVANNI DELLA PORTA;LUCA MALCOVATI;STEFANO PILERI;ALESSANDRO PULSONI;FRANCESCO FORCONI;ROBIN FOÀ;NICHOLAS C.P. CROSS;ADAM P. BUTLER;ADAM SHLIEN;ADEL K. EL‐NAGGAR;ALAN J. WARREN;ANA CVEJIC;ANDREA PELLAGATTI;ANDREJ FISCHER;ANNA GALLÍ;ANNA L. GODFREY;ANTHONY R. GREEN","1553;1532;1527;1438;1406;1389;1379;1319;1318;1145;1139;1139;1139;1139;1139;1139;1139;1139;1139;1139","ERICA TRAVAGLINO;MARIO CAZZOLA;MATTEO GIOVANNI DELLA PORTA;LUCA MALCOVATI;LUCA ARCAINI;CATHERINE KLERSY;STEFANO GHIO;GIOVANNI BAROSI;FRANCO PIOVELLA;ERCOLE BRUSAMOLINO;FAUSTO BALDANTI;PETER J. SCHWARTZ;MANUEL GOTTI;CARLOMAURIZIO MONTECUCCO;MARCO LUCIONI;MARCO PAULLI;MARCO ZECCA;GIUSEPPE GERNA;GIORGIO ANTONIO IOTTI;EMANUELE CEREDA","1551;1499;1438;1139;1138;1045;885;579;561;471;435;431;400;387;373;372;368;367;354;301","CATHERINE KLERSY;CARLOMAURIZIO MONTECUCCO;GIOVANNI BAROSI;MARCO ZECCA;CARMINE TINELLI;MAURO STRONATI;FAUSTO BALDANTI;MAURIZIO LANDOLINA;LAURA OBICI;GIAMPAOLO MERLINI;ROBERTO CAPORALI;LUIGIA SCUDELLER;VITTORIO ROSTI;ANNALISA DE SILVESTRI;ARSENIO SPINILLO;GIUSEPPE GERNA;PAOLO PEDRAZZOLI;MARIO CAZZOLA;RENATO MASERATI;MASSIMO ALLEGRI","19;15;14;13;13;12;11;9;9;8;8;8;8;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;ECONOMICS;BUSINESS;HISTORY;ART;GEOGRAPHY","333;142;30;28;25;13;13;11;10;8;8;8;5;4;3;2;1","INTERNAL MEDICINE;GENETICS;IMMUNOLOGY;PATHOLOGY;SURGERY;CARDIOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;PEDIATRICS;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;CANCER RESEARCH;ONCOLOGY;VIROLOGY;CELL BIOLOGY;ENDOCRINOLOGY;PHYSICAL THERAPY;RADIOLOGY;MOLECULAR BIOLOGY;ANESTHESIA","246;92;86;78;76;46;43;43;37;35;31;27;26;26;23;22;22;22;19;18","GENE;DISEASE;TRANSPLANTATION;POPULATION;ANTIBODY;BONE MARROW;RECEPTOR;STEM CELL;ALTERNATIVE MEDICINE;CHEMOTHERAPY;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;VIRUS;CANCER;MYOCARDIAL INFARCTION;IN VITRO;COHORT;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;RHEUMATOLOGY","69;46;31;29;23;23;22;21;20;19;19;18;18;17;17;16;15;15;15;15;15","MUTATION;EJECTION FRACTION;GENOTYPE;MYELOFIBROSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL LOAD;ESSENTIAL THROMBOCYTHEMIA;MYELODYSPLASTIC SYNDROMES;CD8;CLINICAL ENDPOINT;CYTOTOXIC T CELL;HAEMATOPOIESIS;HAZARD RATIO;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;CONVENTIONAL PCI;HUMAN LEUKOCYTE ANTIGEN;PHENOTYPE;POLYMERASE CHAIN REACTION;T CELL;TOLERABILITY;UNIVARIATE ANALYSIS","18;15;13;13;11;10;9;9;8;8;8;8;8;8;8;7;7;7;7;7;7;7","CARDIAC RESYNCHRONIZATION THERAPY;ANTIRETROVIRAL THERAPY;AL AMYLOIDOSIS;MISSENSE MUTATION;CORONAVIRUS DISEASE 2019 (COVID-19);INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;REVERSE TRANSCRIPTASE;ADOPTIVE CELL TRANSFER;CTL*;GENE MUTATION;HAPLOTYPE;HERPESVIRIDAE;RNA SPLICING;RUXOLITINIB;STROKE VOLUME;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRHEUMATIC DRUGS;APREPITANT;BLADDER PAIN SYNDROME;BUSULFAN;CD38;CENTRAL VENOUS PRESSURE;CHEMOKINE RECEPTOR;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;COMPARATIVE GENOMIC HYBRIDIZATION;CROSSOVER STUDY;ELISPOT;EXOME SEQUENCING;FLUDARABINE;GIANT CELL ARTERITIS;GRANISETRON;GROWTH HORMONE RECEPTOR;IDIOPATHIC SHORT STATURE;IMMUNODOMINANCE;JUVENILE MYELOMONOCYTIC LEUKEMIA;KRAS;MEGAKARYOCYTE;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;NEUROPSYCHOLOGICAL ASSESSMENT;PALONOSETRON;PRENATAL DIAGNOSIS;SCANNING LASER POLARIMETRY;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;SPLENIC MARGINAL ZONE LYMPHOMA;THROMBOPOIETIN;TRANSCRIPTOME;VINCRISTINE","11;9;6;6;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;TREATMENT OUTCOME;HEART FAILURE;HIV INFECTIONS;ADOLESCENT;YOUNG ADULT;CHILD;MYOCARDIAL INFARCTION;MUTATION;AGED, 80 AND OVER;CHILD, PRESCHOOL;HIV-1;ARTHRITIS, RHEUMATOID","237;152;147;118;103;87;86;75;46;44;44;35;35;34;33;32;30;27;27;26","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ACUTE MYELOID LEUKEMIA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;RHEUMATOID ARTHRITIS;MOLECULAR MECHANISMS OF INFLAMMASOME ACTIVATION AND REGULATION;LYMPHOID NEOPLASMS;MULTIPOTENT MESENCHYMAL STEM CELLS;COMPOSITION AND HEALTH EFFECTS OF HUMAN MILK;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;NATURAL KILLER CELLS IN IMMUNITY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA","16;13;11;10;8;8;7;7;6;5;5;4;4;4;4;4;4;4;3;3","REGIMEN;HIV;MYELOFIBROSIS;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;ANTIRETROVIRAL THERAPY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;TOLERABILITY;UNIVARIATE ANALYSIS;AL AMYLOIDOSIS;T CELL RESPONSES;AMYLOID (MYCOLOGY);CUMULATIVE INCIDENCE;HEMATOPOIETIC CELL TRANSPLANTATION;LIGHT CHAIN AMYLOIDOSIS;ADOPTIVE CELL TRANSFER;ATRIAL FIBRILLATION;CARDIAC AMYLOIDOSIS;CLINICAL PRACTICE;CORONARY STENTS","11;10;9;8;8;7;7;7;7;6;6;5;5;5;5;4;4;4;4;4","HEART FAILURE;RHEUMATOID ARTHRITIS;STEM CELL;CELL TRANSPLANTATION;MYOCARDIAL INFARCTION;STEM CELLS;CARDIAC RESYNCHRONIZATION;CLINICAL TRIAL;MYELODYSPLASTIC SYNDROME;PATIENTS TREATED;RESYNCHRONIZATION THERAPY;ACUTE LYMPHOBLASTIC;AL AMYLOIDOSIS;HEMATOPOIETIC STEM;HUMAN CYTOMEGALOVIRUS;IDIOPATHIC ARTHRITIS;JUVENILE IDIOPATHIC;LEFT VENTRICULAR;TRANSPLANT RECIPIENTS;ACUTE MYELOID;ACUTE MYOCARDIAL;ATRIAL FIBRILLATION;BOVINE LACTOFERRIN;CARDIAC CARE;COLORECTAL CANCER;CRITICALLY ILL;CYTOMEGALOVIRUS INFECTION;EMBRYONIC STEM;FUNGAL INFECTIONS;ILL PATIENTS","10;8;8;7;7;7;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PUBMED SCOPUS;CROSSREF PUBMED;LUNG TISSUE;PNEUMONIA CAUSED;HEART FAILURE;AHN INFLUENZA;EXPERIMENTAL PNEUMONIA;INFECT DIS;AERUGINOSAINTENSIVE CARE;CARE MED;HF PATIENTS;INTRAVENOUS COLISTIN;IV ADMINISTRATION;MED -CROSSREF;NATION RL;PANDEMIC AHN;PSEUDOMONAS AERUGINOSAINTENSIVE;CHEMOTHER -CROSSREF;CONFIDENCE INTERVAL;LEFT VENTRICULAR;STEM CELL;CD T-CELL;MULTIDRUG-RESISTANT GRAM-NEGATIVE;PATIENTS RECEIVED;CELL TRANSPLANTATION;COLISTIN METHANESULFONATE;COMBINATION THERAPY;EJECTION FRACTION;HEART ASSOCIATION;HEMORRHAGIC TELANGIECTASIA","48;36;23;20;17;15;13;13;12;12;12;12;12;12;12;12;12;11;11;11;11;10;10;10;9;9;9;9;9;9",67,0.18,3,25.59,6,162.33,16.56,2,116,3.4,1,11,1.67,1,4,0,0,0,3.83,1,10,6.5,1,25,1,1,1,1.29,1,2,18.67,2,133,1,1,1,1,1,1,16.22,1,86,3,2,4,4.25,1,9,1,1,1,3.4,1,9,16.86,1,75,2,1,4,0.56,0,4,0.06,0,1,139.61,16,390,140.22,16,394,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2012,323,11.6222910216718,2.70278637770898,0.369988545246277,0.325077399380805,0.312693498452012,0.18266253869969,0.38390092879257,3,170,61,16,59,0.53,0.19,0.05,0.18,53.2,1.27364767199238,0.39938080495356,0.990712074303406,6.4900442477876,0.450527063889367,0.440179806362379,0.454875283446712,0.486431935411527,"GIOVANNI BAROSI;CATHERINE KLERSY;FAUSTO BALDANTI;ALESSANDRO M. VANNUCCHI;MARCO ZECCA;JEAN‐JACQUES KILADJIAN;CARMINE TINELLI;CLAIRE HARRISON;MAURO STRONATI;TIZIANO BARBUI;FRANCESCO PASSAMONTI;FRANCISCO CERVANTES;ANTONIO PIRALLA;CAMILLO PORTA;CARLOMAURIZIO MONTECUCCO;HEINZ GISSLINGER;PETER J. SCHWARTZ;ROBERTO CAPORALI;ALESSANDRO RAMBALDI;LUIGIA SCUDELLER","24;21;17;16;16;15;15;15;13;12;11;11;11;11;11;11;9;9;9;8","FAUSTO BALDANTI;CATHERINE KLERSY;MAURO STRONATI;GIOVANNI BAROSI;CARMINE TINELLI;PETER J. SCHWARTZ;ANTONIO PIRALLA;MARCO ZECCA;LUIGIA SCUDELLER;GIAMPAOLO MERLINI;CLAIRE HARRISON;JEAN‐JACQUES KILADJIAN;GIUSEPPE GERNA;FRANCESCO BENAZZO;CARLOMAURIZIO MONTECUCCO;GEMMA CATERINA MARIA ROSSI;IRCCS POLICLINICO;ROBERTO CAPORALI;CESARE PEROTTI;GINO ROBERTO CORAZZA","2.25;2.18;1.9;1.85;1.8;1.74;1.4;1.3;1.25;1.16;1.16;1.15;1.12;1.11;1.09;1.01;1;0.97;0.97;0.96","GIOVANNI BAROSI;CATHERINE KLERSY;FAUSTO BALDANTI;MARCO ZECCA;CARMINE TINELLI;MAURO STRONATI;FRANCESCO PASSAMONTI;ANTONIO PIRALLA;CAMILLO PORTA;CARLOMAURIZIO MONTECUCCO;PETER J. SCHWARTZ;ROBERTO CAPORALI;LUIGIA SCUDELLER;GIAMPAOLO MERLINI;ELOISA ARBUSTINI;RICCARDO CACCIALANZA;CLAUDIA DEL FANTE;MARIO CAZZOLA;CESARE PEROTTI;GIUSEPPE GERNA","24;21;17;16;15;13;11;11;11;11;9;9;8;8;7;7;7;7;7;7","FAUSTO BALDANTI;CATHERINE KLERSY;MAURO STRONATI;GIOVANNI BAROSI;CARMINE TINELLI;PETER J. SCHWARTZ;ANTONIO PIRALLA;MARCO ZECCA;LUIGIA SCUDELLER;GIAMPAOLO MERLINI;GIUSEPPE GERNA;FRANCESCO BENAZZO;CARLOMAURIZIO MONTECUCCO;GEMMA CATERINA MARIA ROSSI;IRCCS POLICLINICO;ROBERTO CAPORALI;CESARE PEROTTI;GINO ROBERTO CORAZZA;ELOISA ARBUSTINI;CLAUDIA DEL FANTE","2.25;2.18;1.9;1.85;1.8;1.74;1.4;1.3;1.25;1.16;1.12;1.11;1.09;1.01;1;0.97;0.97;0.96;0.93;0.92","TIZIANO BARBUI;HEINZ GISSLINGER;GIOVANNI BAROSI;ALESSANDRO M. VANNUCCHI;JEAN‐JACQUES KILADJIAN;CLAIRE HARRISON;FRANCISCO CERVANTES;LAURENT KNOOPS;VIKTORIYA STALBOVSKAYA;DEBORAH HUNTER;HAIFA KATHRIN AL‐ALI;MARI MCQUITTY;R. H. LEVY;ROGER J. WALTZMAN;NICOLA CASCAVILLA;LUCA ARCAINI;CATHERINE KLERSY;ALIYAH R. SOHANI;CHRISTINA TRIPSAS;CHRISTOPHER J. PATTERSON","2891;2512;2485;2323;2194;2180;2155;1758;1753;1715;1698;1651;1651;1651;1419;1202;1165;1161;1161;1161","GIOVANNI BAROSI;LUCA ARCAINI;CATHERINE KLERSY;ELOISA ARBUSTINI;CAMILLO PORTA;CARMINE TINELLI;ELISA RUMI;ALESSANDRO CORSO;BARBARA DAL BELLO;G. FILICE;PETER J. SCHWARTZ;MARCO ZECCA;FAUSTO BALDANTI;ANDREA PILOTTO;MICHELE PASOTTI;CLAUDIO DOGLIONI;MAURO STRONATI;RICCARDO CACCIALANZA;MARGHERITA MASSA;LUIGIA SCUDELLER","2341;1202;1145;1064;863;823;724;711;643;635;576;517;508;478;478;432;419;387;379;370","GIOVANNI BAROSI;CATHERINE KLERSY;FAUSTO BALDANTI;MARCO ZECCA;CARMINE TINELLI;MAURO STRONATI;CAMILLO PORTA;ANTONIO PIRALLA;LUIGIA SCUDELLER;PETER J. SCHWARTZ;CARLOMAURIZIO MONTECUCCO;ELOISA ARBUSTINI;RICCARDO CACCIALANZA;CESARE PEROTTI;EMANUELE CEREDA;GIUSEPPE GERNA;LUCA ARCAINI;CLAUDIA DEL FANTE;MARGHERITA MASSA;ROBERTO CAPORALI","22;20;16;16;14;12;11;11;8;8;7;7;6;6;6;6;6;6;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;BUSINESS;ECONOMICS;MATERIALS SCIENCE;PSYCHOLOGY;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;GEOGRAPHY;ART;GEOLOGY","303;119;22;21;16;15;10;7;6;6;5;5;4;4;3;2;2","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;ONCOLOGY;CARDIOLOGY;BIOCHEMISTRY;VIROLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PHYSICAL THERAPY;ENDOCRINOLOGY;CANCER RESEARCH;PEDIATRICS;RADIOLOGY;ANESTHESIA;CELL BIOLOGY;DERMATOLOGY","230;76;70;68;60;58;47;40;34;29;23;21;21;18;16;16;16;15;14;14","GENE;DISEASE;BONE MARROW;TRANSPLANTATION;CHEMOTHERAPY;POPULATION;VIRUS;CANCER;HEART FAILURE;COHORT;ALTERNATIVE MEDICINE;ANTIBODY;CONFIDENCE INTERVAL;STEM CELL;RANDOMIZED CONTROLLED TRIAL;LYMPHOMA;ADVERSE EFFECT;PREGNANCY;BLOOD PRESSURE;CLINICAL TRIAL","58;34;31;28;27;24;24;23;21;20;18;17;17;17;15;14;13;13;11;11","MYELOFIBROSIS;MUTATION;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;GENOTYPE;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL LOAD;CHROMOSOME;EJECTION FRACTION;HAZARD RATIO;ALLELE;HUMAN CYTOMEGALOVIRUS;PLACEBO;VIRAL DISEASE;COLORECTAL CANCER;MYELODYSPLASTIC SYNDROMES;CD34;ESSENTIAL THROMBOCYTHEMIA;FETUS;LONG QT SYNDROME;NEUTROPENIA;RITUXIMAB","23;17;12;10;10;10;10;10;9;9;9;8;8;8;8;7;7;6;6;6;6;6;6","RUXOLITINIB;HERPESVIRIDAE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;ANTIRETROVIRAL THERAPY;FLUDARABINE;MYELOPROLIFERATIVE NEOPLASM;SANGER SEQUENCING;AL AMYLOIDOSIS;CARDIAC RESYNCHRONIZATION THERAPY;CONNECTIVE TISSUE DISEASE;GENOTYPING;GERMLINE MUTATION;HAPLOTYPE;HEMATOPOIETIC CELL;KRAS;LMNA;VINCRISTINE;ADENOCARCINOMA OF THE LUNG;ADIPOKINE;ADIPONECTIN;BENDAMUSTINE;CEBPA;CLADE;FLUORESCENCE IN SITU HYBRIDIZATION;GANCICLOVIR;GENE MUTATION;GLYCATED HEMOGLOBIN;HELICASE;HEMATOPOIETIC STEM CELL;IGHV@;IMMUNOGLOBULIN M;INTERLEUKIN 21;INTERNATIONAL PROGNOSTIC INDEX;INTRAUTERINE GROWTH RESTRICTION;ISCHEMIC CARDIOMYOPATHY;JUVENILE MYELOMONOCYTIC LEUKEMIA;LOSS OF HETEROZYGOSITY;LYMPHOPLASMACYTIC LYMPHOMA;MICROSATELLITE;MONOCLONAL;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;PAZOPANIB;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;POLYMORPHISM (COMPUTER SCIENCE);PRENATAL DIAGNOSIS;REVERSE TRANSCRIPTASE;RUNX1;SCANNING LASER POLARIMETRY;SHORT QT SYNDROME","12;8;6;6;5;5;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;YOUNG ADULT;TREATMENT OUTCOME;ADOLESCENT;CHILD;CYTOMEGALOVIRUS INFECTIONS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FOLLOW-UP STUDIES;BIOMARKERS;CELIAC DISEASE;MYOCARDIAL INFARCTION;RETROSPECTIVE STUDIES","200;150;135;119;99;87;82;50;39;38;36;28;27;26;24;24;22;22;22;22","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;HEMATOPOIETIC STEM CELL BIOLOGY;MOLECULAR MECHANISMS OF AMYLOIDOSIS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;RENAL CELL CARCINOMA;RHEUMATOID ARTHRITIS;DIAGNOSIS AND MANAGEMENT OF DRY EYE DISEASE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;ORGAN TRANSPLANTATION AND REJECTION;STRUCTURE AND FUNCTION OF THE NUCLEAR PORE COMPLEX;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","27;10;10;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;3;3","MYELOFIBROSIS;CLINICAL ENDPOINT;RUXOLITINIB;TREATMENT;RUXOLITINIB THERAPY;CONCOMITANT;CYTOMEGALOVIRUS;HEMATOPOIETIC CELL TRANSPLANTATION;MANTLE CELL LYMPHOMA;REGIMEN;DILATED CARDIOMYOPATHY;FOLLICULAR LYMPHOMA;GLAUCOMA;HEMATOLOGY;HIV;LONG-QT SYNDROME;MYELOPROLIFERATIVE NEOPLASM;TOLERABILITY;ANTIRETROVIRAL THERAPY;CONCORDANCE","13;12;12;12;11;7;7;6;6;6;5;5;5;5;5;5;5;5;4;4","STEM CELL;PHASE II;CELL TRANSPLANTATION;PRIMARY MYELOFIBROSIS;HEART FAILURE;HEMATOPOIETIC STEM;HUMAN CYTOMEGALOVIRUS;CELL CARCINOMA;RENAL CELL;RHEUMATOID ARTHRITIS;ALLOGENEIC HEMATOPOIETIC;ATRIAL FIBRILLATION;CHRONIC LYMPHOCYTIC;FOLLICULAR LYMPHOMA;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LINFOMI FIL;LYMPHOCYTIC LEUKEMIA;METASTATIC RENAL;MYOCARDIAL INFARCTION;PRELIMINARY RESULTS;STUDY COMPARING;SYMPTOM BURDEN;THERAPY BAT;TRANSPLANT RECIPIENTS;CHRONIC OBSTRUCTIVE;CLINICAL PRACTICE;DISEASE ACTIVITY;EVEROLIMUS REGISTRY;HEPATOCELLULAR CARCINOMA","10;9;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","DISEASE TRANSMISSION;DE NOVO;TRANSMISSION EVENTS;TRANSPLANT RECIPIENTS;DISEASE ACTIVITY;SAN MATTEO;CARDIAC SURGERY;HEART FAILURE;IRCCS POLICLINICO;POLICLINICO SAN;CLINICAL PRACTICE;FONDAZIONE IRCCS;MATTEO PAVIA;MD DEPARTMENT;SURGERY FONDAZIONE;ENDOSCOPIC ADRENALECTOMY;ORGAN DONORS;PAVIA ITALYSEARCH;RENAL FUNCTION;RISK FACTORS;CONFIDENCE INTERVAL;NUTRITIONAL RISK;ORGAN TRANSPLANTATION;TNM STAGING;WALDENSTRÖMS MACROGLOBULINEMIA;CB UNIT;DAY REGIMEN;DONOR-DERIVED TRANSMISSION;DOUBLE CBT;HEART TRANSPLANT","20;19;19;17;14;14;12;12;12;12;11;11;11;11;11;10;10;10;10;10;9;9;9;9;9;8;8;8;8;8",82,0.25,1.625,27.28,4.25,115.37,19.45,1,103,2.73,1,11,1.6,1,3,2,2,2,2.18,1,5,7.25,1,26,0,0,0,1.57,1,4,21.23,1,112,0,0,0,1,1,1,12.74,1,79,1,1,1,2.5,1,5,2,1,4,4.22,1,11,8.79,1,55,3.86,1,10,0.41,0,3,0,0,0,168.55,2,532,150.27,2,534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2013,418,10.9354066985646,2.8444976076555,0.351555929352397,0.351674641148325,0.320574162679426,0.148325358851675,0.382775119617225,4,168,86,36,103,0.4,0.21,0.09,0.25,31.15,0.892760907078256,0.31578947368421,0.978468899521531,6.67751780264497,0.462049262222191,0.409603159314198,0.450909730157335,0.446417729204615,"CARMINE TINELLI;ROBERTO CAPORALI;CATHERINE KLERSY;MARCO ZECCA;STEFANO GHIO;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;FRANCO LOCATELLI;GIOVANNI BAROSI;GIORGIO CIPRANDI;LAURA OBICI;GINO ROBERTO CORAZZA;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;MICHELE MIRAGLIA DEL GIUDICE;GIAMPAOLO MERLINI;RICCARDO CACCIALANZA;MARIO CAZZOLA;MARCO BENAZZO;MARIO LA ROSA","23;21;19;15;14;13;13;13;13;12;12;11;10;10;10;10;9;9;9;9","CARMINE TINELLI;ROBERTO CAPORALI;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;CATHERINE KLERSY;FABIO PAGELLA;GIORGIO CIPRANDI;MARCO BENAZZO;STEFANO GHIO;VALERIA BRAZZELLI;GINO ROBERTO CORAZZA;FAUSTO BALDANTI;LAURA OBICI;GIULIA MARIA STELLA;RICCARDO CACCIALANZA;ANTONIO BOZZANI;VITTORIO ARICI;MARCO ZECCA;FRANCESCO BENAZZO;GARIFALLIA SAKELLARIOU","2.88;2.34;1.8;1.79;1.77;1.61;1.6;1.5;1.46;1.45;1.22;1.2;1.2;1.15;1.1;1.08;1.08;1.07;1.04;1.03","CARMINE TINELLI;ROBERTO CAPORALI;CATHERINE KLERSY;MARCO ZECCA;STEFANO GHIO;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;GIOVANNI BAROSI;LAURA OBICI;GINO ROBERTO CORAZZA;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;GIAMPAOLO MERLINI;RICCARDO CACCIALANZA;MARIO CAZZOLA;MARCO BENAZZO;EMANUELE CEREDA;VALERIA BRAZZELLI;GARIFALLIA SAKELLARIOU;LORENZO CAVAGNA","23;21;19;15;14;13;13;13;12;11;10;10;10;9;9;9;8;8;8;7","CARMINE TINELLI;ROBERTO CAPORALI;MAURO STRONATI;CARLOMAURIZIO MONTECUCCO;CATHERINE KLERSY;FABIO PAGELLA;MARCO BENAZZO;STEFANO GHIO;VALERIA BRAZZELLI;GINO ROBERTO CORAZZA;FAUSTO BALDANTI;LAURA OBICI;GIULIA MARIA STELLA;RICCARDO CACCIALANZA;ANTONIO BOZZANI;VITTORIO ARICI;MARCO ZECCA;FRANCESCO BENAZZO;GARIFALLIA SAKELLARIOU;GIAMPAOLO MERLINI","2.88;2.34;1.8;1.79;1.77;1.61;1.5;1.46;1.45;1.22;1.2;1.2;1.15;1.1;1.08;1.08;1.07;1.04;1.03;1.02","CATHERINE KLERSY;STEFANO GHIO;GIOVANNI BAROSI;MARIO CAZZOLA;EZIO BRAMUCCI;SERGIO LEONARDI;ELISA RUMI;PAOLA GUGLIELMELLI;LISA PIERI;PIER LUIGI TEMPORELLI;HARVEY D. WHITE;ROBERT A. HARRINGTON;C. MICHAEL GIBSON;MARCO ZECCA;FRANCO LOCATELLI;DANIELA PIETRA;KENNETH W. MAHAFFEY;ALESSANDRO PANCRAZZI;GIADA ROTUNNO;FRANCISCO CERVANTES","1354;1248;1239;1128;1066;988;972;971;887;882;852;849;834;833;823;798;785;783;783;777","CATHERINE KLERSY;STEFANO GHIO;GIOVANNI BAROSI;EZIO BRAMUCCI;MARCO ZECCA;SERGIO LEONARDI;FAUSTO BALDANTI;CARMINE TINELLI;RICCARDO CACCIALANZA;ELENA PERCIVALLE;MARIA ANTONIETTA AVANZINI;ANTONIO PIRALLA;MARIO CAZZOLA;MARGHERITA MASSA;LAURA OBICI;VITTORIO ROSTI;ANTONELLA SARASINI;GIOVANNA GIORGIANI;MAURO STRONATI;MAURIZIO LANDOLINA","1343;1248;1215;863;833;785;531;468;462;433;426;356;331;314;312;293;281;277;273;269","CARMINE TINELLI;CATHERINE KLERSY;ROBERTO CAPORALI;MARCO ZECCA;STEFANO GHIO;MAURO STRONATI;LAURA OBICI;FAUSTO BALDANTI;GIOVANNI BAROSI;CARLOMAURIZIO MONTECUCCO;GIAN LUIGI MARSEGLIA;RICCARDO CACCIALANZA;GARIFALLIA SAKELLARIOU;GINO ROBERTO CORAZZA;LORENZO CAVAGNA;MAURIZIO LANDOLINA;CAMILLO PORTA;EMANUELE CEREDA;ANNALISA DE SILVESTRI;PAOLO PEDRAZZOLI","22;18;17;15;14;13;11;10;9;9;8;8;7;7;7;7;7;7;6;6","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;ART;BUSINESS;ECONOMICS;HISTORY;SOCIOLOGY;GEOGRAPHY;GEOLOGY","388;158;34;21;12;11;10;9;9;8;7;4;4;4;3;3;1;1","INTERNAL MEDICINE;IMMUNOLOGY;SURGERY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;BIOCHEMISTRY;CARDIOLOGY;PEDIATRICS;ENDOCRINOLOGY;ONCOLOGY;RADIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;VIROLOGY;PHYSICAL THERAPY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;ANATOMY;MICROBIOLOGY","295;105;99;89;88;62;55;43;40;37;34;31;27;27;26;24;23;19;18;16;16","GENE;DISEASE;ANTIBODY;BONE MARROW;CHEMOTHERAPY;CANCER;POPULATION;PREGNANCY;RHEUMATOLOGY;TRANSPLANTATION;CONFIDENCE INTERVAL;STEM CELL;VIRUS;HEART FAILURE;IN VITRO;LUNG;ALTERNATIVE MEDICINE;COHORT;RECEPTOR;INFLAMMATION;RHEUMATOID ARTHRITIS","62;58;30;28;26;25;25;24;24;22;21;21;20;19;19;19;18;18;17;14;14","GENOTYPE;HAZARD RATIO;EJECTION FRACTION;MYELOFIBROSIS;GESTATIONAL AGE;MUTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYELODYSPLASTIC SYNDROMES;CHROMOSOME;GENOME;CLINICAL ENDPOINT;HAEMATOPOIESIS;PERIPHERAL BLOOD MONONUCLEAR CELL;PHENOTYPE;SEROLOGY;AUTOANTIBODY;COLORECTAL CANCER;ESCHERICHIA COLI;FETUS;OVERWEIGHT;PERCUTANEOUS CORONARY INTERVENTION;PLACEBO;VIRAL LOAD","17;16;14;14;10;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6","CARDIAC RESYNCHRONIZATION THERAPY;RUXOLITINIB;ANTIRETROVIRAL THERAPY;DIFFUSING CAPACITY;GENE MUTATION;HAPLOTYPE;HERPESVIRIDAE;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;KLEBSIELLA PNEUMONIAE;MONOCLONAL;RETINOPATHY OF PREMATURITY;SINGLE-NUCLEOTIDE POLYMORPHISM;WHOLE GENOME SEQUENCING;ADIPOKINE;AL AMYLOIDOSIS;CANAKINUMAB;COMPARATIVE GENOMIC HYBRIDIZATION;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);ELECTROCHEMOTHERAPY;MYELOPROLIFERATIVE NEOPLASM;SMALL FOR GESTATIONAL AGE;STROKE VOLUME","7;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;TREATMENT OUTCOME;ADOLESCENT;YOUNG ADULT;HEART FAILURE;AGED, 80 AND OVER;BIOMARKERS;RETROSPECTIVE STUDIES;CHILD;PRIMARY MYELOFIBROSIS;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;HIV INFECTIONS","242;179;178;165;119;96;95;59;52;39;38;33;32;32;31;30;29;27;26;25","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;RHEUMATOID ARTHRITIS;ACUTE MYELOID LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MOLECULAR MECHANISMS OF INFLAMMASOME ACTIVATION AND REGULATION;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ORGAN TRANSPLANTATION AND REJECTION;DIAGNOSIS AND TREATMENT OF RETINOPATHY OF PREMATURITY;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;RENAL CELL CARCINOMA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEMATOPOIETIC STEM CELL BIOLOGY","17;11;10;9;8;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4","TREATMENT;MYELOFIBROSIS;CARDIAC RESYNCHRONIZATION THERAPY;DIAGNOSIS;REFRACTORY (PLANETARY SCIENCE);REGIMEN;CLINICAL ENDPOINT;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;PULMONARY HYPERTENSION;ASTHMA;CARDIAC AMYLOIDOSIS;CUMULATIVE INCIDENCE;DIAGNOSTIC CRITERIA;ECHOCARDIOGRAPHY;HEMATOPOIETIC CELL TRANSPLANTATION;INTERQUARTILE RANGE;LIGHT CHAIN AMYLOIDOSIS;MESENCHYMAL STEM CELLS;PATHOGENESIS;RIGHT HEART ASSESSMENT","16;11;8;8;8;8;7;7;6;5;5;5;5;5;5;5;5;5;5;5","RHEUMATOID ARTHRITIS;HEART FAILURE;CELL TRANSPLANTATION;STEM CELL;SYSTEMIC SCLEROSIS;CARDIAC RESYNCHRONIZATION;RESYNCHRONIZATION THERAPY;ACUTE CORONARY;ATRIAL FIBRILLATION;DISEASE ACTIVITY;MESENCHYMAL STROMAL;STEM CELLS;STROMAL CELLS;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;ARTERY DISEASE;CASO CLINICO;CASO DI;CORD BLOOD;GROWTH HORMONE;HEMATOPOIETIC STEM;KLEBSIELLA PNEUMONIAE;LUNG TRANSPLANT;LYMPHOBLASTIC LEUKEMIA;MESENCHYMAL STEM;PRIMARY MYELOFIBROSIS;RISK FACTORS;STUDIO DI;SYNDROME TRAPS;ULTRASOUND IMAGING","12;8;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;CARDIAC SURGERY;SERUM AMYLOID;AA AMYLOIDOSIS;SAN MATTEO;FONDAZIONE IRCCS;HEART FAILURE;IRCCS POLICLINICO;POLICLINICO SAN;BONE MARROW;MD DEPARTMENT;SURGERY FONDAZIONE;HAZARD RATIO;ARTERY SYSTOLIC;HR CI;MATTEO PAVIA;STEM CELL;SYSTOLIC PRESSURE;AMYLOID CLEARANCE;GROWTH FACTOR;AMYLOID DEPOSITS;ANTITHYMOCYTE GLOBULIN;FACTOR Β;HEMATOPOIETIC STEM;PAVIA ITALYSEARCH;PLASMA CITRULLINE;RATIO HR;STATISTICALLY SIGNIFICANT;TG MICE","35;27;15;15;14;14;13;13;13;13;12;12;12;11;10;10;10;10;10;9;9;8;8;8;8;8;8;8;8;8",107,0.26,2,18.07,5,179.482,14.11,1,120,2.4,1,6,1.56,1,4,1,1,1,3.5,1,14,8.2,1,59,0,0,0,1,1,1,14.81,1,126,0,0,0,1,1,1,9.65,1,74,0,0,0,2,1,4,1.5,1,3,2.31,1,14,8.06,1,51,2.43,1,7,0.19,0,3,0,0,0,104.37,33,395,104.56,33,396,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2014,382,12.8010471204188,3.06020942408377,0.3267750213858,0.335078534031414,0.342931937172775,0.37434554973822,0.392670157068063,4,183,95,30,56,0.48,0.25,0.08,0.15,44.5,1.1775071969759,0.3717277486911,0.984293193717278,6.28812763960582,0.464663651150433,0.396458724202627,0.451395348837209,0.441169941169941,"CARMINE TINELLI;MARIO CAZZOLA;MARCO ZECCA;CATHERINE KLERSY;MAURO STRONATI;FRANCO LOCATELLI;ALESSANDRO RAMBALDI;ELISA RUMI;ALESSANDRO M. VANNUCCHI;FAUSTO BALDANTI;TIZIANO BARBUI;FRANCESCO PASSAMONTI;PAOLA GUGLIELMELLI;ALBERTO BOSI;LUIGIA SCUDELLER;LISA PIERI;GAETANO MARIA DE FERRARI;CRISTIANA PASCUTTO;GIOVANNI BAROSI;VITTORIO ROSTI","25;23;23;20;17;17;15;15;14;13;12;11;11;11;10;10;10;10;10;9","CARMINE TINELLI;MAURO STRONATI;CATHERINE KLERSY;FAUSTO BALDANTI;MARCO ZECCA;MARIO CAZZOLA;GAETANO MARIA DE FERRARI;LUIGIA SCUDELLER;GIOVANNI BAROSI;RICCARDO G. BORRONI;GIAN LUIGI MARSEGLIA;CARLOMAURIZIO MONTECUCCO;GEMMA CATERINA MARIA ROSSI;MANUELA MONTI;FRANCO LOCATELLI;MAURO BOZZOLA;ANTÔNIO RICCI;STEFANO GHIO;STEFANO DE SERVI;LINA BOLLANI","3.35;2.49;1.81;1.56;1.48;1.38;1.36;1.34;1.29;1.2;1.18;1.16;1.14;1.14;1.12;1.04;1;0.96;0.96;0.94","CARMINE TINELLI;MARIO CAZZOLA;MARCO ZECCA;CATHERINE KLERSY;MAURO STRONATI;ELISA RUMI;FAUSTO BALDANTI;LUIGIA SCUDELLER;GAETANO MARIA DE FERRARI;CRISTIANA PASCUTTO;GIOVANNI BAROSI;VITTORIO ROSTI;DANIELA PIETRA;STEFANO GHIO;GIAMPAOLO MERLINI;VIRGINIA VALERIA FERRETTI;RITA CAMPOROTONDO;STEFANO DE SERVI;ARSENIO SPINILLO;GIAN LUIGI MARSEGLIA","25;23;23;20;17;15;13;10;10;10;10;9;8;8;8;7;7;7;7;7","CARMINE TINELLI;MAURO STRONATI;CATHERINE KLERSY;FAUSTO BALDANTI;MARCO ZECCA;MARIO CAZZOLA;GAETANO MARIA DE FERRARI;LUIGIA SCUDELLER;GIOVANNI BAROSI;RICCARDO G. BORRONI;GIAN LUIGI MARSEGLIA;CARLOMAURIZIO MONTECUCCO;GEMMA CATERINA MARIA ROSSI;MANUELA MONTI;MAURO BOZZOLA;ANTÔNIO RICCI;STEFANO GHIO;STEFANO DE SERVI;LINA BOLLANI;SIMONE SAVASTANO","3.35;2.49;1.81;1.56;1.48;1.38;1.36;1.34;1.29;1.2;1.18;1.16;1.14;1.14;1.04;1;0.96;0.96;0.94;0.91","GIAMPAOLO MERLINI;ANGELA DISPENZIERI;ANTONIO PALUMBO;EFSTATHIOS KASTRITIS;ELENA ZAMAGNI;HANS ERIK JOHNSEN;MARÍA‐VICTORIA MATEOS;MELETIOS Α. DIMOPOULOS;XAVIER LELEU;SONJA ZWEEGMAN;MICHÈLE CAVO;BRENDAN M. WEISS;BRIAN G.M. DURIE;BRUNO PAIVA;EVANGELOS TERPOS;HARTMUT GOLDSCHMIDT;JENS HILLENGAß;JESÚS F. SAN MIGUEL;JO CAERS;JOAN BLADÉ","4361;3918;3907;3907;3907;3907;3907;3907;3907;3899;3898;3896;3896;3896;3896;3896;3896;3896;3896;3896","GIAMPAOLO MERLINI;CAMILLO PORTA;CHIARA PAGLINO;CATHERINE KLERSY;MARCO ZECCA;ELOISA ARBUSTINI;EMANUELE CEREDA;MAURIZIA GRASSO;ALESSANDRA SERIO;VITTORIO ROSTI;GIOVANNI BAROSI;REMIGIO MORATTI;CARMINE TINELLI;GAETANO MARIA DE FERRARI;MAURO STRONATI;MANUEL GOTTI;VIRGINIA VALERIA FERRETTI;G. BAROSI;FAUSTO BALDANTI;STEFANO DE SERVI","3939;1993;1937;696;633;547;531;503;500;497;460;422;402;400;390;371;344;289;283;277","MARCO ZECCA;CARMINE TINELLI;CATHERINE KLERSY;MARIO CAZZOLA;MAURO STRONATI;ELISA RUMI;FAUSTO BALDANTI;GAETANO MARIA DE FERRARI;GIOVANNI BAROSI;LUIGIA SCUDELLER;STEFANO GHIO;VITTORIO ROSTI;GIAMPAOLO MERLINI;RITA CAMPOROTONDO;GIAN LUIGI MARSEGLIA;LUCA MALCOVATI;STEFANO DE SERVI;ELOISA ARBUSTINI;PATRIZIA COMOLI;B. ROVERETO","23;21;20;20;16;13;12;10;10;10;8;8;7;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;PSYCHOLOGY;COMPUTER SCIENCE;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;HISTORY;PHILOSOPHY","359;140;41;28;16;13;13;13;10;6;3;2;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;PEDIATRICS;CARDIOLOGY;ONCOLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;ENVIRONMENTAL HEALTH;RADIOLOGY;CELL BIOLOGY;OPTICS;VIROLOGY;ENDOCRINOLOGY;PHARMACOLOGY;ANESTHESIA;PHYSICAL THERAPY;PSYCHIATRY","269;102;92;86;58;54;52;49;45;38;32;31;31;26;25;23;19;17;16;14;14;14","GENE;DISEASE;BONE MARROW;TRANSPLANTATION;POPULATION;CHEMOTHERAPY;ANTIBODY;CANCER;PREGNANCY;STEM CELL;COHORT;MYOCARDIAL INFARCTION;VIRUS;IMMUNE SYSTEM;ADVERSE EFFECT;HEART FAILURE;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;IN VITRO;ALTERNATIVE MEDICINE","49;40;39;33;32;30;25;23;22;22;21;19;19;18;17;17;17;17;16;15","MYELOFIBROSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;MYELODYSPLASTIC SYNDROMES;ESSENTIAL THROMBOCYTHEMIA;PERCUTANEOUS CORONARY INTERVENTION;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;HAEMATOPOIESIS;ACUTE CORONARY SYNDROME;CYTOTOXIC T CELL;HUMAN CYTOMEGALOVIRUS;HUMAN LEUKOCYTE ANTIGEN;EJECTION FRACTION;NEUTROPENIA;PHENOTYPE;PLACEBO;T CELL;CD34;CHROMOSOME;COLORECTAL CANCER;GENOTYPE;HAZARD RATIO;PROGENITOR CELL;TOLERABILITY;VIRAL DISEASE","19;17;17;15;13;13;12;12;11;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7","INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;MYELOPROLIFERATIVE NEOPLASM;HERPESVIRIDAE;RUXOLITINIB;TOTAL BODY IRRADIATION;AL AMYLOIDOSIS;FEBRILE NEUTROPENIA;MISSENSE MUTATION;AMNIOTIC FLUID;BUSULFAN;CHRONIC MYELOMONOCYTIC LEUKEMIA;CORONAVIRUS DISEASE 2019 (COVID-19);DONOR SPECIFIC ANTIBODIES;EXOME SEQUENCING;FANCONI ANEMIA;FLUDARABINE;GENOTYPING;IMATINIB MESYLATE;KRAS;RETINOPATHY OF PREMATURITY;TESTIS DETERMINING FACTOR;TICAGRELOR;VINCRISTINE","10;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;ITALY;ADOLESCENT;TREATMENT OUTCOME;YOUNG ADULT;ACUTE CORONARY SYNDROME;BIOMARKERS;CYTOMEGALOVIRUS INFECTIONS;RETROSPECTIVE STUDIES;CHILD;PROSPECTIVE STUDIES;AGED, 80 AND OVER;HEART FAILURE;CHILD, PRESCHOOL","213;159;157;148;97;96;76;61;45;42;39;38;34;34;34;31;30;27;27;24","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;RENAL CELL CARCINOMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS;FIBER OPTIC SENSOR TECHNOLOGY;HEPATITIS C INFECTION AND TREATMENT;KIDNEY TRANSPLANTATION;MANAGEMENT OF VALVULAR HEART DISEASE;RHEUMATOID ARTHRITIS","21;16;11;8;8;7;7;5;5;5;5;5;4;4;4;4;4;4;4;4","TREATMENT;CLINICAL ENDPOINT;MYELOFIBROSIS;REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;HEMATOLOGY;DIAGNOSIS;MYELOPROLIFERATIVE NEOPLASM;PULMONARY HYPERTENSION;REFRACTORY (PLANETARY SCIENCE);TOLERABILITY;CARDIAC AMYLOIDOSIS;CUMULATIVE INCIDENCE;LIGHT CHAIN AMYLOIDOSIS;TREATMENT OUTCOMES;CALR MUTATION;CORD BLOOD;CYTOMEGALOVIRUS;CYTOPENIA;IMMUNOPHENOTYPING","15;12;11;10;9;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5","STEM CELL;CELL TRANSPLANTATION;BONE MARROW;HEART FAILURE;MYELOID LEUKEMIA;ACUTE CORONARY;CORONARY SYNDROME;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;PULMONARY HYPERTENSION;CORONARY INTERVENTION;PERCUTANEOUS CORONARY;ACUTE LYMPHOBLASTIC;AL AMYLOIDOSIS;CLINICAL TRIAL;MULTICENTER STUDY;MYELODYSPLASTIC SYNDROMES;PRIMARY MYELOFIBROSIS;RHEUMATOID ARTHRITIS;ALLOGENEIC HEMATOPOIETIC;ALLOGENEIC STEM;CELIAC DISEASE;CONTROLLED TRIAL;CORD BLOOD;ENDOTHELIAL CELLS;ESSENTIAL THROMBOCYTHEMIA;HEPATOCELLULAR CARCINOMA;INTERNATIONAL PROGNOSTIC;ITALIAN ASSOCIATION;PARKINSONS DISEASE","12;11;9;9;8;7;7;7;7;7;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","BONE MARROW;RESEARCH FUNDING;PULMONARY HYPERTENSION;STEM CELL;FLOW CYTOMETRIC;HEALTHY CONTROLS;HEART FAILURE;RCC PATIENTS;RISK FACTORS;VENOUS THROMBOSIS;ADVISORY COMMITTEES;ENTITYS BOARD;THROMBOEMBOLIC PULMONARY;CELL TRANSPLANTATION;CHRONIC THROMBOEMBOLIC;FANCONI ANEMIA;LEFT VENTRICULAR;MEDIAN AGE;MEDIAN FOLLOW-UP;PERIPHERAL BLOOD;ENDOTHELIAL CELLS;FUNCTION SUBSCALE;HEMATOPOIETIC STEM;HR CI;LEVODOPA THERAPY;REFRACTORY CYTOPENIA;COMPLEX KARYOTYPES;CYTOMETRIC ABNORMALITIES;FACIAL PALSY;FLOW CYTOMETRY","20;18;15;15;14;13;13;12;12;12;10;10;10;9;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7",115,0.3,3,33.87,6.55,367.779999999999,31,1,423,3.45,1,15,1.25,1,3,1.6,1,3,3.53,1,16,8.9,1,42,0,0,0,2,1,4,48.72,1,892,0,0,0,1,1,1,27.08,1,387,1,1,1,3,1,9,2.7,1,14,7.62,1,58,20.77,1,266,6.64,1,48,0.21,0,2,0,0,0,241.34,19,2597,241.55,19,2598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2015,413,13.590799031477,2.7772397094431,0.360069747166521,0.305084745762712,0.280871670702179,0.309927360774818,0.457627118644068,3,242,74,31,42,0.59,0.18,0.08,0.1,38.97,1.04555877291985,0.397094430992736,0.987893462469734,6.33116601647162,0.482956739214867,0.436130536130536,0.453078018673841,0.466740988480119,"CATHERINE KLERSY;CARMINE TINELLI;MARIO CAZZOLA;MARCO ZECCA;VITTORIO ROSTI;FAUSTO BALDANTI;GIOVANNI BAROSI;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;EMANUELE CEREDA;LUIGIA SCUDELLER;ANTONIO PIRALLA;DANIELA PIETRA;ALESSANDRO M. VANNUCCHI;MAURO STRONATI;FRANCO LOCATELLI;CHIARA ELENA;STEFANO DE SERVI;ROBERTO CAPORALI;ALESSANDRO RAMBALDI","26;25;24;18;17;17;15;14;12;12;12;11;11;11;10;10;10;10;10;10","CARMINE TINELLI;CATHERINE KLERSY;FAUSTO BALDANTI;MARIO CAZZOLA;MAURO STRONATI;LUIGIA SCUDELLER;GIAMPAOLO MERLINI;EMANUELE CEREDA;ANTONIO PIRALLA;FRANCESCO MOJOLI;VITTORIO ROSTI;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;FERDINANDO DRAGHI;CHANDRA BORTOLOTTO;FRANCESCO BENAZZO;MARGHERITA POZZI;MARCO ZECCA;ROBERTO CAPORALI;VALENTINA POLETTO","2.78;2.27;2;1.96;1.87;1.87;1.54;1.52;1.42;1.39;1.32;1.31;1.27;1.25;1.25;1.2;1.18;1.15;1.11;1.08","CATHERINE KLERSY;CARMINE TINELLI;MARIO CAZZOLA;MARCO ZECCA;VITTORIO ROSTI;FAUSTO BALDANTI;GIOVANNI BAROSI;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;EMANUELE CEREDA;LUIGIA SCUDELLER;ANTONIO PIRALLA;DANIELA PIETRA;MAURO STRONATI;FRANCO LOCATELLI;CHIARA ELENA;STEFANO DE SERVI;ROBERTO CAPORALI;LUCA MALCOVATI;FRANCESCO MOJOLI","26;25;24;18;17;17;15;14;12;12;12;11;11;10;10;10;10;10;10;10","CARMINE TINELLI;CATHERINE KLERSY;FAUSTO BALDANTI;MARIO CAZZOLA;MAURO STRONATI;LUIGIA SCUDELLER;GIAMPAOLO MERLINI;EMANUELE CEREDA;ANTONIO PIRALLA;FRANCESCO MOJOLI;VITTORIO ROSTI;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;FERDINANDO DRAGHI;CHANDRA BORTOLOTTO;FRANCESCO BENAZZO;MARGHERITA POZZI;MARCO ZECCA;ROBERTO CAPORALI;VALENTINA POLETTO","2.78;2.27;2;1.96;1.87;1.87;1.54;1.52;1.42;1.39;1.32;1.31;1.27;1.25;1.25;1.2;1.18;1.15;1.11;1.08","GAETANO MARIA DE FERRARI;HARALD DARIUS;BASIL S. LEWIS;ERIN A. BOHULA;EUGENE BRAUNWALD;AMY MCCAGG;ANDREW M. TERSHAKOVEC;CANQING YU;CHRISTOPHER P. CANNON;J. WOUTER JUKEMA;JENNIFER A. WHITE;MARTIN CRAIG;MICHAEL A. BLAZING;MING‐SHYAN LIN;PAUL DE LUCCA;PIERRE THÉROUX;ROBERT M. CALIFF;ROBERT P. GIUGLIANO;STEPHEN D. WIVIOTT;TON OUDE OPHUIS","3832;3819;3747;3747;3747;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746;3746","GAETANO MARIA DE FERRARI;SERGIO LEONARDI;ALESSANDRA REPETTO;CATHERINE KLERSY;CARMINE TINELLI;MARZIA VARETTONI;LUCA MALCOVATI;MARCO FERLINI;GIOVANNI BAROSI;ROSANGELA INVERNIZZI;MARCO ZECCA;FAUSTO BALDANTI;CARLOMAURIZIO MONTECUCCO;MARTINO NAPOLITANI;MARIO CAZZOLA;VITTORIO ROSTI;ANTONIO PIRALLA;EMANUELE CEREDA;LORENZO CAVAGNA;GLÓRIA PELIZZO","3759;1628;1473;818;678;574;570;535;510;492;423;398;397;370;355;330;305;290;284;248","CATHERINE KLERSY;CARMINE TINELLI;MARCO ZECCA;MARIO CAZZOLA;PAOLO PEDRAZZOLI;FAUSTO BALDANTI;ANNALISA DE SILVESTRI;EMANUELE CEREDA;LUIGIA SCUDELLER;MAURO STRONATI;STEFANO DE SERVI;ANTONIO PIRALLA;ELISA RUMI;LUCA ARCAINI;FRANCESCO MOJOLI;LUCA MALCOVATI;CHIARA ELENA;DANIELA PIETRA;ESTER ORLANDI;LAURA OBICI","26;23;18;17;14;14;11;10;10;10;9;9;9;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;ECONOMICS;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;GEOGRAPHY;GEOLOGY","379;158;26;25;18;14;13;12;9;6;5;5;4;4;2;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ONCOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;PEDIATRICS;RADIOLOGY;VIROLOGY;CELL BIOLOGY;ENDOCRINOLOGY;ANESTHESIA;ANATOMY;OPTICS;PALEONTOLOGY;PSYCHIATRY","294;101;93;83;81;70;64;48;44;42;33;30;30;28;24;20;19;18;13;13;13;13","GENE;DISEASE;BONE MARROW;CHEMOTHERAPY;CANCER;TRANSPLANTATION;POPULATION;STEM CELL;MYOCARDIAL INFARCTION;HEART FAILURE;IMMUNE SYSTEM;RECEPTOR;VIRUS;CLINICAL TRIAL;COHORT;MYELOID LEUKEMIA;ANTIBODY;LYMPHOMA;PREGNANCY;IN VITRO;RANDOMIZED CONTROLLED TRIAL","73;60;38;35;33;33;29;29;26;22;21;21;21;19;19;19;18;18;18;16;16","MUTATION;MYELOFIBROSIS;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CLINICAL ENDPOINT;IMATINIB;MYELODYSPLASTIC SYNDROMES;ACUTE CORONARY SYNDROME;EJECTION FRACTION;HAEMATOPOIESIS;PERCUTANEOUS CORONARY INTERVENTION;RITUXIMAB;PHENOTYPE;T CELL;ESSENTIAL THROMBOCYTHEMIA;GENOME;PROGENITOR CELL;CD34;GENE EXPRESSION;BREAST CANCER;CD8;CYCLOPHOSPHAMIDE;GESTATION;NEUTROPENIA;RNA;SALVAGE THERAPY","21;20;17;17;16;12;12;11;11;11;11;11;10;10;9;9;9;8;8;7;7;7;7;7;7;7","MYELOPROLIFERATIVE NEOPLASM;NILOTINIB;CARDIAC RESYNCHRONIZATION THERAPY;FLUDARABINE;HERPESVIRIDAE;IMATINIB MESYLATE;RUXOLITINIB;SANGER SEQUENCING;BUSULFAN;EXOME SEQUENCING;GENOTYPING;BENDAMUSTINE;CLADE;GENE EXPRESSION PROFILING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LYMPHOPLASMACYTIC LYMPHOMA;MISSENSE MUTATION;RECEPTOR ANTAGONIST;SINGLE-NUCLEOTIDE POLYMORPHISM;THIOTEPA","10;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;ACUTE CORONARY SYNDROME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;CHILD;PROSPECTIVE STUDIES;BIOMARKERS;ADOLESCENT;ANTINEOPLASTIC AGENTS;PROGNOSIS;RISK FACTORS;FOLLOW-UP STUDIES","239;168;168;166;112;104;80;64;49;47;43;34;28;28;26;24;24;24;24;23","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;EFFICACY AND RESISTANCE IN CML TREATMENT;ACUTE MYELOID LEUKEMIA;LYMPHOID NEOPLASMS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEMATOPOIETIC STEM CELL BIOLOGY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MULTIPOTENT MESENCHYMAL STEM CELLS;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;HEPATOCELLULAR CARCINOMA;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MOLECULAR MECHANISMS OF INFLAMMASOME ACTIVATION AND REGULATION","24;12;11;10;8;8;8;7;7;5;5;5;5;4;4;4;4;4;4;4","CLINICAL ENDPOINT;MYELOFIBROSIS;MANTLE CELL LYMPHOMA;TREATMENT;MYELOPROLIFERATIVE NEOPLASM;ECHOCARDIOGRAPHY;CARDIAC IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;REFRACTORY (PLANETARY SCIENCE);REGIMEN;DISCONTINUATION;SALVAGE THERAPY;SANGER SEQUENCING;CARDIOVASCULAR RISK ASSESSMENT;CYTOMEGALOVIRUS;IMATINIB MESYLATE;MESENCHYMAL STEM CELLS;RUXOLITINIB;UNIVARIATE ANALYSIS;CARDIAC ULTRASOUND","16;14;12;12;10;9;8;8;8;8;7;7;7;6;6;6;6;6;6;5","STEM CELL;ACUTE CORONARY;MYELOID LEUKEMIA;CELL TRANSPLANTATION;HEMATOPOIETIC STEM;BONE MARROW;CORONARY SYNDROMES;MYELOPROLIFERATIVE NEOPLASMS;PRIMARY MYELOFIBROSIS;STROMAL CELLS;BREAST CANCER;CHRONIC MYELOID;CLINICAL PRACTICE;CLINICAL TRIALS;CORONARY INTERVENTION;ELDERLY PATIENTS;HIGH-DOSE CHEMOTHERAPY;MARROW TRANSPLANTATION;MESENCHYMAL STROMAL;MYELODYSPLASTIC SYNDROMES;MYOCARDIAL INFARCTION;PARKINSONS DISEASE;PERCUTANEOUS CORONARY;PROGNOSTIC IMPACT;ACUTE MYELOID;ATRIAL FIBRILLATION;CANCER PATIENTS;CARDIAC RESYNCHRONIZATION;CELL LYMPHOMA;CORONARY SYNDROME","14;11;10;9;9;8;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","PUBMED SCOPUS;CROSSREF PUBMED;ENDOTHELIAL PROGENITOR;PROGENITOR CELLS;SPEAKERS BUREAU;RISK FACTORS;CA OSCILLATIONS;INTRACELLULAR CA;RESEARCH FUNDING;STEM CELL;GROWTH FACTOR;ENDOTHELIAL GROWTH;CLINICAL TRIALS;BONE MARROW;CA ENTRY;ADVISORY COMMITTEES;CELLS ISOLATED;ENTITYS BOARD;PATIENTS TREATED;CV RISK;GESTATIONAL AGE;MEDIAN AGE;PATIENTS UNDERGOING;PMF PATIENTS;SIGNIFICANTLY LOWER;CONFIDENCE INTERVAL;MYELOID LEUKEMIA;ODDS RATIO;STEM CELLS;CA SPIKES","59;51;35;32;29;26;24;24;21;19;18;17;16;15;15;14;14;14;14;12;12;12;12;12;12;11;11;11;11;10",152,0.37,3,26.39,6.5,137.564,18.08,1,108,3.12,1,9,1.88,1,4,2,1,3,2.5,1,10,2,1,3,0,0,0,1.5,1,3,20.32,1,129,1,1,1,1,1,1,14.74,1,90,1,1,1,1.33,1,2,1.6,1,3,5.47,1,12,9.51,1,63,4,1,13,0.39,0,7,0,0,0,132.24,12,574,132.63,12,574,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2016,445,13.1101123595506,2.89887640449438,0.344961240310078,0.323595505617978,0.314606741573034,0.346067415730337,0.451685393258427,4,242,97,30,53,0.54,0.22,0.07,0.12,25.44,0.783261666055165,0.404494382022472,0.995505617977528,6.22739944245321,0.502783247107665,0.434609473242979,0.436135638950208,0.441647940074906,"CATHERINE KLERSY;ALICE CHANDRA VERTICCHIO VERCELLIN;MARCO ZECCA;EMANUELE CEREDA;ALON HARRIS;MARIO CAZZOLA;BRENT SIESKY;FAUSTO BALDANTI;CARMINE TINELLI;LUIGIA SCUDELLER;GEORGE J. ECKERT;NICHOLAS MOORE;FEDERICA MELONI;STEFANO DE SERVI;ANNALISA DE SILVESTRI;PAOLO PEDRAZZOLI;VIRGINIA VALERIA FERRETTI;VITTORIO ROSTI;GABRIELE CRIMI;STEFANO GHIO","30;19;18;17;17;17;17;16;15;14;14;14;13;13;12;12;11;11;11;11","CATHERINE KLERSY;ALICE CHANDRA VERTICCHIO VERCELLIN;MANUELA MONTI;FAUSTO BALDANTI;ALON HARRIS;BRENT SIESKY;GIAN LUIGI MARSEGLIA;CARMINE TINELLI;EMANUELE CEREDA;GEORGE J. ECKERT;NICHOLAS MOORE;GUIDO TAVAZZI;LUIGIA SCUDELLER;ANNALISA DE SILVESTRI;GABRIELE CRIMI;FEDERICA MELONI;MASSIMILIANO GNECCHI;VALERIA CALCATERRA;PAOLO PEDRAZZOLI;FRANCESCO MOJOLI","2.9;2.32;2.22;2.05;1.95;1.95;1.83;1.74;1.68;1.62;1.62;1.61;1.54;1.49;1.49;1.38;1.36;1.3;1.29;1.26","CATHERINE KLERSY;ALICE CHANDRA VERTICCHIO VERCELLIN;MARCO ZECCA;EMANUELE CEREDA;MARIO CAZZOLA;FAUSTO BALDANTI;CARMINE TINELLI;LUIGIA SCUDELLER;FEDERICA MELONI;STEFANO DE SERVI;ANNALISA DE SILVESTRI;PAOLO PEDRAZZOLI;VIRGINIA VALERIA FERRETTI;VITTORIO ROSTI;GABRIELE CRIMI;STEFANO GHIO;GIOVANNI BAROSI;MASSIMILIANO GNECCHI;CARLOMAURIZIO MONTECUCCO;CHIARA ELENA","30;19;18;17;17;16;15;14;13;13;12;12;11;11;11;11;11;10;9;9","CATHERINE KLERSY;ALICE CHANDRA VERTICCHIO VERCELLIN;MANUELA MONTI;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;CARMINE TINELLI;EMANUELE CEREDA;GUIDO TAVAZZI;LUIGIA SCUDELLER;ANNALISA DE SILVESTRI;GABRIELE CRIMI;FEDERICA MELONI;MASSIMILIANO GNECCHI;VALERIA CALCATERRA;PAOLO PEDRAZZOLI;FRANCESCO MOJOLI;MARIO CAZZOLA;GLÓRIA PELIZZO;MARCO ZECCA;MARIA CHIARA CIUFFREDA","2.9;2.32;2.22;2.05;1.83;1.74;1.68;1.61;1.54;1.49;1.49;1.38;1.36;1.3;1.29;1.26;1.18;1.16;1.13;1.07","EMANUELE CEREDA;CATHERINE KLERSY;GIANNI PEZZOLI;RICCARDO CACCIALANZA;MICHELA BARICHELLA;ERICA CASSANI;MARCO ZECCA;STEFANO GHIO;MARIO CAZZOLA;ROBERTO CILIA;MARGHERITA CANESI;ALESSANDRO RAMBALDI;LAURA SCELSI;C. PUSANI;CARLOTTA BOLLIRI;GIOVANNA PINELLI;LAURA IORIO;FRANCESCO PASSAMONTI;RICCARDO ALBERTINI;CHIARA SIRI","1523;1304;992;928;905;565;530;523;489;476;468;467;463;449;449;449;449;441;436;421","EMANUELE CEREDA;CATHERINE KLERSY;RICCARDO CACCIALANZA;MARCO ZECCA;STEFANO GHIO;MARIO CAZZOLA;LAURA SCELSI;RICCARDO ALBERTINI;GIULIA MARIA STELLA;ANNALISA TURRI;B. CAMELETTI;DANIELA MAGNO;MARILISA CARACCIA;SILVIA CAPPELLO;VITTORIO ROSTI;MATTEO GIOVANNI DELLA PORTA;CHIARA BROGLIA;C. PUSANI;CARLOTTA BOLLIRI;CLAUDIO PACCHETTI","1523;1304;928;530;523;478;463;436;420;390;390;390;390;390;334;316;308;302;302;302","CATHERINE KLERSY;MARCO ZECCA;EMANUELE CEREDA;ALICE CHANDRA VERTICCHIO VERCELLIN;FAUSTO BALDANTI;CARMINE TINELLI;STEFANO GHIO;ANNALISA DE SILVESTRI;STEFANO DE SERVI;PAOLO PEDRAZZOLI;LUIGIA SCUDELLER;FEDERICA MELONI;CHIARA ELENA;GABRIELE CRIMI;MASSIMILIANO GNECCHI;RICCARDO CACCIALANZA;ANTONIO PIRALLA;MARCO FERLINI;MARIO CAZZOLA;SIMONE SAVASTANO","29;18;17;17;16;15;11;11;11;11;10;10;9;9;9;9;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;POLITICAL SCIENCE;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;GEOLOGY;ART;BUSINESS;PHILOSOPHY;GEOGRAPHY;HISTORY","428;128;35;32;20;18;17;16;16;15;8;8;7;4;4;4;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;CARDIOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;PEDIATRICS;ENDOCRINOLOGY;VIROLOGY;ANESTHESIA;OPHTHALMOLOGY;CANCER RESEARCH;CELL BIOLOGY;PHYSICAL THERAPY","340;105;84;83;77;69;59;56;37;35;33;33;31;29;27;24;24;23;20;20","DISEASE;GENE;TRANSPLANTATION;BONE MARROW;POPULATION;MYOCARDIAL INFARCTION;HEART FAILURE;CANCER;VIRUS;CHEMOTHERAPY;ANTIBODY;COHORT;CLINICAL TRIAL;CONFIDENCE INTERVAL;LUNG;RANDOMIZED CONTROLLED TRIAL;STEM CELL;IMMUNE SYSTEM;GLAUCOMA;PREGNANCY","48;47;34;33;33;30;28;26;26;22;21;21;20;20;20;20;20;19;18;18","PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CLINICAL ENDPOINT;MYELOFIBROSIS;GENOTYPE;MUTATION;OPEN ANGLE GLAUCOMA;HAZARD RATIO;ACUTE CORONARY SYNDROME;CONVENTIONAL PCI;LUNG TRANSPLANTATION;FETUS;GENE EXPRESSION;MYELODYSPLASTIC SYNDROMES;PLACEBO;CYCLOPHOSPHAMIDE;HEPATITIS C VIRUS;HUMAN CYTOMEGALOVIRUS;IMATINIB;VIRAL LOAD","17;15;15;14;14;11;11;11;10;9;9;9;8;8;8;8;7;7;7;7;7","CARDIAC RESYNCHRONIZATION THERAPY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;AL AMYLOIDOSIS;ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;TIMI;BENDAMUSTINE;BRONCHIOLITIS OBLITERANS;MYELOPROLIFERATIVE NEOPLASM;PRASUGREL;RUXOLITINIB;TOTAL BODY IRRADIATION;AMNIOTIC FLUID;BUSULFAN;DNA METHYLATION;DRUG-ELUTING STENT;ELISPOT;GERMLINE MUTATION;IBRUTINIB;IMATINIB MESYLATE;PRENATAL DIAGNOSIS;RIBAVIRIN;TRANSIENT ELASTOGRAPHY;UMBILICAL CORD BLOOD TRANSPLANTATION","7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;FEMALE;;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;HEART FAILURE;RETROSPECTIVE STUDIES;YOUNG ADULT;MYOCARDIAL INFARCTION;FOLLOW-UP STUDIES;ADOLESCENT;PERCUTANEOUS CORONARY INTERVENTION;ANTINEOPLASTIC AGENTS;RISK FACTORS;PROSPECTIVE STUDIES","259;197;182;182;142;117;104;71;54;50;45;44;39;38;36;35;31;29;29;28","GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;HEMATOPOIETIC STEM CELL BIOLOGY;ACUTE MYELOID LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATITIS C INFECTION AND TREATMENT;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;EFFICACY AND RESISTANCE IN CML TREATMENT;LYMPHOID NEOPLASMS;MANAGEMENT OF VALVULAR HEART DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MULTIPOTENT MESENCHYMAL STEM CELLS","16;14;11;9;9;9;9;8;8;8;8;7;7;7;7;6;6;6;5;5","TREATMENT;CLINICAL ENDPOINT;ECHOCARDIOGRAPHY;PRIMARY OPEN-ANGLE GLAUCOMA;GLAUCOMA;HEMATOPOIETIC CELL TRANSPLANTATION;MYELOFIBROSIS;REGIMEN;CARDIAC RESYNCHRONIZATION THERAPY;DISCONTINUATION;HEMATOLOGY;HEPATITIS C;CUMULATIVE INCIDENCE;ETIOLOGY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTRAOCULAR PRESSURE;STROKE (ENGINE);UNIVARIATE ANALYSIS;AL AMYLOIDOSIS;CARDIAC IMAGING","22;15;14;14;12;11;9;9;8;7;7;7;6;6;6;6;6;6;5;5","GLAUCOMA PATIENTS;MYOCARDIAL INFARCTION;ACUTE CORONARY;BLOOD FLOW;BONE MARROW;HEART FAILURE;OPEN-ANGLE GLAUCOMA;REAL LIFE;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;PERCUTANEOUS CORONARY;RETROBULBAR BLOOD;STEM CELL;HUMAN CYTOMEGALOVIRUS;PARKINSONS DISEASE;STEM CELLS;VALVE IMPLANTATION;CARDIAC RESYNCHRONIZATION;CELL TRANSPLANTATION;CLINICAL TRIAL;CORONARY INTERVENTION;DIABETES MELLITUS;FUNCTIONAL PROGRESSION;HEMATOPOIETIC STEM;MULTICENTER STUDY;MULTIPLE MYELOMA;RETROSPECTIVE STUDY;AL AMYLOIDOSIS;BALLOON-EXPANDABLE VALVE","13;12;8;8;8;8;8;8;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4","RESEARCH FUNDING;STEM CELL;PUBMED SCOPUS;ITALY HEMATOLOGY;MM HG;HEMATOLOGY UNIT;ADVERSE EVENTS;MYOCARDIAL INFARCTION;LEFT VENTRICULAR;RISK FACTORS;HEART FAILURE;BONE MARROW;CROSSREF PUBMED;HEART DISEASE;PATIENTS RECEIVED;CELL TRANSPLANTATION;CONFIDENCE INTERVAL;CLINICAL PRACTICE;EJECTION FRACTION;HR CI;LEFT VENTRICLE;MPN-ASSOCIATED MYELOFIBROSIS;PATIENTS AFFECTED;PULMONARY EMBOLISM;SPONTANEOUS MI;ACUTE CORONARY;BLOOD LACTATE;CARCINOMA PTS;CLINICAL TRIALS;FLOW CYTOMETRY","26;24;22;20;18;17;16;16;15;15;14;13;13;13;13;12;12;11;11;11;11;11;11;11;11;10;10;10;10;10",176,0.4,3,46.61,7,637.9,22.76,1,331,2.12,1,6,1.12,1,2,1,1,1,5.77,1,85,2.57,1,7,0,0,0,1.14,1,2,25.98,1,403,0,0,0,1,1,1,19.69,1,327,1,1,1,1,1,1,1.72,1,7,5.38,1,55,13.74,1,238,4.58,1,26,0.13,0,2,0,0,0,97.15,13,392,94.63,4,392,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2017,421,14.7814726840855,2.89073634204275,0.345932621199671,0.306413301662708,0.263657957244656,0.285035629453682,0.524940617577197,3,216,87,47,41,0.51,0.21,0.11,0.1,27.54,0.934484060022359,0.401425178147268,0.997624703087886,6.13596657804788,0.480706110361865,0.425089210747271,0.456127653708299,0.499236189819149,"CARMINE TINELLI;GAETANO MARIA DE FERRARI;ANNALISA DE SILVESTRI;CATHERINE KLERSY;FAUSTO BALDANTI;MARIO CAZZOLA;MARCO ZECCA;PAOLO PEDRAZZOLI;LUIGI OLTRONA VISCONTI;GABRIELE CRIMI;GIAMPAOLO MERLINI;MARCO FERLINI;ALESSANDRO RAMBALDI;VITTORIO ROSTI;ALESSANDRO M. VANNUCCHI;VIRGINIA VALERIA FERRETTI;LUIGIA SCUDELLER;RITA CAMPOROTONDO;STEFANO DE SERVI;GIOVANNI PALLADINI","23;19;18;18;17;16;16;15;15;14;14;13;13;12;12;11;11;11;11;11","CARMINE TINELLI;ANNALISA DE SILVESTRI;GIOVANNI ROSTI;PAOLO PEDRAZZOLI;CATHERINE KLERSY;GAETANO MARIA DE FERRARI;GABRIELE CRIMI;GIAMPAOLO MERLINI;FAUSTO BALDANTI;LUIGI OLTRONA VISCONTI;PAOLO MILANI;SIMONE SAVASTANO;ALICE CHANDRA VERTICCHIO VERCELLIN;MARCO FERLINI;FILIPPO ANTONACCI;G.L. GILIBERTO;LUIGIA SCUDELLER;RITA CAMPOROTONDO;JOSH GROSS;ALON HARRIS","3.03;2.05;1.8;1.69;1.64;1.63;1.54;1.51;1.42;1.42;1.31;1.23;1.21;1.21;1.19;1.14;1.14;1.09;1.07;1.07","CARMINE TINELLI;GAETANO MARIA DE FERRARI;ANNALISA DE SILVESTRI;CATHERINE KLERSY;FAUSTO BALDANTI;MARIO CAZZOLA;MARCO ZECCA;PAOLO PEDRAZZOLI;LUIGI OLTRONA VISCONTI;GABRIELE CRIMI;GIAMPAOLO MERLINI;MARCO FERLINI;VITTORIO ROSTI;VIRGINIA VALERIA FERRETTI;LUIGIA SCUDELLER;RITA CAMPOROTONDO;STEFANO DE SERVI;GIOVANNI PALLADINI;PAOLO MILANI;EMANUELE CEREDA","23;19;18;18;17;16;16;15;15;14;14;13;12;11;11;11;11;11;11;10","CARMINE TINELLI;ANNALISA DE SILVESTRI;GIOVANNI ROSTI;PAOLO PEDRAZZOLI;CATHERINE KLERSY;GAETANO MARIA DE FERRARI;GABRIELE CRIMI;GIAMPAOLO MERLINI;FAUSTO BALDANTI;LUIGI OLTRONA VISCONTI;PAOLO MILANI;SIMONE SAVASTANO;ALICE CHANDRA VERTICCHIO VERCELLIN;MARCO FERLINI;FILIPPO ANTONACCI;G.L. GILIBERTO;LUIGIA SCUDELLER;RITA CAMPOROTONDO;VALERIA CALCATERRA;FEDERICA MELONI","3.03;2.05;1.8;1.69;1.64;1.63;1.54;1.51;1.42;1.42;1.31;1.23;1.21;1.21;1.19;1.14;1.14;1.09;1.06;1.05","GAETANO MARIA DE FERRARI;ROBERT P. GIUGLIANO;MARIO CAZZOLA;ANTHONY KEECH;MARC S. SABATINE;PETER S. SEVER;TERJE R. PEDERSEN;ARMANDO LIRA PINEDA;IOANNA GOUNI‐BERTHOLD;GIOVANNA FERRAIOLI;VITO CANTISANI;ADRIAN SǍFTOIU;ANNALISA BERZIGOTTI;BOGDAN PROCOPEȚ;DAVID O. COSGROVE;FABIO PISCAGLIA;IOAN SPOREA;JEFFREY C. BAMBER;LAURENT CASTÉRA;MAJA THIELE","1503;1231;1181;1072;1072;1072;1072;1071;1071;1017;947;932;932;932;932;932;932;932;932;932","GAETANO MARIA DE FERRARI;GIOVANNA FERRAIOLI;EMANUELE CEREDA;MARIO CAZZOLA;CARLOMAURIZIO MONTECUCCO;EMANUELA BOVERI;CATHERINE KLERSY;DANIELA PIETRA;SERGIO LEONARDI;MASSIMILIANO GNECCHI;LUCA MALCOVATI;FRANCESCA ROVIDA;FAUSTO BALDANTI;PAOLO PEDRAZZOLI;ELISA RUMI;RICCARDO CACCIALANZA;GIAMPAOLO MERLINI;MARCO ZECCA;GIOVANNI PALLADINI;MANUELA MURA","1502;932;813;539;511;507;458;433;362;349;312;301;294;294;289;288;278;268;264;258","CARMINE TINELLI;ANNALISA DE SILVESTRI;CATHERINE KLERSY;MARCO ZECCA;GABRIELE CRIMI;LUIGI OLTRONA VISCONTI;PAOLO PEDRAZZOLI;FAUSTO BALDANTI;MARCO FERLINI;VITTORIO ROSTI;LUIGIA SCUDELLER;RITA CAMPOROTONDO;EMANUELE CEREDA;MARIO CAZZOLA;GAETANO MARIA DE FERRARI;SIMONE SAVASTANO;FRANCESCA ROVIDA;GIOVANNI ROSTI;P. MARONE;STEFANIA PAOLUCCI","21;16;16;15;14;14;14;13;11;11;11;11;10;10;9;9;8;8;8;8","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;PHILOSOPHY;SOCIOLOGY;GEOGRAPHY;ECONOMICS;HISTORY;MATERIALS SCIENCE;GEOLOGY;ART;BUSINESS","397;121;36;33;17;16;14;12;10;8;8;7;6;6;6;5;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;CARDIOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;CANCER RESEARCH;VIROLOGY;ENDOCRINOLOGY;PEDIATRICS;ANESTHESIA;NURSING;CELL BIOLOGY;PHYSICAL THERAPY","300;102;82;79;77;71;61;45;40;37;31;30;28;26;24;24;21;20;18;18","GENE;TRANSPLANTATION;DISEASE;BONE MARROW;POPULATION;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;VIRUS;COHORT;RETROSPECTIVE COHORT STUDY;CHEMOTHERAPY;CONFIDENCE INTERVAL;ALTERNATIVE MEDICINE;LYMPHOMA;CANCER;LUNG;ADVERSE EFFECT;HEART FAILURE;INCIDENCE (GEOMETRY);REGIMEN;STEM CELL","55;36;34;33;32;30;29;27;27;24;24;23;23;21;21;20;20;17;17;16;16;16","CLINICAL ENDPOINT;MUTATION;MYELOFIBROSIS;GENOTYPE;MYELODYSPLASTIC SYNDROMES;PERCUTANEOUS CORONARY INTERVENTION;EJECTION FRACTION;IMMUNOGLOBULIN LIGHT CHAIN;PLACEBO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;IMATINIB;ACUTE CORONARY SYNDROME;ESSENTIAL THROMBOCYTHEMIA;HAZARD RATIO;OPEN ANGLE GLAUCOMA;PHENOTYPE;HUMAN LEUKOCYTE ANTIGEN;KIDNEY TRANSPLANTATION;TOLERABILITY;VIRAL LOAD","20;18;15;13;13;13;12;11;11;10;10;9;8;8;8;8;8;7;7;7;7","AL AMYLOIDOSIS;ANTIRETROVIRAL THERAPY;RIBAVIRIN;GROWTH HORMONE DEFICIENCY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;NILOTINIB;BRONCHIOLITIS OBLITERANS;CARDIAC INDEX;GENE EXPRESSION PROFILING;IMATINIB MESYLATE;MISSENSE MUTATION;MYELOPROLIFERATIVE NEOPLASM;RUXOLITINIB;TRANSCRIPTOME;ACROMEGALY;APOLIPOPROTEIN A1;BOSENTAN;CARDIAC RESYNCHRONIZATION THERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);CROSSOVER STUDY;DASATINIB;GENOTYPING;HAPLOTYPE;HERPESVIRIDAE;IBRUTINIB;KIDNEY TRANSPLANT;MARGINAL ZONE;MOLECULAR EPIDEMIOLOGY;MONOCLONAL;PLASMA CELL DYSCRASIA;SINGLE-NUCLEOTIDE POLYMORPHISM","9;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;ADOLESCENT;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;RISK FACTORS;FOLLOW-UP STUDIES;YOUNG ADULT;CHILD;BIOMARKERS;ACUTE CORONARY SYNDROME;PROSPECTIVE STUDIES;HIV INFECTIONS","228;189;164;161;110;89;69;63;49;44;39;32;30;29;29;28;27;26;26;23","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;HEPATITIS C INFECTION AND TREATMENT;ACUTE MYELOID LEUKEMIA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;LYMPHOID NEOPLASMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;ORGAN TRANSPLANTATION AND REJECTION;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;TESTICULAR GERM CELL TUMORS AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;CHOLESTEROL-LOWERING TREATMENT","16;14;13;12;11;10;9;8;7;7;7;7;7;6;6;6;6;5;5;4","TREATMENT;CLINICAL ENDPOINT;REGIMEN;AL AMYLOIDOSIS;LIGHT CHAIN AMYLOIDOSIS;REFRACTORY (PLANETARY SCIENCE);CARDIAC AMYLOIDOSIS;MYELOFIBROSIS;NUTRITIONAL STATUS;PRIMARY OPEN-ANGLE GLAUCOMA;CARDIAC IMAGING;DISCONTINUATION;GLAUCOMA;STROKE (ENGINE);TOLERABILITY;DIAGNOSIS;ANTIVIRAL THERAPY;CHOLESTEROL-LOWERING;GROWTH HORMONE;HEMATOPOIETIC CELL TRANSPLANTATION","24;20;16;9;9;9;8;8;8;8;7;7;7;7;7;6;5;5;5;5","STEM CELL;CELL TRANSPLANTATION;GLAUCOMA PATIENTS;MARROW TRANSPLANTATION;AL AMYLOIDOSIS;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;RETROSPECTIVE STUDY;DIABETES MELLITUS;EUROPEAN SOCIETY;HEMATOPOIETIC STEM;HIGH-DOSE CHEMOTHERAPY;PERCUTANEOUS CORONARY;POLYCYTHEMIA VERA;ACUTE CORONARY;CARDIAC ARREST;PULMONARY ARTERIAL;ANGLE GLAUCOMA;BONE MARROW;CANCER PATIENTS;CHRONIC MYELOID;ESSENTIAL THROMBOCYTHEMIA;GERM CELL;GROWTH HORMONE;HEART FAILURE;LEFT VENTRICULAR;NORTHERN ITALY;OUT-OF-HOSPITAL CARDIAC;PATIENTS PTS;PRIMARY MYELOFIBROSIS","11;9;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5","GASTRIC ACIDITY;SAN MATTEO;CONFIDENCE INTERVAL;FONDAZIONE IRCCS;IRCCS POLICLINICO;POLICLINICO SAN;PERICARDIAL EFFUSION;MGKG ATLG;CLINICAL PRACTICE;PUBMED SCOPUS;MYOCARDIAL INFARCTION;PAVIA PAVIA;ADVERSE EVENTS;IDDVT PATIENTS;MEDIAN FOLLOW-UP;OBSERVATIONAL STUDY;PRIMARY ENDPOINT;SITE BLEEDING;DAY MORTALITY;DISEASE DURATION;HR CI;MATTEO UNIVERSITY;RESPONSE RATE;RISK FACTORS;SIGNIFICANT DIFFERENCES;BONE MARROW;CROSSREF PUBMED;DERMATOLOGY FONDAZIONE;LEFT VENTRICULAR;MEDIAN AGE","22;19;18;18;18;18;17;16;15;15;13;13;12;12;12;12;12;12;11;11;11;11;11;11;11;10;10;10;10;10",170,0.4,2.175,46.96,9.08,302.058,44.81,3,245,2.63,1,8,1.12,1,2,1,1,1,5.74,1,25,2.22,1,4,0,0,0,1.25,1,2,51.51,3,318,1,1,1,1,1,1,39.26,2,240,1,1,1,1.5,1,2,2.28,1,10,8.03,1,59,26.51,2,165,4.92,1,35,0.09,0,2,0,0,0,155.42,21,1362,155.88,21,1362,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2018,449,16.2160356347439,2.86859688195991,0.34860248447205,0.271714922048998,0.276169265033408,0.420935412026726,0.565701559020045,4,235,100,25,53,0.52,0.22,0.06,0.12,21.42,0.70206272854515,0.409799554565702,0.984409799554566,5.96979621542942,0.499634181199926,0.51313375181072,0.485251605995717,0.494973575367647,"GAETANO MARIA DE FERRARI;CATHERINE KLERSY;MARCO ZECCA;MAURIZIO FERRARIO;LUIGI OLTRONA VISCONTI;GABRIELE CRIMI;MARCO FERLINI;EMANUELE CEREDA;FRANCO LOCATELLI;SIMONE SAVASTANO;SERGIO LEONARDI;VALERIA CALCATERRA;STEFANO GHIO;CARMINE TINELLI;ENRICO BALDI;GIOVANNI BAROSI;GLÓRIA PELIZZO;STEFANO CORNARA;CARLOMAURIZIO MONTECUCCO;LAURA SCELSI","29;27;24;18;18;17;17;16;16;16;15;15;15;13;13;13;12;12;11;11","CATHERINE KLERSY;GIOVANNI BAROSI;GAETANO MARIA DE FERRARI;MASSIMILIANO GNECCHI;SIMONE SAVASTANO;LUIGI OLTRONA VISCONTI;FAUSTO BALDANTI;VALERIA CALCATERRA;ENRICO BALDI;EMANUELE CEREDA;MARCO ZECCA;FRANCESCO BENAZZO;CARMINE TINELLI;GLÓRIA PELIZZO;GABRIELE CRIMI;MARCO FERLINI;LUIGIA SCUDELLER;STEFANO GHIO;GIOVANNI ROSTI;FRANCO LOCATELLI","2.61;2.48;2.47;2.11;2.09;1.82;1.82;1.68;1.67;1.65;1.53;1.45;1.42;1.38;1.33;1.33;1.15;1.11;1.08;1.07","GAETANO MARIA DE FERRARI;CATHERINE KLERSY;MARCO ZECCA;MAURIZIO FERRARIO;LUIGI OLTRONA VISCONTI;GABRIELE CRIMI;MARCO FERLINI;EMANUELE CEREDA;FRANCO LOCATELLI;SIMONE SAVASTANO;SERGIO LEONARDI;VALERIA CALCATERRA;STEFANO GHIO;CARMINE TINELLI;ENRICO BALDI;GIOVANNI BAROSI;STEFANO CORNARA;CARLOMAURIZIO MONTECUCCO;LAURA SCELSI;ALBERTO SOMASCHINI","29;27;24;18;18;17;17;16;16;16;15;15;15;13;13;13;12;11;11;11","CATHERINE KLERSY;GIOVANNI BAROSI;GAETANO MARIA DE FERRARI;MASSIMILIANO GNECCHI;SIMONE SAVASTANO;LUIGI OLTRONA VISCONTI;FAUSTO BALDANTI;VALERIA CALCATERRA;ENRICO BALDI;EMANUELE CEREDA;MARCO ZECCA;FRANCESCO BENAZZO;CARMINE TINELLI;GABRIELE CRIMI;MARCO FERLINI;LUIGIA SCUDELLER;STEFANO GHIO;GIOVANNI ROSTI;FRANCO LOCATELLI;RITA CAMPOROTONDO","2.61;2.48;2.47;2.11;2.09;1.82;1.82;1.68;1.67;1.65;1.53;1.45;1.42;1.33;1.33;1.15;1.11;1.08;1.07;1.07","MAURIZIO FERRARIO;DIK HEG;KURT HUBER;CHRISTIAN W. HAMM;MARCELLO DOMINICI;EDOUARD BENIT;PLY CHICHAREON;MARCO VALGIMIGLI;STEPHAN WINDECKER;PASCAL VRANCKX;PETER JÜNI;ANTONIO COLOMBO;LEONARDO BOLOGNESE;SALVATORE CURELLO;GIUSEPPE GARGIULO;ARIS MOSCHOVITIS;DAVID HILDICK‐SMITH;EMANUELE BARBATO;YOSHINOBU ONUMA;JOSÉ FRANCISCO DÍAZ FERNÁNDEZ","1808;1721;1517;1316;1308;1302;1302;1213;1135;1060;968;950;909;887;743;705;705;705;705;678","MAURIZIO FERRARIO;SERGIO LEONARDI;STEFANO GHIO;EMANUELE CEREDA;MARCO ZECCA;CATHERINE KLERSY;LAURA SCELSI;DANIELE BONGETTA;GAETANO MARIA DE FERRARI;MIRKO BELLIATO;PAOLO GAETANI;STEFANIA PAOLUCCI;FABIO FERRARI;LUIGIA SCUDELLER;MAURIZIO TURTURO;MARIO CAZZOLA;ANITA ORLANDO;FRANCESCO MOJOLI;SILVIA MONGODI;LUCA ARCAINI","1784;662;548;498;445;384;376;318;289;253;248;240;236;236;236;234;229;229;229;228","CATHERINE KLERSY;MARCO ZECCA;GAETANO MARIA DE FERRARI;MAURIZIO FERRARIO;LUIGI OLTRONA VISCONTI;SIMONE SAVASTANO;SERGIO LEONARDI;STEFANO GHIO;EMANUELE CEREDA;GABRIELE CRIMI;GIOVANNI BAROSI;CARMINE TINELLI;MARCO FERLINI;RITA CAMPOROTONDO;LAURA SCELSI;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;CARLOMAURIZIO MONTECUCCO;FAUSTO BALDANTI;ROBERTO RORDORF","26;23;19;17;16;15;15;14;14;13;13;13;13;11;11;10;10;9;9;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;PHILOSOPHY;BUSINESS;GEOLOGY;ART;GEOGRAPHY;HISTORY","432;129;34;33;21;20;18;12;11;10;9;9;5;4;4;3;3;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;ONCOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PEDIATRICS;CANCER RESEARCH;INTENSIVE CARE MEDICINE;RADIOLOGY;CELL BIOLOGY;PHYSICAL THERAPY;VIROLOGY;ENDOCRINOLOGY;PSYCHIATRY;OPTICS","335;111;89;79;72;69;63;52;48;41;35;33;33;31;30;25;24;20;19;16","DISEASE;GENE;POPULATION;TRANSPLANTATION;CANCER;MYOCARDIAL INFARCTION;CHEMOTHERAPY;COHORT;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;STEM CELL;RETROSPECTIVE COHORT STUDY;VIRUS;ANTIBODY;ADVERSE EFFECT;HEART FAILURE;CLINICAL TRIAL;LUNG;LYMPHOMA;BONE MARROW","59;45;41;39;35;34;30;28;24;22;21;20;20;19;18;18;17;17;17;16","HEMATOPOIETIC STEM CELL TRANSPLANTATION;PERCUTANEOUS CORONARY INTERVENTION;HAZARD RATIO;CLINICAL ENDPOINT;ACUTE CORONARY SYNDROME;VIRAL LOAD;MUTATION;PARKINSON'S DISEASE;EJECTION FRACTION;CUMULATIVE INCIDENCE;HAEMATOPOIESIS;RITUXIMAB;CONVENTIONAL PCI;GENE EXPRESSION;HEPATITIS C VIRUS;IMATINIB;CD34;CYCLOPHOSPHAMIDE;GENOTYPE;MYELOFIBROSIS;SEROLOGY","23;18;17;16;15;13;12;12;11;9;9;9;8;8;8;8;7;7;7;7;7","BUSULFAN;ANTIRETROVIRAL THERAPY;RIBAVIRIN;FLUDARABINE;IMATINIB MESYLATE;INDUCED PLURIPOTENT STEM CELL;LEVODOPA;NILOTINIB;AL AMYLOIDOSIS;ANTISYNTHETASE SYNDROME;BMPR2;BRENTUXIMAB VEDOTIN;CONNECTIVE TISSUE DISEASE;CROSSOVER STUDY;DASATINIB;DIFFUSING CAPACITY;DNA METHYLATION;DRUG-ELUTING STENT;GRANULOMATOSIS WITH POLYANGIITIS;HERPESVIRIDAE;IBRUTINIB;INTERNATIONAL PROGNOSTIC INDEX;MACE;MICROSCOPIC POLYANGIITIS;MODIFIED RANKIN SCALE;RETURN OF SPONTANEOUS CIRCULATION;THIOTEPA;THROMBOPOIETIN;TICAGRELOR","8;7;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;AGED, 80 AND OVER;ADOLESCENT;CHILD;RISK FACTORS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYOCARDIAL INFARCTION;CHILD, PRESCHOOL;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","226;218;165;156;109;90;78;64;51;50;47;43;35;34;33;30;29;29;27;24","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYMPHOID NEOPLASMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY, CLASSIFICATION, AND CLINICAL FEATURES OF INFLAMMATORY MYOPATHIES;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;TISSUE ENGINEERING AND REGENERATIVE MEDICINE;ACUTE MYELOID LEUKEMIA","15;11;10;10;10;10;9;9;8;8;7;6;5;5;5;5;5;5;5;4","TREATMENT;CLINICAL ENDPOINT;HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;STROKE (ENGINE);CUMULATIVE INCIDENCE;DISCONTINUATION;ECHOCARDIOGRAPHY;MANTLE CELL LYMPHOMA;MYELOFIBROSIS;REFRACTORY (PLANETARY SCIENCE);HEMATOLOGY;HEPATITIS C;PERCUTANEOUS CORONARY INTERVENTION;UNIVARIATE ANALYSIS;ANTIRETROVIRAL THERAPY;CONCOMITANT;DIABETES","20;17;14;13;12;9;9;8;8;8;8;7;7;6;6;6;6;5;5;5","STEM CELL;CELL TRANSPLANTATION;ACUTE CORONARY;HEMATOPOIETIC STEM;PATIENTS UNDERGOING;PARKINSONS DISEASE;CARDIAC ARREST;MYOCARDIAL INFARCTION;CANCER PATIENTS;PEDIATRIC PATIENTS;ALLOGENEIC HEMATOPOIETIC;CLINICAL PRACTICE;CORONARY INTERVENTION;CORONARY SYNDROME;CORONARY SYNDROMES;HEART FAILURE;MYELOID LEUKEMIA;PERCUTANEOUS CORONARY;RANDOMIZED CONTROLLED;RETROSPECTIVE STUDY;CHRONIC MYELOID;CLINICAL OUTCOMES;COHORT STUDY;CONTROLLED TRIAL;CORONARY ARTERY;HODGKIN LYMPHOMA;MESENCHYMAL STROMAL;ARTERIAL HYPERTENSION;CLINICAL TRIAL;ELEVATION MYOCARDIAL","20;18;12;10;10;9;8;8;7;7;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HR CI;CONFIDENCE INTERVAL;STEM CELL;CUMULATIVE INCIDENCE;HAZARD RATIO;CD CELLS;CELL TRANSPLANTATION;HONORARIA RESEARCH;MEDIAN AGE;RISK FACTORS;STATISTICALLY SIGNIFICANT;CONDITIONING REGIMEN;MEDIAN FOLLOW-UP;MULTIVARIATE ANALYSIS;QUARTERLY COST;SIGNIFICANT DIFFERENCES;PATIENTS TREATED;HONORARIA MEMBERSHIP;LUNG ULTRASOUND;NOVARTIS CONSULTANCY;PHYSICAL ACTIVITY;RETROSPECTIVE STUDY;CANCER PATIENTS;PERIPHERAL BLOOD;TRANSPLANTATION HSCT","82;82;64;43;30;28;26;26;24;24;20;20;20;18;18;17;16;16;16;16;16;15;14;14;14;14;14;13;13;13",177,0.39,2.5,29.71,8.33,269.33,28.98,2,124,1.94,1,4,1.1,1,2,1.25,1,2,3.94,1,31,1,1,1,1,1,1,1.2,1,2,33.84,2,190,1,1,1,1,1,1,25.87,1,120,1,1,1,3,3,3,2.63,1,11,5.03,1,24,16.98,1,81,5.59,1,19,0.09,0,3,0,0,0,110.07,11,666,110.16,11,666,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2019,474,15.6708860759494,2.9789029535865,0.335694050991501,0.30379746835443,0.240506329113924,0.20253164556962,0.559071729957806,1,230,92,33,49,0.49,0.19,0.07,0.1,18.58,0.763911481394337,0.436708860759494,0.991561181434599,5.90884985084523,0.484140505452292,0.429022240032058,0.441385582010582,0.434592227695676,"CATHERINE KLERSY;MARCO ZECCA;GAETANO MARIA DE FERRARI;LUCA ARCAINI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;VITTORIO ROSTI;GABRIELE CRIMI;VALERIA CALCATERRA;MARZIA VARETTONI;MAURIZIO FERRARIO;ENRICO BALDI;ALESSANDRA IURLO;FEDERICA MELONI;GIAN LUIGI MARSEGLIA;SIMONE SAVASTANO;MASSIMILIANO BONIFACIO;LORENZO CAVAGNA;FRANCO LOCATELLI;MASSIMILIANO GNECCHI","29;23;22;20;17;17;14;14;14;14;14;14;13;13;13;13;13;12;12;12","CATHERINE KLERSY;GIAN LUIGI MARSEGLIA;VALERIA CALCATERRA;AMELIA LICARI;GAETANO MARIA DE FERRARI;ANNALISA DE SILVESTRI;PAMELA MAFFIOLI;GIUSEPPE DEROSA;ANGELA D’ANGELO;GLÓRIA PELIZZO;MARCO ZECCA;FAUSTO BALDANTI;GABRIELE CRIMI;GEMMA CATERINA MARIA ROSSI;ENRICO BALDI;VITTORIO ROSTI;FEDERICA MELONI;SIMONE SAVASTANO;GIOVANNI BAROSI;GIORGIO CIPRANDI","2.37;2.2;2.13;1.93;1.91;1.79;1.74;1.74;1.63;1.59;1.48;1.47;1.31;1.27;1.23;1.22;1.19;1.18;1.17;1.15","CATHERINE KLERSY;MARCO ZECCA;GAETANO MARIA DE FERRARI;LUCA ARCAINI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;VITTORIO ROSTI;GABRIELE CRIMI;VALERIA CALCATERRA;MARZIA VARETTONI;MAURIZIO FERRARIO;ENRICO BALDI;FEDERICA MELONI;GIAN LUIGI MARSEGLIA;SIMONE SAVASTANO;LORENZO CAVAGNA;MASSIMILIANO GNECCHI;ELISA RUMI;GIOVANNI BAROSI;LUIGI OLTRONA VISCONTI","29;23;22;20;17;17;14;14;14;14;14;14;13;13;13;12;12;12;12;12","CATHERINE KLERSY;GIAN LUIGI MARSEGLIA;VALERIA CALCATERRA;AMELIA LICARI;GAETANO MARIA DE FERRARI;ANNALISA DE SILVESTRI;PAMELA MAFFIOLI;GIUSEPPE DEROSA;ANGELA D’ANGELO;MARCO ZECCA;FAUSTO BALDANTI;GABRIELE CRIMI;GEMMA CATERINA MARIA ROSSI;ENRICO BALDI;VITTORIO ROSTI;FEDERICA MELONI;SIMONE SAVASTANO;GIOVANNI BAROSI;LUCA ARCAINI;MASSIMILIANO GNECCHI","2.37;2.2;2.13;1.93;1.91;1.79;1.74;1.74;1.63;1.48;1.47;1.31;1.27;1.23;1.22;1.19;1.18;1.17;1.14;1.08","BHASKAR DASGUPTA;CRISTINA PONTE;RAASHID LUQMANI;SARA MONTI;WOLFGANG SCHMIDT;ALFRED MAHR;ANA ÁGUEDA;BERNHARD HELLMICH;CARL TURESSON;CARLO SALVARANI;CHETAN MUKHTYAR;CHRIS YOUNG;CHRISTIAN DEJACO;ELISABETH BROUWER;FRANK BUTTGEREIT;GUNNAR TÓMASSON;GÜLEN HATEMI;HUBERT DE BOYSSON;MARÍA C. CID;NICOLE HOLLINGER","889;889;889;889;889;863;863;863;863;863;863;863;863;863;863;863;863;863;863;863","SARA MONTI;CHIARA ELENA;MAURIZIO FERRARIO;CATHERINE KLERSY;MARIO CAZZOLA;ELOISA ARBUSTINI;MIRKO BELLIATO;STEFANO GAIARSA;MARCO ZECCA;LUCA ARCAINI;ANDREA PIETRABISSA;ANNALISA DE SILVESTRI;LUCA MALCOVATI;GIANLUCA VIARENGO;ELISA RUMI;CARMINE TINELLI;SABINO LUZZI;GIOVANNI BAROSI;FAUSTO BALDANTI;LORENZO CAVAGNA","863;339;332;328;302;299;291;278;276;259;254;232;207;204;193;184;184;180;174;173","CATHERINE KLERSY;MARCO ZECCA;LUCA ARCAINI;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;MAURIZIO FERRARIO;GABRIELE CRIMI;SIMONE SAVASTANO;MARZIA VARETTONI;LUIGI OLTRONA VISCONTI;VITTORIO ROSTI;CHIARA ELENA;LORENZO CAVAGNA;GAETANO MARIA DE FERRARI;MASSIMILIANO GNECCHI;PAOLO BERNASCONI;SARA RATTOTTI;ELISA RUMI;AMELIA LICARI;ENRICO BALDI","29;23;19;16;14;14;13;13;12;12;11;11;11;10;10;10;10;9;9;9","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;ECONOMICS;GEOGRAPHY;GEOLOGY;PHILOSOPHY;BUSINESS;ART;ENVIRONMENTAL SCIENCE;HISTORY","440;157;42;33;16;16;15;15;15;12;8;6;3;3;3;2;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GENETICS;CARDIOLOGY;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;PEDIATRICS;INTENSIVE CARE MEDICINE;RADIOLOGY;VIROLOGY;CELL BIOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;PSYCHIATRY;ANESTHESIA;EMERGENCY MEDICINE","352;118;106;88;72;64;63;63;53;48;43;38;35;31;29;28;27;24;20;18","GENE;DISEASE;POPULATION;TRANSPLANTATION;CANCER;BONE MARROW;COHORT;STEM CELL;ANTIBODY;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;VIRUS;LYMPHOMA;CHEMOTHERAPY;CLINICAL TRIAL;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;LEUKEMIA;ALTERNATIVE MEDICINE;HEART FAILURE;LUNG","63;57;50;43;42;39;36;31;30;29;29;28;27;26;25;25;24;22;20;20;20","CLINICAL ENDPOINT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYELOFIBROSIS;PERCUTANEOUS CORONARY INTERVENTION;GENOTYPE;HAZARD RATIO;RITUXIMAB;EJECTION FRACTION;HAEMATOPOIESIS;MYELODYSPLASTIC SYNDROMES;BREAST CANCER;CARDIOPULMONARY RESUSCITATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;GENE EXPRESSION;PLACEBO;VIRAL LOAD;IMATINIB;MUTATION;WALDENSTROM MACROGLOBULINEMIA","25;25;21;17;15;15;14;13;13;13;12;12;11;10;10;10;10;9;9;9","IBRUTINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INDUCED PLURIPOTENT STEM CELL;MONOCLONAL;ANTIRETROVIRAL THERAPY;DASATINIB;HERPESVIRIDAE;MYELOPROLIFERATIVE NEOPLASM;RETURN OF SPONTANEOUS CIRCULATION;AL AMYLOIDOSIS;BUSULFAN;CLADE;ELISPOT;HAPLOTYPE;HEPACIVIRUS;JUVENILE MYELOMONOCYTIC LEUKEMIA;KARYOTYPE;KLEBSIELLA PNEUMONIAE;MULTILOCUS SEQUENCE TYPING;NILOTINIB;RUXOLITINIB;SOX2","8;8;7;7;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;AGED, 80 AND OVER;YOUNG ADULT;MYOCARDIAL INFARCTION;FOLLOW-UP STUDIES;ADOLESCENT;CHILD;RISK FACTORS;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;PLATELET AGGREGATION INHIBITORS;PROSPECTIVE STUDIES","246;225;165;164;121;101;82;80;47;42;35;31;30;29;27;27;27;24;24;24","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ORGAN TRANSPLANTATION AND REJECTION;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA","22;14;12;12;11;10;9;8;7;7;7;7;7;7;6;6;6;5;5;5","CLINICAL ENDPOINT;TREATMENT;REGIMEN;MYELOFIBROSIS;HEMATOPOIETIC CELL TRANSPLANTATION;MANTLE CELL LYMPHOMA;WALDENSTRÖM MACROGLOBULINEMIA;HEMATOLOGY;REFRACTORY (PLANETARY SCIENCE);DIABETES;ECHOCARDIOGRAPHY;ETIOLOGY;EXTRACORPOREAL MEMBRANE OXYGENATION;NUTRITIONAL STATUS;EXTRACORPOREAL;HIV;IBRUTINIB;MYELOPROLIFERATIVE NEOPLASM;PRESENTATION (OBSTETRICS);STROKE (ENGINE)","25;21;17;14;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;6","STEM CELL;CELL TRANSPLANTATION;CARDIAC ARREST;HEMATOPOIETIC STEM;PATIENTS TREATED;CHRONIC MYELOID;MULTIPLE MYELOMA;OUT-OF-HOSPITAL CARDIAC;ELDERLY PATIENTS;PRIMARY MYELOFIBROSIS;BREAST CANCER;HEART DISEASE;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;PHASE II;STEM CELLS;ACUTE CORONARY;BONE MARROW;HEART FAILURE;INDUCED PLURIPOTENT;MYELOPROLIFERATIVE NEOPLASMS;PATIENTS UNDERGOING;PILOT STUDY;PLURIPOTENT STEM;VENTRICULAR FIBRILLATION;ALLOGENEIC HEMATOPOIETIC;CANCER PATIENTS;CELL HIPSC;CLINICAL PRACTICE;HUMAN CYTOMEGALOVIRUS","21;16;11;10;10;9;9;9;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;PUBMED SCOPUS;STEM CELL;HONORARIA RESEARCH;BONE MARROW;MEDIAN AGE;HONORARIA MEMBERSHIP;EQUITY OWNERSHIP;CROSSREF PUBMED;PATIENTS RECEIVED;PATIENTS TREATED;BRISTOL-MYERS SQUIBB;CONSULTANCY MEMBERSHIP;COMMITTEES SPEAKERS;CELL TRANSPLANTATION;CONSULTANCY RESEARCH;PMF PATIENTS;RISK FACTORS;CONSULTANCY SPEAKERS;HR CI;NOVARTIS CONSULTANCY;COMMITTEES RESEARCH;MEDIAN FOLLOW-UP;SURVIVAL OS;CD CELLS;HEALTHY CONTROLS","223;170;170;147;55;51;47;41;36;36;34;33;31;31;31;30;28;27;26;26;26;26;25;24;24;21;21;21;20;20",197,0.42,2,27.92,7.35,168.15,31.22,1,182,2,1,6,1,1,1,0,0,0,2.67,1,10,1.5,1,2,0,0,0,1.5,1,2,39.8,1,239,0,0,0,1,1,1,30.55,1,167,1,1,1,1.5,1,2,2.33,1,8,5.65,1,29,20.69,1,125,5.63,1,19,0,0,0,0,0,0,79.3,1,582,79.3,1,582,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2020,669,18.3512705530643,3.23467862481315,0.309149722735675,0.331838565022422,0.270553064275037,0.312406576980568,0.630792227204783,3,347,153,52,44,0.52,0.23,0.08,0.07,37.51,1.48850614829684,0.391629297458894,0.995515695067265,7.19982648930015,0.531069611390425,0.457839092315627,0.482606310013717,0.516698218533081,"CATHERINE KLERSY;RAFFAELE BRUNO;FAUSTO BALDANTI;EMANUELE CEREDA;STEFANO PERLINI;CARLOMAURIZIO MONTECUCCO;ANNALISA DE SILVESTRI;LUIGI OLTRONA VISCONTI;STEFANO GHIO;ENRICO BALDI;ANTONIO DI SABATINO;SABINO LUZZI;MASSIMILIANO GNECCHI;PAOLO PEDRAZZOLI;MIRKO BELLIATO;LORENZO CAVAGNA;ANTONIO PIRALLA;RICCARDO CACCIALANZA;LAURA OBICI;MARCO FERLINI","51;37;36;27;24;24;23;23;22;20;20;18;18;18;18;17;17;17;17;16","CATHERINE KLERSY;RAFFAELE BRUNO;FAUSTO BALDANTI;ANNALISA DE SILVESTRI;SABINO LUZZI;EMANUELE CEREDA;GUIDO TAVAZZI;CARLOMAURIZIO MONTECUCCO;STEFANO PERLINI;LUIGI OLTRONA VISCONTI;ENRICO BALDI;LORENZO COBIANCHI;STEFANO GHIO;ALICE GIOTTA LUCIFERO;ANTONIO PIRALLA;MIRKO BELLIATO;SIMONE SAVASTANO;FRANCESCA DAL MAS;MASSIMILIANO GNECCHI;MATTIA DEL MAESTRO","3.87;2.98;2.92;2.5;2.44;2.39;2.26;2.2;1.85;1.84;1.68;1.66;1.66;1.62;1.56;1.51;1.45;1.45;1.38;1.37","CATHERINE KLERSY;RAFFAELE BRUNO;FAUSTO BALDANTI;EMANUELE CEREDA;STEFANO PERLINI;CARLOMAURIZIO MONTECUCCO;ANNALISA DE SILVESTRI;LUIGI OLTRONA VISCONTI;STEFANO GHIO;ENRICO BALDI;ANTONIO DI SABATINO;SABINO LUZZI;MASSIMILIANO GNECCHI;PAOLO PEDRAZZOLI;MIRKO BELLIATO;LORENZO CAVAGNA;ANTONIO PIRALLA;RICCARDO CACCIALANZA;LAURA OBICI;MARCO FERLINI","51;37;36;27;24;24;23;23;22;20;20;18;18;18;18;17;17;17;17;16","CATHERINE KLERSY;RAFFAELE BRUNO;FAUSTO BALDANTI;ANNALISA DE SILVESTRI;SABINO LUZZI;EMANUELE CEREDA;GUIDO TAVAZZI;CARLOMAURIZIO MONTECUCCO;STEFANO PERLINI;LUIGI OLTRONA VISCONTI;ENRICO BALDI;LORENZO COBIANCHI;STEFANO GHIO;ALICE GIOTTA LUCIFERO;ANTONIO PIRALLA;MIRKO BELLIATO;SIMONE SAVASTANO;MASSIMILIANO GNECCHI;MATTIA DEL MAESTRO;RICCARDO CACCIALANZA","3.87;2.98;2.92;2.5;2.44;2.39;2.26;2.2;1.85;1.84;1.68;1.66;1.66;1.62;1.56;1.51;1.45;1.38;1.37;1.37","RAFFAELE BRUNO;MASSIMILIANO GRECO;GIORGIO ANTONIO IOTTI;FRANCESCO MOJOLI;PAOLO BONFANTI;EUGENIA QUIRÓS-ROLDÁN;GIACOMO GRASSELLI;ANTONIO COLUCCELLO;FERDINANDO LUCA LORINI;GIACOMO BELLANI;GIANPAOLO CASTELLI;GIOVANNI ALBANO;GIUSEPPE FOTI;LUCA CABRINI;MAURIZIO CECCONI;ROBERTO FUMAGALLI;SERGIO COLOMBO;THOMAS LÄNGER;NICOLA LATRONICO;ANDREA FORASTIERI MOLINARI","5447;4430;4389;3905;3122;2977;2967;2965;2965;2965;2965;2965;2965;2965;2965;2965;2965;2965;2951;2930","RAFFAELE BRUNO;FRANCESCO MOJOLI;DANIELA MONTAGNA;GIORGIO ANTONIO IOTTI;FAUSTO BALDANTI;MARTA COLANERI;MIRKO BELLIATO;ANGELA DI MATTEO;DI FILIPPO A;CATHERINE KLERSY;GUIDO TAVAZZI;RITA CAMPOROTONDO;STEFANIA PAOLUCCI;SERENA LUDOVISI;ELOISA ARBUSTINI;STEFANO PELENGHI;EMANUELE CEREDA;CARLO PELLEGRINI;FABIO SCIUTTI;ANDREA BOTTAZZI","4932;3554;2725;2705;2417;2382;2193;1876;1831;1269;1183;1156;1046;1037;991;980;969;959;954;926","CATHERINE KLERSY;FAUSTO BALDANTI;RAFFAELE BRUNO;EMANUELE CEREDA;ANNALISA DE SILVESTRI;LUIGI OLTRONA VISCONTI;STEFANO GHIO;CARLOMAURIZIO MONTECUCCO;RICCARDO CACCIALANZA;MIRKO BELLIATO;LAURA OBICI;FRANCESCO MOJOLI;SIMONE SAVASTANO;ENRICO BALDI;LORENZO CAVAGNA;ANTONIO PIRALLA;SABINO LUZZI;MARCO FERLINI;MARZIA VARETTONI;STEFANO PERLINI","47;29;28;25;23;23;21;18;16;15;15;15;15;15;15;15;14;14;14;14","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;POLITICAL SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;BUSINESS;PHILOSOPHY;MATERIALS SCIENCE;GEOGRAPHY;HISTORY;ART;GEOLOGY;ENVIRONMENTAL SCIENCE","644;166;55;48;46;44;31;25;23;23;17;14;11;10;8;5;2;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;IMMUNOLOGY;CARDIOLOGY;VIROLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;GENETICS;ONCOLOGY;PEDIATRICS;RADIOLOGY;BIOCHEMISTRY;EMERGENCY MEDICINE;NURSING;PSYCHIATRY;PALEONTOLOGY;MEDICAL EMERGENCY;ANESTHESIA;LAW","506;148;135;107;104;87;82;76;74;72;66;66;65;53;47;40;38;32;31;29;29","DISEASE;POPULATION;OUTBREAK;GENE;COHORT;CANCER;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;HEART FAILURE;CHEMOTHERAPY;VIRUS;LUNG;ANTIBODY;CONFIDENCE INTERVAL;TRANSPLANTATION;ALTERNATIVE MEDICINE;PNEUMONIA;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;LEUKEMIA","192;71;67;58;54;50;44;40;36;34;33;32;28;27;27;26;25;24;24;23;23","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;EJECTION FRACTION;ACUTE CORONARY SYNDROME;HAZARD RATIO;PHENOTYPE;CHRONIC LYMPHOCYTIC LEUKEMIA;PERCUTANEOUS CORONARY INTERVENTION;CYCLOPHOSPHAMIDE;HEPATITIS C VIRUS;BREAST CANCER;MYELOFIBROSIS;CARDIOPULMONARY RESUSCITATION;CONVENTIONAL PCI;CUMULATIVE INCIDENCE;GENOTYPE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;UNIVARIATE ANALYSIS;FETUS;PLACEBO","127;54;23;20;17;17;13;12;12;11;11;10;10;9;9;9;9;9;9;8;8","CORONAVIRUS DISEASE 2019 (COVID-19);IBRUTINIB;RIBAVIRIN;BUSULFAN;CARDIAC RESYNCHRONIZATION THERAPY;HERPESVIRIDAE;AL AMYLOIDOSIS;DIFFUSING CAPACITY;FLUDARABINE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KLEBSIELLA PNEUMONIAE;PIPERACILLIN;PLACENTA;PRASUGREL;RETURN OF SPONTANEOUS CIRCULATION;RUXOLITINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;BENDAMUSTINE;CHRONIC MYELOMONOCYTIC LEUKEMIA;DASATINIB;GIANT CELL ARTERITIS;GOLIMUMAB;HEPACIVIRUS;IMIPENEM;MEROPENEM;MODIFIED RANKIN SCALE;MYELOPROLIFERATIVE NEOPLASM;TELEHEALTH;TOTAL BODY IRRADIATION;TRANSIENT ELASTOGRAPHY;VENETOCLAX","127;9;8;6;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;MALE;FEMALE;MIDDLE AGED;COVID-19;AGED;ITALY;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;ADULT;SARS-COV-2;RETROSPECTIVE STUDIES;PANDEMICS;AGED, 80 AND OVER;BETACORONAVIRUS;TREATMENT OUTCOME;PROSPECTIVE STUDIES;RISK FACTORS;PROGNOSIS","366;298;185;183;148;124;116;114;103;99;95;69;62;52;51;45;39;36;33;32","CORONAVIRUS DISEASE 2019;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;HEPATITIS C INFECTION AND TREATMENT;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;ACUTE MYELOID LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;LYMPHOID NEOPLASMS;ORGAN TRANSPLANTATION AND REJECTION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CORONAVIRUS DISEASE 2019 RESEARCH;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE","40;27;16;16;16;11;10;10;9;8;8;8;7;7;7;7;7;6;6;6","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;CLINICAL ENDPOINT;TREATMENT;CORONAVIRUS;BETACORONAVIRUS;REGIMEN;CORONA VIRUS;STROKE (ENGINE);CLINICAL CHARACTERISTICS;NUTRITIONAL STATUS;CUMULATIVE INCIDENCE;REFRACTORY (PLANETARY SCIENCE);RIGHT HEART ASSESSMENT;UNIVARIATE ANALYSIS;DEEP VEIN THROMBOSIS;ECHOCARDIOGRAPHY;EMERGENCY DEPARTMENT VISITS;HYDROXYCHLOROQUINE;INTERQUARTILE RANGE","51;46;26;23;21;19;17;16;13;11;10;9;9;9;9;8;8;8;8;8","NORTHERN ITALY;COVID- PANDEMIC;COVID- PATIENTS;ACUTE CORONARY;PULMONARY ARTERIAL;RISK FACTORS;PATIENTS TREATED;CANCER PATIENTS;CORONARY INTERVENTION;HEART FAILURE;PERCUTANEOUS CORONARY;SARS-COV- INFECTION;STEM CELL;ARTERIAL HYPERTENSION;ELDERLY PATIENTS;MULTICENTER STUDY;PARKINSONS DISEASE;CARDIAC ARREST;CORONARY SYNDROME;CORONARY SYNDROMES;COVID- OUTBREAK;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;OUT-OF-HOSPITAL CARDIAC;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;COHORT STUDY;CORONAVIRUS DISEASE;EMERGENCY DEPARTMENT;LYMPHOCYTIC LEUKEMIA","17;15;15;14;12;12;11;10;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6","RESEARCH FUNDING;ENTITYS BOARD;ADVISORY COMMITTEES;SPEAKERS BUREAU;CONSULTANCY HONORARIA;PUBMED SCOPUS;SAN MATTEO;POLICLINICO SAN;PULMONARY ARTERIAL;COMMITTEES SPEAKERS;MATTEO PAVIA;HONORARIA MEMBERSHIP;INTENSIVE CARE;CROSSREF PUBMED;CORONAVIRUS DISEASE;MARGINAL ZONE;PAVIA ITALY;IRCCS POLICLINICO;FONDAZIONE IRCCS;ACUTE RESPIRATORY;PATIENTS TREATED;MEDIAN AGE;COVID- PATIENTS;HR CI;ARTERIAL HYPERTENSION;CONSULTANCY RESEARCH;SARS-COV- INFECTION;DISEASE COVID-;PAVIA ITALYSEARCH;CARE UNIT","253;233;217;185;105;84;83;74;65;64;64;60;59;57;53;52;51;49;47;45;45;44;43;43;42;41;40;38;38;37",339,0.51,2.6,144.46,10.65,4109.94599999998,159.18,2,3110,2.35,1,12,2.37,1,31,0,0,0,12.16,1,289,2.14,1,8,0,0,0,1.56,1,4,190.42,2,3987,1.67,1,5,1,1,1,154.55,1,2751,1.67,1,3,2.14,1,6,5.32,1,41,13.26,1,188,127.86,1,1999,19.59,1,517,0,0,0,0,0,0,215.36,1,1836,214.98,1,1836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2021,665,19.203007518797,3.26315789473684,0.306451612903226,0.27218045112782,0.27218045112782,0.222556390977444,0.711278195488722,3,303,145,58,42,0.46,0.22,0.09,0.06,15.2,0.985882367089,0.393984962406015,1,7.83163398692813,0.55100941648145,0.452447512551347,0.482884291911352,0.478037396981065,"FAUSTO BALDANTI;CATHERINE KLERSY;ANNALISA DE SILVESTRI;RAFFAELE BRUNO;ENRICO BALDI;SABINO LUZZI;SERGIO LEONARDI;IRENE CASSANITI;DANIELE LILLERI;PAOLO PEDRAZZOLI;ELENA PERCIVALLE;ALICE GIOTTA LUCIFERO;STEFANO GHIO;CARLOMAURIZIO MONTECUCCO;ROBERTO RORDORF;MARCO ZECCA;GIAN LUIGI MARSEGLIA;LUCA ARCAINI;ARSENIO SPINILLO;MASSIMILIANO GNECCHI","37;37;33;27;23;22;22;22;20;20;19;18;18;17;17;17;17;16;15;15","ANNALISA DE SILVESTRI;SABINO LUZZI;CATHERINE KLERSY;ENRICO BALDI;FAUSTO BALDANTI;ALICE GIOTTA LUCIFERO;GABRIELE SAVIOLI;RAFFAELE BRUNO;STEFANO GHIO;SERGIO LEONARDI;CARLOMAURIZIO MONTECUCCO;DANIELE LILLERI;SILVIA PISANI;IRIDE FRANCESCA CERESA;ROSANGELA INVERNIZZI;ARSENIO SPINILLO;GIAN LUIGI MARSEGLIA;IRENE CASSANITI;RENATO GALZIO;MATTIA DEL MAESTRO","4.16;3.15;2.87;2.72;2.52;2.43;1.96;1.95;1.69;1.67;1.66;1.64;1.63;1.62;1.5;1.48;1.47;1.45;1.44;1.44","FAUSTO BALDANTI;CATHERINE KLERSY;ANNALISA DE SILVESTRI;RAFFAELE BRUNO;ENRICO BALDI;SABINO LUZZI;SERGIO LEONARDI;IRENE CASSANITI;DANIELE LILLERI;PAOLO PEDRAZZOLI;ELENA PERCIVALLE;ALICE GIOTTA LUCIFERO;STEFANO GHIO;CARLOMAURIZIO MONTECUCCO;ROBERTO RORDORF;MARCO ZECCA;GIAN LUIGI MARSEGLIA;LUCA ARCAINI;ARSENIO SPINILLO;MASSIMILIANO GNECCHI","37;37;33;27;23;22;22;22;20;20;19;18;18;17;17;17;17;16;15;15","ANNALISA DE SILVESTRI;SABINO LUZZI;CATHERINE KLERSY;ENRICO BALDI;FAUSTO BALDANTI;ALICE GIOTTA LUCIFERO;GABRIELE SAVIOLI;RAFFAELE BRUNO;STEFANO GHIO;SERGIO LEONARDI;CARLOMAURIZIO MONTECUCCO;DANIELE LILLERI;SILVIA PISANI;IRIDE FRANCESCA CERESA;ROSANGELA INVERNIZZI;ARSENIO SPINILLO;GIAN LUIGI MARSEGLIA;IRENE CASSANITI;MATTIA DEL MAESTRO;CHANDRA BORTOLOTTO","4.16;3.15;2.87;2.72;2.52;2.43;1.96;1.95;1.69;1.67;1.66;1.64;1.63;1.62;1.5;1.48;1.47;1.45;1.44;1.43","FAUSTO BALDANTI;RAFFAELE BRUNO;IRENE CASSANITI;ELENA PERCIVALLE;ANTONIO PIRALLA;GIAMPAOLO MERLINI;SERGIO LEONARDI;FEDERICA MELONI;MARCO VALGIMIGLI;MARTA COLANERI;EFSTATHIOS KASTRITIS;PASCAL VRANCKX;STEPHAN WINDECKER;CATHERINE KLERSY;ENRICO FRIGOLI;FEDERICO PREFUMO;ANTONELLA SARASINI;ASHUTOSH D. WECHALEKAR;PETER JÜNI;VAISHALI SANCHORAWALA","1333;978;829;717;649;632;586;568;500;491;482;481;481;470;440;436;413;411;409;404","FAUSTO BALDANTI;IRENE CASSANITI;ELENA PERCIVALLE;RAFFAELE BRUNO;ANTONIO PIRALLA;SERGIO LEONARDI;MARTA COLANERI;CATHERINE KLERSY;ANTONELLA SARASINI;DANIELE LILLERI;FEDERICA BERGAMI;EFSTATHIOS KASTRITIS;MELETIOS Α. DIMOPOULOS;MARCO ZECCA;VALENTINA ZUCCARO;ROSA MARIA CERBO;JOSÈ CAMILLA SAMMARTINO;FEDERICA GIARDINA;MARCO VECCHIA;FRANCESCA ROVIDA","1018;829;717;703;649;585;485;450;413;403;395;381;381;331;325;316;315;301;294;264","CATHERINE KLERSY;ANNALISA DE SILVESTRI;FAUSTO BALDANTI;IRENE CASSANITI;SABINO LUZZI;RAFFAELE BRUNO;DANIELE LILLERI;ELENA PERCIVALLE;ENRICO BALDI;STEFANO GHIO;SERGIO LEONARDI;ROBERTO RORDORF;MARCO ZECCA;CARLOMAURIZIO MONTECUCCO;PAOLO PEDRAZZOLI;SIMONE SAVASTANO;GIAN LUIGI MARSEGLIA;EMANUELE CEREDA;LUIGI OLTRONA VISCONTI;RICCARDO CACCIALANZA","35;33;32;22;22;22;20;19;19;18;18;17;17;15;15;15;14;13;13;13","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;CHEMISTRY;SOCIOLOGY;ECONOMICS;ENGINEERING;POLITICAL SCIENCE;MATERIALS SCIENCE;GEOGRAPHY;GEOLOGY;PHILOSOPHY;BUSINESS;ART;ENVIRONMENTAL SCIENCE;HISTORY","646;167;63;45;32;31;27;26;21;18;17;15;6;6;5;4;3;2;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;PATHOLOGY;CARDIOLOGY;GENETICS;ONCOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;VIROLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;EMERGENCY MEDICINE;OPTICS;PSYCHIATRY;CANCER RESEARCH;PHYSICAL THERAPY;ENDOCRINOLOGY","502;148;126;117;103;98;86;77;69;68;63;60;54;40;39;35;35;26;26;24","DISEASE;CANCER;GENE;POPULATION;ANTIBODY;MYOCARDIAL INFARCTION;HEART FAILURE;COHORT;OUTBREAK;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;LUNG;RANDOMIZED CONTROLLED TRIAL;INCIDENCE (GEOMETRY);CONFIDENCE INTERVAL;LYMPHOMA;TRANSPLANTATION;IMMUNE SYSTEM;VIRUS;BONE MARROW","174;71;65;64;50;46;44;42;42;41;36;35;34;32;31;31;31;29;28;26","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;HAZARD RATIO;RITUXIMAB;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;GENOTYPE;SEROLOGY;BREAST CANCER;IMMUNOTHERAPY;T CELL;ACUTE CORONARY SYNDROME;PROGRESSION-FREE SURVIVAL;CARDIOGENIC SHOCK;CARDIOPULMONARY RESUSCITATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CRONBACH'S ALPHA;CYCLOPHOSPHAMIDE;HAEMATOPOIESIS;INTERSTITIAL LUNG DISEASE;MYELOFIBROSIS;PHASES OF CLINICAL RESEARCH;UNIVARIATE ANALYSIS","111;35;30;24;20;16;16;15;15;13;13;12;12;11;10;10;9;9;9;9;9;9;9;9;9;9","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;BENDAMUSTINE;IBRUTINIB;VANCOMYCIN;ANTIRETROVIRAL THERAPY;HERPESVIRIDAE;SINGLE-NUCLEOTIDE POLYMORPHISM;AL AMYLOIDOSIS;AMYLOID POLYNEUROPATHY;CARDIAC RESYNCHRONIZATION THERAPY;DARATUMUMAB;DIFFUSING CAPACITY;GERMLINE MUTATION;INTRA-AORTIC BALLOON PUMPING;MACE;MAMMOGRAPHY;RIBAVIRIN;RUXOLITINIB;SEROPREVALENCE;VINCRISTINE","111;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4",";HUMANS;COVID-19;FEMALE;MALE;MIDDLE AGED;ITALY;SARS-COV-2;ADULT;AGED;RETROSPECTIVE STUDIES;PROSPECTIVE STUDIES;AGED, 80 AND OVER;TREATMENT OUTCOME;NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROGNOSIS;HEART FAILURE;CHILD;ANTIBODIES, VIRAL","361;302;154;130;110;86;84;83;80;80;66;42;36;34;31;27;27;26;25;24","CORONAVIRUS DISEASE 2019 RESEARCH;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;CORONAVIRUS DISEASE 2019;LYMPHOID NEOPLASMS;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;RHEUMATOID ARTHRITIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE","23;23;17;17;17;12;11;11;10;10;10;10;10;8;8;8;7;7;7;6","PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;TREATMENT;CARDIAC IMAGING;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC ULTRASOUND;CLINICAL CHARACTERISTICS;CONCOMITANT;NUTRITIONAL STATUS;PROGRESSION-FREE SURVIVAL;REGIMEN;CARDIAC AMYLOIDOSIS;IMMUNITY;UNIVARIATE ANALYSIS;CANCER;CORONA VIRUS;CORONAVIRUS;DELPHI METHOD;DISCONTINUATION","56;33;32;18;11;11;10;10;10;10;10;10;9;9;9;8;8;8;8;8","CANCER PATIENTS;COVID- PATIENTS;SARS-COV- INFECTION;COVID- PANDEMIC;HEART FAILURE;COHORT STUDY;MYOCARDIAL INFARCTION;CARDIAC ARREST;CELL TRANSPLANTATION;ELDERLY PATIENTS;MULTICENTER STUDY;MULTICENTRE STUDY;NORTHERN ITALY;OUT-OF-HOSPITAL CARDIAC;PATIENTS TREATED;PHASE II;ACUTE CORONARY;PANDEMIC WAVE;PROSPECTIVE STUDY;STEM CELL;ATRIAL FIBRILLATION;CORONARY INTERVENTION;FONDAZIONE ITALIANA;ITALIANA LINFOMI;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;PERCUTANEOUS CORONARY;PILOT STUDY;ST-SEGMENT ELEVATION;BONE MARROW","19;15;12;11;11;10;10;9;9;9;9;9;9;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;5","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;SPEAKERS BUREAU;CONSULTANCY HONORARIA;HR CI;COMMITTEES SPEAKERS;CORONARY ARTERY;PUBMED SCOPUS;HONORARIA MEMBERSHIP;MYOCARDIAL INFARCTION;ADVISORY BOARD;COMMITTEES RESEARCH;CONFIDENCE INTERVAL;SARS-COV- INFECTION;COVID- PATIENTS;CROSSREF PUBMED;RISK FACTORS;MEDIAN AGE;MEDIAN FOLLOW-UP;COVID- PANDEMIC;PATIENTS TREATED;RESEARCH GRANTFUNDING;CONSULTANCY MEMBERSHIP;CANCER PATIENTS;DISEASE ACTIVITY;HONORARIA RESEARCH;CLINICAL TRIALS;SYSTEMIC SCLEROSIS;JANSSEN CONSULTANCY","290;290;245;209;92;87;66;64;59;57;52;49;48;47;46;44;44;42;41;41;39;39;39;36;35;35;35;31;30;29",323,0.49,2.5,73.83,9.4,638.930000000004,80.89,2,1039,1.65,1,5,1.25,1,5,0,0,0,6.04,1,51,4,1,10,1,1,1,1,1,1,94.86,2,1150,1.29,1,2,1,1,1,77.75,1,1024,1,1,1,1,1,1,3.25,1,17,8.92,1,73,61.3,1,952,10.48,1,108,0,0,0,0,0,0,69.19,3,401,66.47,3,401,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2022,750,19.8826666666667,3.25066666666667,0.307629204265792,0.277333333333333,0.264,0.182666666666667,0.774666666666667,6,330,149,73,32,0.44,0.2,0.1,0.04,7.64,0.855699626174937,0.421333333333333,0.993333333333333,7.09849047265524,0.538435239007036,0.463506212604987,0.480475617655224,0.494785826418479,"FAUSTO BALDANTI;CATHERINE KLERSY;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;DANIELE LILLERI;IRENE CASSANITI;LUCA ARCAINI;STEFANO GHIO;MARCO ZECCA;RAFFAELE BRUNO;GABRIELE SAVIOLI;LORENZO PREDA;FEDERICA MELONI;ENRICO BALDI;CARLOMAURIZIO MONTECUCCO;A MUZZI;MARCO FERLINI;SIMONE SAVASTANO;F FUMOSO;ANTONIO PIRALLA","46;33;30;26;25;24;22;21;20;20;19;18;18;18;17;17;17;17;16;16","FAUSTO BALDANTI;ANNALISA DE SILVESTRI;CATHERINE KLERSY;GUIDO TAVAZZI;SABINO LUZZI;IRENE CASSANITI;PAOLO PEDRAZZOLI;VALERIA SCOTTI;DANIELE LILLERI;ALICE GIOTTA LUCIFERO;ENRICO BALDI;LUCA ARCAINI;STEFANO GHIO;GABRIELE SAVIOLI;ANGIOLETTA LASAGNA;RAFFAELE BRUNO;ARSENIO SPINILLO;MARCO FERLINI;CESARE ZOIA;AMELIA LICARI","3.66;2.63;2.62;2.32;2.3;2.09;2.07;2;1.91;1.85;1.77;1.69;1.67;1.63;1.56;1.47;1.46;1.45;1.44;1.42","FAUSTO BALDANTI;CATHERINE KLERSY;PAOLO PEDRAZZOLI;ANNALISA DE SILVESTRI;DANIELE LILLERI;IRENE CASSANITI;LUCA ARCAINI;STEFANO GHIO;MARCO ZECCA;RAFFAELE BRUNO;GABRIELE SAVIOLI;LORENZO PREDA;FEDERICA MELONI;ENRICO BALDI;CARLOMAURIZIO MONTECUCCO;A MUZZI;MARCO FERLINI;SIMONE SAVASTANO;F FUMOSO;ANTONIO PIRALLA","46;33;30;26;25;24;22;21;20;20;19;18;18;18;17;17;17;17;16;16","FAUSTO BALDANTI;ANNALISA DE SILVESTRI;CATHERINE KLERSY;GUIDO TAVAZZI;SABINO LUZZI;IRENE CASSANITI;PAOLO PEDRAZZOLI;VALERIA SCOTTI;DANIELE LILLERI;ENRICO BALDI;LUCA ARCAINI;STEFANO GHIO;GABRIELE SAVIOLI;ANGIOLETTA LASAGNA;RAFFAELE BRUNO;ARSENIO SPINILLO;MARCO FERLINI;CESARE ZOIA;AMELIA LICARI;FEDERICA MELONI","3.66;2.63;2.62;2.32;2.3;2.09;2.07;2;1.91;1.77;1.69;1.67;1.63;1.56;1.47;1.46;1.45;1.44;1.42;1.41","FAUSTO BALDANTI;PAOLO PEDRAZZOLI;IRENE CASSANITI;JOSÈ CAMILLA SAMMARTINO;ANTONIO PIRALLA;ANNA SUREDA;QIANG PAN‐HAMMARSTRÖM;ALESSANDRA NERVIANI;COSTANTINO PITZALIS;FELICE RIVELLESE;FRANCES HUMBY;GEORGINA THORBORN;GIOVANNI GIORLI;LILIANE FOSSATI‐JIMACK;MYLES LEWIS;STEFANO BOMBARDIERI;AMELIA LICARI;BÉNÉDICTE NÉVEN;GIAN LUIGI MARSEGLIA;ARJAN C. LANKESTER","691;528;511;374;349;338;325;316;316;316;316;316;316;316;316;316;313;312;302;282","FAUSTO BALDANTI;IRENE CASSANITI;PAOLO PEDRAZZOLI;JOSÈ CAMILLA SAMMARTINO;AMELIA LICARI;GIAN LUIGI MARSEGLIA;CARLOMAURIZIO MONTECUCCO;ANTONIO PIRALLA;FEDERICA BERGAMI;LAURA OBICI;DANIELE LILLERI;DANIELA MONTAGNA;MARIA DE FILIPPO;MARTINA VOTTO;LORENZA MONTAGNA;SERENA BUGATTI;CATHERINE KLERSY;ELENA PERCIVALLE;MARCO ZECCA;RAFFAELE BRUNO","519;504;471;367;302;290;276;274;264;256;237;214;201;194;178;174;168;167;139;139","FAUSTO BALDANTI;CATHERINE KLERSY;ANNALISA DE SILVESTRI;IRENE CASSANITI;DANIELE LILLERI;STEFANO GHIO;PAOLO PEDRAZZOLI;MARCO ZECCA;LUCA ARCAINI;GABRIELE SAVIOLI;A MUZZI;ENRICO BALDI;MARCO FERLINI;SERGIO LEONARDI;CARLOMAURIZIO MONTECUCCO;FEDERICA MELONI;LORENZO PREDA;RAFFAELE BRUNO;SIMONE SAVASTANO;GUIDO TAVAZZI","38;32;25;23;23;21;21;20;19;19;17;17;16;16;16;16;16;16;16;15","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PSYCHOLOGY;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;MATERIALS SCIENCE;SOCIOLOGY;BUSINESS;PHILOSOPHY;GEOLOGY;GEOGRAPHY;HISTORY","720;183;65;46;45;42;23;18;18;18;17;15;14;8;6;3;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ONCOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;VIROLOGY;BIOCHEMISTRY;EMERGENCY MEDICINE;PSYCHIATRY;ANESTHESIA;OPTICS;FAMILY MEDICINE;NURSING","573;169;156;144;126;108;96;90;77;76;67;67;54;53;53;51;40;33;31;28","DISEASE;POPULATION;COHORT;GENE;CANCER;MYOCARDIAL INFARCTION;ANTIBODY;RETROSPECTIVE COHORT STUDY;HEART FAILURE;LUNG;CONFIDENCE INTERVAL;CLINICAL TRIAL;CHEMOTHERAPY;PREGNANCY;TRANSPLANTATION;ADVERSE EFFECT;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;VACCINATION","166;90;70;69;60;60;58;57;56;49;43;40;39;35;35;33;33;33;33;32","INFECTIOUS DISEASE (MEDICAL SPECIALTY);EJECTION FRACTION;CLINICAL ENDPOINT;HAZARD RATIO;2019-20 CORONAVIRUS OUTBREAK;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;GENOTYPE;IMMUNOTHERAPY;MYELOFIBROSIS;TITER;INTERSTITIAL LUNG DISEASE;RITUXIMAB;CARDIOGENIC SHOCK;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;NEUTROPENIA;AUTOANTIBODY;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;FETUS;HAEMATOPOIESIS;MUTATION;UNIVARIATE ANALYSIS","100;35;34;26;22;18;18;17;15;15;14;14;13;13;12;12;12;12;10;10;10;10;10;10;10","CORONAVIRUS DISEASE 2019 (COVID-19);AL AMYLOIDOSIS;BUSULFAN;TICAGRELOR;FLUDARABINE;HERPESVIRIDAE;IBRUTINIB;DNA METHYLATION;FEBRILE NEUTROPENIA;NIVOLUMAB;ANTIRETROVIRAL THERAPY;BOOSTER DOSE;CONNECTIVE TISSUE DISEASE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MACE;MYELOPROLIFERATIVE NEOPLASM;RETURN OF SPONTANEOUS CIRCULATION;RUXOLITINIB;THIOTEPA;ACUTE LYMPHOCYTIC LEUKEMIA;ANTISYNTHETASE SYNDROME;BRENTUXIMAB VEDOTIN;CARDIAC INDEX;CARDIAC RESYNCHRONIZATION THERAPY;DIFFUSE ALVEOLAR DAMAGE;EXOME SEQUENCING;EXTRACORPOREAL PHOTOPHERESIS;FRACTIONAL FLOW RESERVE;GERMLINE MUTATION;IMMUNE CHECKPOINT;LAMIVUDINE;MONOCLONAL;OBINUTUZUMAB;PRASUGREL;STROKE VOLUME;TOTAL BODY IRRADIATION;VENETOCLAX","100;7;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;COVID-19;FEMALE;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;PROSPECTIVE STUDIES;SARS-COV-2;MALE;CHILD;NEOPLASMS;ITALY;HEART FAILURE;MIDDLE AGED;AGED;ADULT;ACUTE CORONARY SYNDROME;PANDEMICS;PERCUTANEOUS CORONARY INTERVENTION;INFANT, NEWBORN","371;363;127;75;75;52;49;49;45;40;38;35;33;33;32;29;28;26;24;22","CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;CORONAVIRUS DISEASE 2019;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;LYMPHOID NEOPLASMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;ACUTE MYELOID LEUKEMIA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY, CLASSIFICATION, AND CLINICAL FEATURES OF INFLAMMATORY MYOPATHIES;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;ORGAN TRANSPLANTATION AND REJECTION;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS","33;18;18;16;15;15;14;14;13;12;11;11;11;9;8;8;8;8;8;8","CLINICAL ENDPOINT;PANDEMIC;TREATMENT;2019-20 CORONAVIRUS OUTBREAK;CARDIAC IMAGING;INTERQUARTILE RANGE;REGIMEN;CARDIOVASCULAR RISK ASSESSMENT;CONCOMITANT;VACCINES;REFRACTORY (PLANETARY SCIENCE);STROKE (ENGINE);DISCONTINUATION;MITRAL REGURGITATION;PULMONARY EMBOLISM;CARDIAC AMYLOIDOSIS;DIAGNOSIS;MYELOFIBROSIS;PULMONARY HYPERTENSION;ECHOCARDIOGRAPHY","36;27;21;20;18;16;16;15;15;15;14;14;13;13;12;11;11;11;11;10","COHORT STUDY;ACUTE CORONARY;HEART FAILURE;PULMONARY EMBOLISM;COVID- PATIENTS;ITALIANA DI;CARDIAC ARREST;CELL TRANSPLANTATION;OBSERVATIONAL STUDY;SOCIETÀ ITALIANA;STEM CELL;ARTERIAL HYPERTENSION;CORONARY SYNDROME;OUT-OF-HOSPITAL CARDIAC;PHASE STUDY;PULMONARY ARTERIAL;CARDIAC MAGNETIC;CARDIOGENIC SHOCK;COVID- PANDEMIC;ELDERLY PATIENTS;HEMATOPOIETIC STEM;LUNG DISEASE;MAGNETIC RESONANCE;MITRAL REGURGITATION;MULTICENTER STUDY;MULTICENTRE STUDY;PROSPECTIVE COHORT;CLINICAL OUTCOMES;FONDAZIONE ITALIANA;LUNG CANCER","18;14;14;13;12;12;11;11;11;11;11;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;7;7;7","MEDIAN AGE;HR CI;PULMONARY EMBOLISM;ADVERSE EVENTS;VIEW LARGEDOWNLOAD;STATISTICALLY SIGNIFICANT;BONE MARROW;MEDIAN FOLLOW-UP;RISK FACTORS;ORGAN DAMAGE;PATIENTS UNDERGOING;INTENSIVE CARE;COVID- PANDEMIC;PRIMARY ENDPOINT;ENROLLED PATIENTS;OBSERVATIONAL STUDY;CARDIAC ARREST;CONFIDENCE INTERVAL;COVID- DIAGNOSIS;SIGNIFICANT DIFFERENCE;STEM CELL;FUNDING SOURCES;HEART FAILURE;SARS-COV- INFECTION;COVID- PATIENTS;MASSIVE PULMONARY;CLINICAL PRACTICE;MEDIAN TIME;PATIENTS RECEIVED;PATIENTS TREATED","74;71;67;53;52;46;45;40;39;36;36;35;34;34;33;33;32;32;32;32;31;30;30;30;29;29;28;28;28;28",342,0.46,2.175,42.91,7,885.980000000008,54.14,1,1312,1.18,1,2,1.04,1,2,0,0,0,3.55,1,16,0,0,0,0,0,0,1,1,1,62.22,1,1509,1.33,1,2,1,1,1,55.74,1,1292,0,0,0,1.5,1,2,2.17,1,7,5.12,1,21,45.46,1,1191,7.05,1,72,0,0,0,0,0,0,30.47,0,175,30.47,0,175,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANMATTEO",2023,654,20.1666666666667,3.14525993883792,0.317938745746232,0.2782874617737,0.282874617737003,0.203363914373089,0.749235474006116,1,298,122,39,48,0.46,0.19,0.06,0.07,4.85,1.10725803926482,0.440366972477064,1,6.36591595077781,0.52109639288654,0.463345864661654,0.452665507750253,0.456335058462718,"FAUSTO BALDANTI;LUCA ARCAINI;ANNALISA DE SILVESTRI;ENRICO BALDI;CARLOMAURIZIO MONTECUCCO;PAOLO PEDRAZZOLI;SIMONE SAVASTANO;CATHERINE KLERSY;GUIDO TAVAZZI;MARCO ZECCA;RICCARDO CACCIALANZA;ANDREA ANDERLONI;PATRIZIA ZAPPASODI;SILVIA MANGIACAVALLI;RAFFAELE BRUNO;GIOVANNI PALLADINI;ANTONIO PIRALLA;LUCA ANSALONI;FEDERICA MELONI;GIAN LUIGI MARSEGLIA","33;26;25;24;23;21;19;19;18;16;15;15;15;14;14;14;13;13;13;13","ANNALISA DE SILVESTRI;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;CARLOMAURIZIO MONTECUCCO;SABINO LUZZI;ENRICO BALDI;PAOLO PEDRAZZOLI;LUCA ANSALONI;GUIDO TAVAZZI;SIMONE SAVASTANO;RAFFAELE BRUNO;ALICE GIOTTA LUCIFERO;LUCA ARCAINI;RICCARDO CACCIALANZA;CATHERINE KLERSY;FEDERICA MELONI;FRANCESCO MOJOLI;ANDREA MICHELERIO;ANGIOLETTA LASAGNA;MARCO ZECCA","2.9;2.75;2.31;2.08;2.03;1.98;1.88;1.8;1.7;1.61;1.54;1.53;1.49;1.49;1.43;1.27;1.25;1.25;1.17;1.12","FAUSTO BALDANTI;LUCA ARCAINI;ANNALISA DE SILVESTRI;ENRICO BALDI;CARLOMAURIZIO MONTECUCCO;PAOLO PEDRAZZOLI;SIMONE SAVASTANO;CATHERINE KLERSY;GUIDO TAVAZZI;MARCO ZECCA;RICCARDO CACCIALANZA;ANDREA ANDERLONI;PATRIZIA ZAPPASODI;SILVIA MANGIACAVALLI;RAFFAELE BRUNO;GIOVANNI PALLADINI;ANTONIO PIRALLA;LUCA ANSALONI;FEDERICA MELONI;GIAN LUIGI MARSEGLIA","33;26;25;24;23;21;19;19;18;16;15;15;15;14;14;14;13;13;13;13","ANNALISA DE SILVESTRI;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;CARLOMAURIZIO MONTECUCCO;SABINO LUZZI;ENRICO BALDI;PAOLO PEDRAZZOLI;LUCA ANSALONI;GUIDO TAVAZZI;SIMONE SAVASTANO;RAFFAELE BRUNO;LUCA ARCAINI;RICCARDO CACCIALANZA;CATHERINE KLERSY;FEDERICA MELONI;FRANCESCO MOJOLI;ANDREA MICHELERIO;ANGIOLETTA LASAGNA;MARCO ZECCA;COSTANZA NATALIA JULIA COLOMBO","2.9;2.75;2.31;2.08;2.03;1.98;1.88;1.8;1.7;1.61;1.54;1.49;1.49;1.43;1.27;1.25;1.25;1.17;1.12;1.11","SARA MONTI;F BONETTI;ALVISE BERTI;FAUSTO BALDANTI;FRANCO LOCATELLI;PIETRO MERLI;CHETAN MUKHTYAR;DANIËL BLOCKMANS;AUGUSTO VAGLIO;DAVID JAYNE;ANGELA MASTRONUZZI;ANNALISA SERRA;BENJAMIN TERRIER;BIAGIO DE ANGELIS;CONCETTA QUINTARELLI;DARIA PAGLIARA;FEDERICA GALAVERNA;FRANCESCA DEL BUFALO;GIADA DEL BALDO;GIOVANNA LEONE","311;255;252;252;250;249;243;243;237;237;233;232;232;232;232;232;232;232;232;232","SARA MONTI;F BONETTI;FAUSTO BALDANTI;FRANCESCA DEL BUFALO;ANTONIO PIRALLA;LAURA OBICI;SILVIA MANGIACAVALLI;IRENE CASSANITI;FRANCESCA ROVIDA;SIMONE SAVASTANO;ANNALISA DE SILVESTRI;A. BORGHESI;DANIELE LILLERI;PAOLO PEDRAZZOLI;STEFANO GHIRARDELLO;LORENZO COBIANCHI;ALESSANDRO FERRARI;ELENA PERCIVALLE;GIOVANNI PALLADINI;CATHERINE KLERSY","296;255;245;232;173;163;138;132;124;114;112;105;105;93;89;86;78;78;71;62","FAUSTO BALDANTI;ANNALISA DE SILVESTRI;ENRICO BALDI;LUCA ARCAINI;CARLOMAURIZIO MONTECUCCO;SIMONE SAVASTANO;PAOLO PEDRAZZOLI;CATHERINE KLERSY;PATRIZIA ZAPPASODI;MARCO ZECCA;RICCARDO CACCIALANZA;SILVIA MANGIACAVALLI;ANDREA ANDERLONI;VERONICA CODULLO;ANTONIO PIRALLA;IRENE CASSANITI;ALESSIA CURRAO;GUIDO TAVAZZI;ROBERTO PRIMI;DANIELE LILLERI","29;24;23;22;20;19;17;17;15;15;15;14;14;13;13;13;13;12;12;11","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;MATHEMATICS;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;GEOGRAPHY;ART;PHILOSOPHY;HISTORY;ENVIRONMENTAL SCIENCE","626;191;64;47;42;24;20;18;15;13;13;13;10;5;4;4;3;2","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;CARDIOLOGY;GENETICS;PEDIATRICS;GASTROENTEROLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;RADIOLOGY;VIROLOGY;CANCER RESEARCH;ANESTHESIA;NURSING;PALEONTOLOGY;EMERGENCY MEDICINE;ENDOCRINOLOGY","495;175;120;101;100;91;85;79;75;68;64;61;53;43;38;35;35;34;32;26","DISEASE;GENE;CANCER;COHORT;POPULATION;RETROSPECTIVE COHORT STUDY;ANTIBODY;CHEMOTHERAPY;CONFIDENCE INTERVAL;CLINICAL TRIAL;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;ADVERSE EFFECT;LEUKEMIA;LUNG;HEART FAILURE;LYMPHOMA;IMMUNE SYSTEM;MULTIPLE MYELOMA","120;77;76;60;58;47;45;45;41;38;35;33;33;32;31;31;30;30;29;24","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;RITUXIMAB;HEMATOPOIETIC STEM CELL TRANSPLANTATION;EJECTION FRACTION;LENALIDOMIDE;2019-20 CORONAVIRUS OUTBREAK;CARDIOGENIC SHOCK;COLORECTAL CANCER;MUTATION;CHRONIC LYMPHOCYTIC LEUKEMIA;IMMUNOGLOBULIN LIGHT CHAIN;VASCULITIS;BORTEZOMIB;CYCLOPHOSPHAMIDE;HAEMATOPOIESIS;MINIMAL RESIDUAL DISEASE;CARDIOPULMONARY RESUSCITATION","44;32;22;19;19;18;15;15;14;14;14;14;13;13;12;11;11;11;11;10","CORONAVIRUS DISEASE 2019 (COVID-19);AL AMYLOIDOSIS;DARATUMUMAB;VENETOCLAX;DNA METHYLATION;HERPESVIRIDAE;IBRUTINIB;DIFFUSING CAPACITY;GERMLINE MUTATION;GRANULOMATOSIS WITH POLYANGIITIS;PEMBROLIZUMAB;RETURN OF SPONTANEOUS CIRCULATION;CARFILZOMIB;GIANT CELL ARTERITIS;KLEBSIELLA PNEUMONIAE;KRAS;MICROVESICLES;MODIFIED RANKIN SCALE;BENDAMUSTINE;BLINATUMOMAB;BRCA MUTATION;CYTOREDUCTIVE SURGERY;ELISPOT;FLUDARABINE;MICROSCOPIC POLYANGIITIS;NIVOLUMAB;POMALIDOMIDE;TRANSCRIPTOME;VINCRISTINE;WHOLE GENOME SEQUENCING","44;12;11;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;COVID-19;RETROSPECTIVE STUDIES;ADULT;MALE;TREATMENT OUTCOME;AGED;ITALY;CHILD;MIDDLE AGED;PROSPECTIVE STUDIES;SARS-COV-2;ANTI-BACTERIAL AGENTS;HEART FAILURE;NEOPLASMS;ANIMALS;STROKE;NEOPLASM RECURRENCE, LOCAL","347;301;61;57;54;39;39;39;32;32;31;30;29;29;24;22;21;18;16;14","MOLECULAR MECHANISMS OF AMYLOIDOSIS;ACUTE MYELOID LEUKEMIA;LYMPHOID NEOPLASMS;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;CORONAVIRUS DISEASE 2019 RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PANCREATIC CANCER RESEARCH AND TREATMENT;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY","24;20;17;17;16;14;13;12;10;10;10;10;8;7;7;7;7;6;6;6","CLINICAL ENDPOINT;TREATMENT;REFRACTORY (PLANETARY SCIENCE);PANDEMIC;REGIMEN;2019-20 CORONAVIRUS OUTBREAK;CARDIAC AMYLOIDOSIS;AL AMYLOIDOSIS;DISCONTINUATION;MANTLE CELL LYMPHOMA;DARATUMUMAB;LIGHT CHAIN AMYLOIDOSIS;MINIMAL RESIDUAL DISEASE;TRANSCATHETER AORTIC-VALVE REPLACEMENT;INTERQUARTILE RANGE;FAMILIAL AMYLOID POLYNEUROPATHY;HEMATOLOGY;PROSTHETIC VALVES EVALUATION;TRANSTHYRETIN;TREATMENT OUTCOMES","32;31;19;17;15;13;13;12;12;12;11;11;11;11;10;9;9;9;9;9","MYELOID LEUKEMIA;CARDIAC ARREST;STEM CELL;COHORT STUDY;ACUTE MYELOID;OUT-OF-HOSPITAL CARDIAC;OBSERVATIONAL STUDY;PATIENTS TREATED;SYSTEMIC SCLEROSIS;MULTIPLE MYELOMA;NORTHERN ITALY;RHEUMATOID ARTHRITIS;ACUTE CORONARY;AORTIC VALVE;CARDIOGENIC SHOCK;CELL TRANSPLANTATION;SARS-COV- INFECTION;FONDAZIONE ITALIANA;HEART FAILURE;HEMATOPOIETIC STEM;HODGKIN LYMPHOMA;ITALIANA LINFOMI;LUNG CANCER;MULTICENTER STUDY;PATIENTS UNDERGOING;AL AMYLOIDOSIS;CANCER PATIENTS;IMMUNE RESPONSE;PRIMARY MEDIASTINAL;TRANSCATHETER AORTIC","17;16;14;13;12;12;10;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6;6","HR CI;PATIENTS TREATED;MEDIAN FOLLOW-UP;MEDIAN AGE;ADVERSE EVENTS;SPEAKERS BUREAU;AL AMYLOIDOSIS;SARS-COV- INFECTION;ADVISORY ROLE;PATIENTS RECEIVED;CLINICAL PRACTICE;RISK FACTORS;STEM CELL;NEWLY DIAGNOSED;BOEHRINGER INGELHEIM;CARDIAC ARREST;HAZARD RATIO;PRIMARY ENDPOINT;STATISTICALLY SIGNIFICANT;CONFIDENCE INTERVAL;MEDIAN TIME;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;BONE MARROW;CONSECUTIVE PATIENTS;MEDIAN OS;MONTHS NA;RESEARCH FUNDING;SIGNIFICANT DIFFERENCES;CLINICAL TRIALS","87;60;58;55;53;51;44;44;42;37;36;34;34;33;32;32;32;32;32;29;29;29;28;27;27;27;27;27;27;26",278,0.43,3,86.52,11,864.36,66.79,2,453,1.56,1,4,1.29,1,3,0,0,0,13.61,1,90,0,0,0,0,0,0,1,1,1,79.13,2,559,1.33,1,2,1,1,1,60.74,2,366,1,1,1,1,1,1,2.51,1,7,7.6,1,53,42.13,1,271,10.62,1,97,0,0,0,0,0,0,15.52,0,157,15.52,0,157,4,0,0,8,0,0,0,0,0,0,0,0,5,0,3,0,5.5,3.25,0,8,2,0,0,0,0,0,0,0,0,3,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ACKERMAN MARGARET E;ARPICCO SILVIA;AVANZINI MARIA ANTONIETTA;BENAZZO MARCO;CASCINO PASQUALE;CODULLO VERONICA;CONTI BICE;COVA EMANUELA;CUZZOCREA SALVATORE;DI PAOLA ROSANNA","2;2;2;2;2;2;2;2;2;2","FOND IRCCS POLICLINICO SAN MATTEO;UNIV DEGLI STUDI DI PAVIA;ACKERMAN MARGARET E;DARTMOUTH COLLEGE;HEDERMAN ANDREW;LILLERI DANIELE;MARCHANT ARNAUD;UNIV BRUXELLES;UNIV DEGLI STUDI DI TORINO","8;4;2;2;2;2;2;2;2","31 BIOLOGICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;40 ENGINEERING;4611 MACHINE LEARNING;4003 BIOMEDICAL ENGINEERING;51 PHYSICAL SCIENCES;5106 NUCLEAR AND PLASMA PHYSICS","5;4;2;2;2;1;1;1","CLINICAL RESEARCH;HEALTH SERVICES;INFECTIOUS DISEASES","2;2;2",NA,NA,"A61K;A61K31/506;A61K39/245;A61K47/36;A61K9/127;A61L27/00;A61P11/00;C12M3/00;C12Q;C12Q1/6806","1;1;1;1;1;1;1;1;1;1","A61K31/506;A61K47/36;A61K9/0073;A61K9/1271;A61K9/1278;A61L2300/64;A61L2400/16;A61L2430/22;A61L27/18;A61L27/26","2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;ZENODO;KARGER PUBLISHERS;FUTURE SCIENCE GROUP;TAYLOR & FRANCIS GROUP","13;8;6;5;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;3105 GENETICS;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4205 NURSING;5202 BIOLOGICAL PSYCHOLOGY;3207 MEDICAL MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3213 PAEDIATRICS;36 CREATIVE ARTS AND WRITING;3601 ART HISTORY, THEORY AND CRITICISM","60;19;10;8;4;4;3;3;3;3;3;3;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;PREVENTION;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;HEMATOLOGY;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC;DIABETES;GENETIC TESTING;GENETICS;HUMAN GENOME;INFANT MORTALITY;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;BIOMEDICAL IMAGING","12;10;8;7;6;6;4;4;4;4;4;4;3;3;3;3;3;3;3;2","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","6;4;4;3;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","4;4;3;2;1;1;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","18;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","23;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER","3;3;2;2","3 GOOD HEALTH AND WELL BEING","7",22,3.77,1748.36,8,93.18,0,0,5,1,7,0,0,9,0,15,7,0,0,0,0,0,0,22,0,0,22,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan;Ireland;Switzerland","7;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","22;13;8;4;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;CARDIOVASCULAR;HEART DISEASE;LUNG;LUNG CANCER;LYMPHOMA;PATIENT SAFETY;AGING;DIGESTIVE DISEASES;GENETICS;PREVENTION;BIOTECHNOLOGY;BRAIN DISORDERS;IMMUNIZATION;INFECTIOUS DISEASES;NEUROSCIENCES","20;16;11;5;5;4;4;4;4;4;4;3;3;3;3;2;2;2;2;2","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;INFECTION","11;3;2;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.4 VACCINES;6.4 SURGERY","15;2;2;2;2;1;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA","4;4;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","8;2;1;1;1"
"IRCCS_SANMATTEO",2024,593,18.8532883642496,3.09949409780776,0.322633297062024,0.269814502529511,0.283305227655987,0.185497470489039,0.610455311973018,1,274,107,38,44,0.46,0.18,0.06,0.07,0.9,0.945771998874155,0.421585160202361,0.996627318718381,5.08366721659201,0.534667390109562,0.484119241192412,0.457758941877794,0.466181784489947,"CATHERINE KLERSY;FAUSTO BALDANTI;ANDREA ANDERLONI;GUIDO TAVAZZI;ANNALISA DE SILVESTRI;GIAN LUIGI MARSEGLIA;ANNA ODONE;ENRICO BALDI;SIMONE SAVASTANO;ANTONIO DI SABATINO;ROBERTO RORDORF;MARCO VINCENZO LENTI;MARCO ZECCA;LUCA ARCAINI;CARLOMAURIZIO MONTECUCCO;CARLO FABBRI;ANGELO GUIDO CORSICO;AURELIO MAURO;STEFANO GHIO;ALESSANDRO FUGAZZA","31;28;25;21;19;19;19;19;18;18;17;16;16;15;14;14;13;13;13;12","GUIDO TAVAZZI;ANNALISA DE SILVESTRI;ANNA ODONE;CATHERINE KLERSY;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;ANDREA ANDERLONI;ANTONIO DI SABATINO;ROBERTO RORDORF;ENRICO BALDI;SIMONE SAVASTANO;MARCO VINCENZO LENTI;SABINO LUZZI;AMANDA CASIRATI;MARCO ZECCA;PAOLA BERTUCCIO;RICCARDO CACCIALANZA;AMELIA LICARI;PAOLO PEDRAZZOLI;GIACOMO PIETRO VIGEZZI","3.06;2.39;2.3;2.13;2.07;1.99;1.83;1.59;1.52;1.5;1.49;1.37;1.28;1.27;1.2;1.16;1.1;1.08;1.07;1.06","CATHERINE KLERSY;FAUSTO BALDANTI;ANDREA ANDERLONI;GUIDO TAVAZZI;ANNALISA DE SILVESTRI;GIAN LUIGI MARSEGLIA;ANNA ODONE;ENRICO BALDI;SIMONE SAVASTANO;ANTONIO DI SABATINO;ROBERTO RORDORF;MARCO VINCENZO LENTI;MARCO ZECCA;LUCA ARCAINI;CARLOMAURIZIO MONTECUCCO;ANGELO GUIDO CORSICO;AURELIO MAURO;STEFANO GHIO;ALESSIA CURRAO;EMANUELE CEREDA","31;28;25;21;19;19;19;19;18;18;17;16;16;15;14;13;13;13;12;11","GUIDO TAVAZZI;ANNALISA DE SILVESTRI;ANNA ODONE;CATHERINE KLERSY;FAUSTO BALDANTI;GIAN LUIGI MARSEGLIA;ANDREA ANDERLONI;ANTONIO DI SABATINO;ROBERTO RORDORF;ENRICO BALDI;SIMONE SAVASTANO;MARCO VINCENZO LENTI;SABINO LUZZI;AMANDA CASIRATI;MARCO ZECCA;RICCARDO CACCIALANZA;AMELIA LICARI;PAOLO PEDRAZZOLI;ALESSANDRO IVONE;AURELIO MAURO","3.06;2.39;2.3;2.13;2.07;1.99;1.83;1.59;1.52;1.5;1.49;1.37;1.28;1.27;1.2;1.1;1.08;1.07;1;0.98","GIULIO CONTE;ENRICO BALDI;ANGELO AURICCHIO;FAUSTO BALDANTI;ERIKA ASPERGES;GIANFRANCO TOLA;IGNACIO MARTÍN‐LOECHES;JORDI RELLO;STIJN BLOT;MARCO ZECCA;ANDREA BUTERA;ANDREA CORTEGIANI;ANDREA SCRIBANTE;FRANCESCO GIUSEPPE DE ROSA;MATTEO BASSETTI;MAURIZIO PASCADOPOLI;ROBERTO RORDORF;SIMONE SAVASTANO;ALESSIA CURRAO;ANTONIO VENA","38;37;35;32;25;25;25;25;25;24;23;23;23;23;23;23;23;23;22;22","ENRICO BALDI;FAUSTO BALDANTI;ERIKA ASPERGES;MARCO ZECCA;ROBERTO RORDORF;SIMONE SAVASTANO;ALESSIA CURRAO;FRANCESCA ROMANA GENTILE;SARA COMPAGNONI;ROBERTO PRIMI;SARA BENDOTTI;VALENTINA ZUCCARO;AURELIO MAURO;LUCA ARCAINI;ANTONIO SANZO;ANNA ODONE;ANTÓNIO TOSCANO;SARA VARGIU;CARLOMAURIZIO MONTECUCCO;PAOLA FUGAZZOLA","37;29;25;24;23;23;22;22;22;21;21;21;20;20;19;18;18;18;17;17","CATHERINE KLERSY;FAUSTO BALDANTI;ANDREA ANDERLONI;ANNA ODONE;ANNALISA DE SILVESTRI;GUIDO TAVAZZI;GIAN LUIGI MARSEGLIA;ENRICO BALDI;SIMONE SAVASTANO;MARCO ZECCA;CARLOMAURIZIO MONTECUCCO;ROBERTO RORDORF;ANGELO GUIDO CORSICO;AURELIO MAURO;LUCA ARCAINI;STEFANO GHIO;ANTONIO DI SABATINO;MARCO VINCENZO LENTI;ALESSIA CURRAO;EMANUELE CEREDA","29;25;24;19;19;18;17;16;16;16;14;14;13;13;13;13;13;11;11;11","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;CHEMISTRY;MATHEMATICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;BUSINESS;MATERIALS SCIENCE;PHILOSOPHY;GEOGRAPHY;GEOLOGY;HISTORY;ART","565;149;66;50;41;36;29;29;24;19;16;15;15;9;7;5;4;2","INTERNAL MEDICINE;SURGERY;INTENSIVE CARE MEDICINE;PATHOLOGY;IMMUNOLOGY;CARDIOLOGY;ONCOLOGY;GENETICS;RADIOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PEDIATRICS;VIROLOGY;NURSING;DERMATOLOGY;PSYCHIATRY;CANCER RESEARCH;EMERGENCY MEDICINE;OPTICS;PALEONTOLOGY","401;114;102;102;94;91;71;70;55;50;49;40;40;36;34;31;28;26;25;24;24","DISEASE;CANCER;GENE;RETROSPECTIVE COHORT STUDY;POPULATION;COHORT;RANDOMIZED CONTROLLED TRIAL;ANTIBODY;TRANSPLANTATION;HEART FAILURE;MYOCARDIAL INFARCTION;IMMUNE SYSTEM;VIRUS;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;CLINICAL TRIAL;LUNG;CONFIDENCE INTERVAL;ADVERSE EFFECT;LYMPHOMA;OBSERVATIONAL STUDY","80;71;51;41;35;34;31;30;30;26;25;24;24;23;22;20;20;20;18;17;17;17","BREAST CANCER;MULTICENTER STUDY;CARDIOGENIC SHOCK;IMMUNOTHERAPY;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HAZARD RATIO;CLINICAL ENDPOINT;COLORECTAL CANCER;EJECTION FRACTION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);ESCHERICHIA COLI;HAEMATOPOIESIS;INFLAMMATORY BOWEL DISEASE;GENOME;PHENOTYPE;RITUXIMAB;VASCULITIS;VIRAL DISEASE;CARDIOPULMONARY RESUSCITATION;CUMULATIVE INCIDENCE;EOSINOPHILIC ESOPHAGITIS;GRAFT-VERSUS-HOST DISEASE;HUMAN CYTOMEGALOVIRUS;INTERSTITIAL LUNG DISEASE;LENALIDOMIDE;MYELOFIBROSIS;NEURORADIOLOGY;PLACEBO","15;15;13;13;12;11;10;10;10;10;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6","CORONAVIRUS DISEASE 2019 (COVID-19);COLONOSCOPY;HEMATOPOIETIC CELL;HERPESVIRIDAE;AUTOIMMUNE GASTRITIS;KLEBSIELLA PNEUMONIAE;RETURN OF SPONTANEOUS CIRCULATION;AL AMYLOIDOSIS;ANCA-ASSOCIATED VASCULITIS;BUSULFAN;DARATUMUMAB;ECHOVIRUS;EXTRACORPOREAL PHOTOPHERESIS;FUNCTIONAL MITRAL REGURGITATION;GIANT CELL ARTERITIS;IBRUTINIB;NIVOLUMAB;SERRATIA MARCESCENS;ARTICULAR CARTILAGE;ATROPHIC GASTRITIS;CARFILZOMIB;COLPOSCOPY;CONTINUOUS GLUCOSE MONITORING;CYTOMEGALOVIRUS INFECTIONS;DONOR LYMPHOCYTE INFUSION;GASTROENTEROSTOMY;GERD;INFLAMMATORY BOWEL DISEASES;KIDNEY DONATION;MACHINE PERFUSION;MAMMOGRAPHY;MARGINAL ZONE;MASTECTOMY;MICROSCOPIC COLITIS;MISSENSE MUTATION;MYELOPROLIFERATIVE NEOPLASM;RUXOLITINIB;SOLID ORGAN;SUPAR;TRACTOGRAPHY;WHOLE GENOME SEQUENCING","10;7;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;CHILD;TREATMENT OUTCOME;ADOLESCENT;YOUNG ADULT;AGED, 80 AND OVER;PROSPECTIVE STUDIES;REGISTRIES;CHILD, PRESCHOOL;INFANT;INFANT, NEWBORN;PROGNOSIS","348;239;128;114;89;72;67;49;45;42;38;36;27;25;24;20;17;15;15;15","DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION;MANAGEMENT OF VALVULAR HEART DISEASE;MOLECULAR MECHANISMS OF AMYLOIDOSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;FACTORS AFFECTING VACCINE HESITANCY AND ACCEPTANCE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;ASTHMA","15;11;11;11;10;10;9;9;9;8;7;7;7;7;6;6;6;6;6;5","TREATMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;BILIARY DRAINAGE;CLINICAL ENDPOINT;MANTLE CELL LYMPHOMA;STROKE (ENGINE);DIAGNOSIS;HEMATOPOIETIC CELL TRANSPLANTATION;CARDIAC IMAGING;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTERQUARTILE RANGE;CARDIOGENIC SHOCK;ECHOCARDIOGRAPHY;ENDOSCOPIC ULTRASOUND;EOSINOPHILIC ESOPHAGITIS;PATHOGENESIS;PULMONARY HYPERTENSION;RIGHT HEART ASSESSMENT;BREAST CANCER;CARDIAC AMYLOIDOSIS","31;11;10;10;10;10;9;9;8;8;8;7;7;7;7;7;7;7;6;6","COHORT STUDY;CARDIAC ARREST;CELL TRANSPLANTATION;CARDIOGENIC SHOCK;RETROSPECTIVE STUDY;STEM CELL;ARTERIAL HYPERTENSION;MULTICENTER STUDY;PULMONARY ARTERIAL;SYSTEMIC SCLEROSIS;BREAST CANCER;CLINICAL TRIAL;HEART FAILURE;INTENSIVE CARE;INFLAMMATORY BOWEL;MULTIPLE MYELOMA;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;PULMONARY HYPERTENSION;RHEUMATOID ARTHRITIS;BILIARY DRAINAGE;CLINICAL PRACTICE;GANGLION BLOCK;ITALIAN SOCIETY;MESENCHYMAL STROMAL;NORTHERN ITALY;PERCUTANEOUS STELLATE;PILOT STUDY;RETROSPECTIVE MULTICENTER;STELLATE GANGLION","13;11;10;9;9;9;8;8;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5","MEDIAN AGE;ADVERSE EVENTS;CARDIAC ARREST;HR CI;PUBLIC HEALTH;SIGNIFICANT DIFFERENCES;PATIENTS TREATED;CANCER PATIENTS;RISK FACTORS;CLINICAL PRACTICE;BODY COMPOSITION;SUPPORTING INFORMATION;INTENSIVE CARE;MULTIVARIATE ANALYSIS;PRIMARY OUTCOME;RETROSPECTIVE STUDY;VACCINE HESITANCY;HAZARD RATIO;INCREASED RISK;MEDIAN FOLLOW-UP;MEDIAN MONTHS;OBSERVATIONAL STUDY;SAN MATTEO;ATRIAL FIBRILLATION;BREAST CANCER;CLINICAL TRIALS;CONFIDENCE INTERVAL;PATIENTS UNDERGOING;V-A ECMO;CARDIAC AMYLOIDOSIS","26;24;24;23;23;22;19;18;18;17;16;16;15;14;14;14;14;13;13;13;13;13;13;12;12;12;12;12;12;11",4,0.01,3.625,11.85,11.85,11.85,17,17,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,21,21,0,0,0,0,0,0,17,17,17,0,0,0,0,0,0,0,0,0,2,2,2,13,13,13,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
